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ABSTRACT 
Due to the emergence and dissemination of multidrug resistance, bacterial pathogens 
have been causing a serious public health problem in recent years. To address the existing drug 
resistant problem, there is an urgent need to find new antimicrobials, especially those against 
drug-resistant bacteria. SecA is the central component of Sec-dependent secretion pathway, 
which is responsible for the secretion of many essential proteins as well as many toxins and viru-
lence factors. Two SecA homologues are indentified in some important Gram-positive patho-
gens. SecA1 is involved in general secretion pathway and essential for viability, whereas SecA2 
contribute to secretion of specific virulence factors. The high conservation among a wide range 
of bacteria and no human counterpart make SecA homologues attractive targets for exploring 
novel antimicrobials. We hypothesize that inhibition of these SecA homologues could reduce 
virulence, inhibit bacteria growth, and kill bacteria. SecA1 and SecA2 from four different species 
were cloned, purified, and characterized. All these SecA homologues show ATPase activities, 
thus screening ATPase inhibitors might help to develop new antimicrobials. In this study, three 
structurally different classes of SecA inhibitors were developed and optimized: 1) Rose Bengal 
(RB) and RB analogs derived from systematical dissection RB and Structure-Activity relation-
ship (SAR) study; 2) pyrimidine analogs derived from virtual screening based on the ATP bind-
ing pocket of EcSecA and SAR study; and 3) bistriazole analogs derived from random screening 
and SAR study. Several potent SecA inhibitors show promising enzymatic inhibition against Se-
cA homologues as well as bacteriostatic and bactericidal effects. Two major efflux pumps of S. 
aureus, NorA and MepA, have little negative effect on the antimicrobial activities of SecA inhi-
bitors, suggesting that targeting SecA could by-pass efflux pumps. Moreover, these inhibitors 
impair the secretion of important toxins of S. aureus and B. anthracis, indicating the inhibition of 
in vivo SecA function could reduce virulence. Target identification assays confirm that these in-
hibitors could directly bind to SecA homologues, and specifically identify SecA from whole cell 
lysate of E. coli and S. aureus, suggesting that these inhibitors are really targeting on SecA. 
These studies validate that SecA is a good target for development antimicrobials. 
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INTRODUCTION 
In the past sixty year, antibiotics have dramatically improve the prognoses of bacterial in-
fectious diseases, and made a major contribution to on the improvement of public health [1]. 
However, drug resistance has co-developed with the discovery of new antibiotics [1-3]. In recent 
years, due to the misusage of antibiotics, multidrug resistance has been increased and widely 
spread [4-5]. In recent years, multi drug-resistant bacteria pathogens cause a serious public 
health problem, with high mortality rates, prolonged hospital stays, and increased healthcare 
costs [6]. Therefore, there is an urgent need to find new antimicrobial drugs against those drug-
resistant bacterial pathogens [7]. Common mechanisms of antibiotics are inhibition on essential 
enzymatic processes in the bacterium to interrupt replication, or transcription, or translation, or 
cell wall synthesis [8]. Because the emergence of drug resistance against all these antibacterial 
mechanisms [9-10], there is an urgent need to develop new antimicrobials with novel mechan-
isms.  
In our study, we target on protein translocation system, because bacterial exported pro-
teins play important roles in bacterial physiology, viability, or/and pathogenicity [11-16]. Some 
exported proteins function as essential proteins, required for bacterial growth, cell wall mainten-
ance, and cell division [17-18]; moreover, some exported proteins function as toxins or virulence 
factors required for establishment of infection, invasion in human tissue, protection from host 
defense system, or inducing toxic syndrome [19-22] . Therefore, further understanding of protein 
secretion mechanism may provide opportunities to target therapies or to create a vaccine candi-
date by interrupting components of the secretion pathway [23]. In both Gram-positive and Gram-
negative bacteria, two major conserved protein export systems requiring N-terminal signal pep-
tides are responsible for transporting proteins across cytoplasmic membrane [24-26]: General 
secretion (Sec) pathway and Twin-arginine translocation (Tat) pathway. Most export proteins are 
20 
transported unfolded through Sec-pathway [25]; some folded proteins and cofactor-containing 
proteins are transported through Tat pathway [27]. In some bacteria, there are also specialized 
export systems responsible for secretion specific virulence factors [28-30]. 
In this study, we focus on Sec pathway, because it plays an essential role in bacteria and 
highly conserved in bacteria. Sec pathway is responsible for export precursor proteins, which 
contain classical amino-terminal signal sequences across the cytoplasmic membrane [25, 31-32]. 
Majority of exported proteins are translocated through this pathway. Sec system is not only re-
sponsible for the secretion of many essential proteins, and it is also responsible for the secretion 
of many toxins and virulence factors [15, 33-35]. In S. aureus, there are many secretary toxin 
precursors containing Sec-dependent signal peptide  [34]. The table 0.1 showed these toxins play 
important roles in the pathogenesis of S. aureus infection, involving in colonization or spread in 
human tissue, protecting bacteria from host defensive attack, eliciting immune responses.   
The Sec pathway is well-characterized through studies with E. coli and B. subtilis. In 
these two model systems, SecA is an essential protein, which interacts with virtually all the other 
components of the system, acting as a molecular chaperone and a molecular motor providing 
driving force for translocation and pushing preprotein export through transmembrane channel 
[32, 36-37], and being involved in forming protein-conducting channel [38-39]. SecA is highly 
conserved in bacteria and essential for viability, moreover it has no counterpart in mammalian 
cell [40]. Thus SecA might be an ideal target for developing antimicrobial agents [13, 23]. It was 
long believed that all bacteria have a single SecA [41]. However, in recent years, two SecA ho-
mologues are identified in over thirty Gram-positive bacteria [28, 42-48] (Fig. 0.1). Majority of 
these bacteria are human pathogens, including some pathogens lethal to human or causing se-
rious multi drug resistant problems, such as B. anthracis, S. aureus, and M. tuberculosis.  
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Table 0.1 List of toxins with Sec-dependent signal peptide in S. aureus (Adapted from [34]) 
Pathogenic action Virulence factors 
Colonization of host tissues 
ClfA, Fibrinogen-binding protein A 
ClfB, Clumping factor B 
IsdA, Cell surface protein 
SdrC, Ser-Asp-rich, fibrinogen-binding bone, sialoprotein-binding protein  
SdrE, Ser-Asp-rich, fibrinogen-binding bone, sialoprotein-binding protein 
Lysis of eukaryotic cell 
membranes and bacterial 
spread 
Geh, Glycerol ester hydrolase 
Hla, α-hemolysin   
Hld, β-hemolysin /phospholipase C  
HlgA, γ-hemolysin chain A-C precursor 
HlgB-C, γ-hemolysin B and C component  
Lip, Triacylglycerol lipase precursor 
LukD, Leukotoxin D 
LukE, Leukotoxin E 
LukF, Panton-valentine leukocidin chain F precursor 
LukS, Panton-valentine leukocidin chain S precursor 
Survival in phagocytes 
Efb, Hypothetical protein  
Spa, Immunoglobulin G binding protein A precursor 
Immunological disguise and 
modulation 
ClfA, Fibrinogen-binding protein A 
ClfB, Clumping factor B, have signal peptide 
Coa, Staphylocoagulase precursor 
Spa, Immunoglobulin G binding protein A precursor 
Septic shock symptom 
SEB, Staphylococcal enterotoxin B 
TSST-1, Toxic shock syndrome toxin 1 
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Figure 0.1 Bacteria containing two SecA homologues 
For those two SecA homologues, the one with the higher homology to E. coli SecA (Ec-
SecA) was named SecA1, and the other one with lower homology to EcSecA was named SecA2. 
Previous genetic studies show that SecA1 essential for viability and might be involved in general 
secretion pathway [28, 49-50]; while SecA2 is not essential, except in Corynebacterium. gluta-
micum [51] and Clostridium. difficile [52]. In C. difficile and C. corynebacterium, both SecA1 
and SecA2 are essential protein required for growth [51-52]. In C. difficile, SecA2 is required for 
the export of the S-layer proteins and a cell wall protein [52] (Table 0.2). SecA2 is not essential 
for the viability in other strains, but they are involved in secretion of specific proteins related 
with virulence, such as protective enzyme, adhesion, autolysin [44-46, 48, 53-54] (Table 0.2). In 
S. gordonii [42] and S. aureus [48],  SecA2 is required for virulence by mediating export of ad-
hesions, GspB [42] and SraP [48], which are responsible for human platelet binding. In L. mono-
cytogenes, SecA2 is
 
required for persistent colonization in host tissues by mediating secretion of 
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two autolysins, p60 and NamA [44, 53]; and SecA2 is also required for secretion of SodA [55]. 
In S. parasanguis FW213, SecA2 mediate secretion of two adhesions, FimA and Fap1 [45]. All 
these findings support SecA2 contribute to the virulence of some important Gram-positive pa-
thogen by playing a role in a specialized secretion pathway. SecA2 also plays a role in creating 
immune response. In M. tuberculosis, SecA2 is required for secretion of SodA [54] and restricts 
maturing of antigen specific CD
8+ 
T cells and protection in vivo [56]; while in L. monocytogenes, 
SecA2 promotes protective immune response [57].  Thus, targeting SecA2 might lead to identify 
drugs that specifically target pathogenic bacteria without disrupting the normal microflora [8, 
58].  
Table 0.2 The summary of SecA2’s function from previous studies 
Bacteria  Protein   Pathogenic action 
M. tuberculosis, [54]  SodA , manganese superoxide dismutase Protect from oxidative attack 
M. smegmatis, [59] Msmeg1704, lipoprotein  Periplasmic sugar binding 
Msmeg1712, lipoprotein Periplasmic sugar binding 
S. aureus, [48]  SraP, adhesin  Colonization of host tissues 
S. gordoni, [42]  GspB, adhesin  Colonization of host tissues 
S. parasanguis, [45]  Fap1, fimbrial adhesin     Colonization of host tissues 
FimA, adhesin  Colonization of host tissues 
L. monocytogenes, [44]  p60, autolysin  Bacterial spread 
NamA, autolysin  Bacterial spread 
 SodA, manganese superoxide dismutase Protect from oxidative attack 
    C. difficile, [52]  SLPs, S-layer proteins Protection 
 CwpV, Cell wall protein  
A good antimicrobial target should be involved in essential process of bacteria life cycle, 
interacting with it could inhibit bacteria growth or cause bacteria death, and it should be specific 
for pathogen without human counterpart. The potential target should contain ligand binding do-
main(s), be assayable for high throughput investigating in vitro and in vivo function. SecA homo-
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logues fit all these criteria pretty well. 1) They are required for bacterial viability and/or viru-
lence; highly conserved in bacteria with no human counterpart [40], therefore targeting these 
proteins may represent a way to combat bacterial pathogens with minimal human toxicity. 2) Se-
cA could bind with ATP, preproteins, SecYEG, and molecular chaperones. And ligand binding 
pockets of SecA were identified from crystal structure [60] and NMR structure [61-62], support-
ing SecA is reasonable for drug targeting by small molecules. 3) Malachite green is used to 
measure the ATPase activity of SecA, and this method is applied for high-throughput screening 
for SecA inhibitors [63-64]. High-throughput-screening compatible fluorescence and surface 
plasmon resonance techniques were used to investigate the interaction between SecA and other 
proteins [62, 65-67].  In vivo techniques using β-galactosidase fusion reporter [68] and anti-sense 
interference [69], were used to study the in vivo inhibition of SecA. 4) SecA homologues plays 
important role during all infection life stages. They have important functions not only in expo-
nential phase but also in stationary phase [34, 70-71]; they are required for colonization and 
spread in human tissue; they can protect bacteria from host defensive attack; also play roles in 
eliciting immune responses [56-57].  Thus, inhibition SecA could have dramatically impact on 
bacteria, causing growth inhibition, death, and virulence reduction. 5) For those Gram-positive 
pathogens containing two SecA homologues, like MRSA, MTB, B. anthracis, and C. diphtheria, 
drug targeting SecA might have two targets making SecAs more attractive targets for the devel-
opment of novel antimicrobials. Dual target inhibition could increase the change of combat in-
fection and reduce the occurrence of drug resistance. 6) SecA is involved in forming transmem-
brane channel [38-39], implying that it might be accessible directly from the extracellular envi-
ronment in Gram-positive bacteria. Thus, targeting SecA might be able to by-pass the effect of 
efflux, which is one of the major and common mechanisms for bacterial drug-resistance devel-
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opment [72-76]. Based on all these features of SecA homologues, we hypothesize that SecA is 
an excellent target for antimicrobial development. Inhibition of these SecA homologues 
could reduce bacteria virulence, inhibit bacteria growth, and/or kill bacteria.  
Although the critical role of SecA in bacteria has been noted for a long time, a few small-
molecule inhibitors of SecA have been reported [62, 64, 69, 77-82]. Sodium azide is the first re-
ported SecA inhibitors [77]. Sodium azide could only inhibit the translocation ATPase activity of 
EcSecA and BsSecA [77], but not for intrinsic ATPase activity. Although azide-resistant mutants 
have been mapped on SecA [78], azide could inhibit activities of many other enzymes, like cy-
tochrome c oxidase [83], proton ATPase [84], superoxide dismutase [85], alcohol dehydrogenase 
[86], and ceruloplasmin [87]. Previous studies demonstrated that azide stabilize the membrane-
inserted and ADP-bound state of SecA, and inhibit the function of SecA by trapping SecA in this 
transitional state [37, 62, 88-89].  In 2002, an organic compound (CJ-21058), isolated from the 
fermentation broth of fungus, was reported as an inhibitor against SecA translocation ATPase 
activities [79]. Pannomycin is the second SecA inhibitor isolated from the fermentation broth of 
fungus [69], which had weak antibacterial activity against Gram-positive bacteria [62, 69]. Both 
CJ-201058 and pannomycin contain the decalin-tetramic acid scaffold with a quaternary cabon 
center at position C-6 [62], which might be important for SecA inhibition. In 2008, two SecA 
inhibitors were discovered from virtual ligand screening against EcSecA crystal structure [80]. 
Two pyrimidine analogs was developed from optimization those two compounds, with improved 
inhibition effect against EcSecAN68 [81]. Several SecA inhibitors were developed from high-
throughput screening or virtual screening, with IC50 values between 50-150 μM [64, 82].     
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Although the function of SecA is well studied in E. coli and B. subtilis, and genetic stu-
dies have been demonstrated that SecA1 and SecA2 are involved in translocation, the biochemi-
cal properties of SecA1 and SecA2 have not been well characterized. It is not clear whether these 
proteins have similar functions as EcSecA and BsSecA. Alignment result showed that nine mo-
tifs of DEAD helicase were highly conserved in all SecA homologues (Fig. 0.2). In EcSecA, 
these nine motifs form two nucleotide binding domains (NBD);  NBD1 has high affinity to nuc-
leotide, and contains minimal ATPase catalytic machinery; NBD2 has low affinity to nucleotide, 
and acts as an activator of ATP hydrolysis by controlling ADP release and optimal ATP catalysis 
at NBD1 [90]. Thus, NBD1 and NBD2 are very important to the translocase activity of EcSecA. 
The conservation of these domains suggests SecA1 and SecA2 might have similar translocase 
activity as EcSecA. Thus, we hypothesize that SecA1 and SecA2 are ATPase that hydrolyses 
ATP to promote translocation of specific proteins; and drugs targeting those two nucleotide bind-
ing domains might have dual targets in those Gram positive pathogens containing two SecA ho-
mologues. 
 
Figure 0.2 Alignment SecA1s and SecA2s with EcSecA and BsSecA 
In this study, SecA1 and SecA2 were cloned from M. tuberculosis H37Rv, M. smegmatis 
mc
2
155, S. aureus 35556, and B. anthracis Sterne, over-expressed in E. coli, and purified. The 
biochemical properties of these SecA homologues were comparatively characterized. To deter-
mine whether these SecA1 and SecA2 could be molecular motor, ATPase assay was used to in-
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E. coli SecA ---------- ---------- ---------- ---------- MLIKLLTKVF GSRNDRTLRR MRKVVNIINA MEPEMEKLSD EELKGKTAEF RARLEKGEVL
B. subtilis SecA ---------- ---------- ---------- ---------- -MLGILNKMF DP-TKRTLNR YEKIANDIDA IRGDYENLSD DALKHKTIEF KERLEKGATT
B. anthracis SecA1 ---------- ---------- ---------- ---------- -MIGILKKVF DV-NQRQIKR MQKTVEQIDA LESSIKPLTD EQLKGKTLEF KERLTKGETV
B. anthracis SecA2 ---------- ---------- ---------- ---------- -MLNSVKKLL GDSQKRKLKK YEQLVQEINN LEEKLSDLSD EELRHKTITF KDMLRDGKTV
S. aureus SecA1 ---------- ---------- ---------- ---------- --MGFLSKIL DG-NNKEIKQ LGKLADKVIA LEEKTAILTD EEIRNKTKQF QTELADIDNV
S. aureus SecA2 ---------- ---------- ---------- ---------- ----MKHKLD VTINELRLKS IRKIVKRINT WSDEVKSYSD DALKQKTIEF KERLASGVDT
TB SecA1 ---------- ---------- ---------- ---------- ----MLSKLL RLGEGRMVKR LKKVADYVGT LSDDVEKLTD AELRAKTDEF KRRLADQKNP
TB SecA2 MNVHGCPRIA ACRCTDTHPR GRPAFAYRWF VPKTTRAQPG RLSSRFWRLL GASTEKNRSR SLADVTASAE YDKEAADLSD EKLRKAAGLL NLDDLAESAD
MS SecA1 ---------- ---------- ---------- ---------- ----MLSKLL RLGEGRMVKR LRKVADYVNA LSDDVEKLSD AELRAKTEEF KKRVADG---
MS SecA2 ---------- ------MANE SWRTSAYRKR VPKTSSAKPG RLSSKFWKLL GASTERNQAR SLSEVKGAAD FEKKAADLDD EQLTKAAKLL KLEDLAGASD
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....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA -------ENL IPEAFAVVRE ASKRVFGMRH FDVQLLGGMV LNERCIAEMR TGEGKTLTAT LPAYLNALTG KGVHVVTVND YLAQRDAENN RPLFEFLGLT
B. subtilis SecA -------DDL LVEAFAVVRE ASRRVTGMFP FKVQLMGGVA LHDGNIAEMK TGEGKTLTST LPVYLNALTG KGVHVVTVNE YLASRDAEQM GKIFEFLGLT
B. anthracis SecA1 -------DDL LPEAFAVVRE AATRVLGMRP YGVQLMGGIA LHEGNISEMK TGEGKTLTST LPVYLNALTG KGVHVVTVNE YLAQRDANEM GQLHEFLGLT
B. anthracis SecA2 -------DDI KVEAFAVVRE AAKRVLGLRH YDVQLIGGLV LLEGNIAEMP TGEGKTLVSS LPTYVRALEG KGVHVITVND YLAKRDKELI GQVHEFLGLK
S. aureus SecA1 KKQNDYLDKI LPEAYALVRE GSKRVFNMTP YKVQIMGGIA IHKGDIAEMR TGEGKTLTAT MPTYLNALAG RGVHVITVNE YLSSVQSEEM AELYNFLGLT
S. aureus SecA2 ------LDTL LPEAYAVARE ASWRVLGMYP KEVQLIGAIV LHEGNIAEMQ TGEGKTLTAT MPLYLNALSG KGTYLITTND YLAKRDFEEM QPLYEWLGLT
TB SecA1 ----ETLDDL LPEAFAVARE AAWRVLDQRP FDVQVMGAAA LHLGNVAEMK TGEGKTLTCV LPAYLNALAG NGVHIVTVND YLAKRDSEWM GRVHRFLGLQ
TB SecA2 ---------- IPQFLAIARE AAERRTGLRP FDVQLLGALR MLAGDVIEMA TGEGKTLAGA IAAAGYALAG RHVHVVTIND YLARRDAEWM GPLLDAMGLT
MS SecA1 ----EDLDDL LPEAFAVARE AAWRVLNQRH FDVQVMGGAA LHFGNVAEMK TGEGKTLTAV LPSYLNALSG KGVHVVTVND YLARRDSEWM GRVHRFLGLD
MS SecA2 ---------- ITQFLAIARE AAERTTGLRP FDVQLLAALR MLAGDVVEMA TGEGKTLAGA IAAAGYALGG RRVHVITIND YLARRDAEWM GPLLKALGLT
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA VGINLPGMP- ----APAKRE AYAADITYGT NNEYGFDYLR DNMAFSPEER VQRKLHYALV DEVDSILIDE ARTPLIISGP AEDSSEMYKR VNKIIPHLIR
B. subtilis SecA VGLNLNSMS- ----KDEKRE AYAADITYST NNELGFDYLR DNMVLYKEQM VQRPLHFAVI DEVDSILIDE ARTPLIISGQ AAKSTKLYVQ ANAFVRTLKA
B. anthracis SecA1 VGINLNSMS- ----REEKQE AYAADITYST NNELGFDYLR DNMVLYKEQC VQRPLHFAII DEVDSILVDE ARTPLIISGQ AQKSTELYMF ANAFVRTLEN
B. anthracis SecA2 VGLNIPQID- ----PSEKKL AYEADITYGI GTEFGFDYLR DNMAASKNEQ VQRPYHFAII DEIDSVLIDE AKTPLIIAGK KSSSSDLHYL CAKVIKSFQD
S. aureus SecA1 VGLNLNSKT- ----TEEKRE AYAQDITYST NNELGFDYLR DNMVNYSEDR VMRPLHFAII DEVDSILIDE ARTPLIISGE AEKSTSLYTQ ANVFAKMLKQ
S. aureus SecA2 ASLGFVDIVD YEYQKGEKRN IYEHDIIYTT NGRLGFDYLI DNLADSAEGK FLPQLNYGII DEVDSIILDA AQTPLVISGA PRLQSNLFHI VKEFVDTLIE
TB SecA1 VGVILATMT- ----PDERRV AYNADITYGT NNEFGFDYLR DNMAHSLDDL VQRGHHYAIV DEVDSILIDE ARTPLIISGP ADGASNWYTE FARLAPLMEK
TB SecA2 VGWITADST- ----PDERRT AYDRDVTYAS VNEIGFDVLR DQLVTDVNDL VSPNPDVALI DEADSVLVDE ALVPLVLAGT THRETPRLEI IRLVAELVGD
MS SecA1 VGVILSGMT- ----PDERRA AYAADITYGT NNEFGFDYLR DNMAHSVDDM VQRGHNFAIV DEVDSILIDE ARTPLIISGP ADGASHWYQE FARIVPMMEK
MS SecA2 VGWITADST- ----ADERRE AYQCDVTYAS VNEIGFDVLR DQLVTDVADL VSPNPDVALI DEADSVLVDE ALVPLVLAGT SHREQPRVEI IRMVGELEAG
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA QEKEDSETFQ GEGHFSVDEK SRQVN----L TERGLVLIEE LLVKEGIMDE GESLYSPANI -MLMHHVTAA LRAHALFTRD VDYIVKDGEV IIVDEHTGRT
B. subtilis SecA EK-------- ---DYTYDIK TKAVQ----L TEEGMTKAEK AFGID----- --NLFDVKHV - LNHHINQA LKAHVAMQKD VDYVVEDGQV VIVDSFTGRL
B. anthracis SecA1 EK-------- ---DYSFDVK TKNVM----L TEDGITKAEK AFHIE----- --NLFDLKHV -ALLHHINQA LRAHVVMHRD TDYVVQEGEI VIVDQFTGRL
B. anthracis SecA2 TL-------- ---HYTYDAE SKSAS----F TEDGITKIED LFDID----- --NLYDLEHQ -TLYHYMIQA LRAHVAFQCD VDYIVHDEKI LLVDIFTGRV
S. aureus SecA1 DE-------- ---DYKYDEK TKAVH----L TEQGADKAER MFKVE----- --NLYDVQNV -DVISHINTA LRAHVTLQRD VDYMVVDGEV LIVDQFTGRT
S. aureus SecA2 DV-------- ---HFKMKKT KKEIW----L LNQGIEAAQS YFNVE----- --DLYSEQAM -VLVRNINLA LRAQYLFESN VDYFVYNGDI VLIDRITGRM
TB SecA1 DV-------- ---HYEVDLR KRTVG----V HEKGVEFVED QLGID----- --NLYEAANS -PLVSYLNNA LKAKELFSRD KDYIVRDGEV LIVDEFTGRV
TB SecA2 KDADE----- ---YFATDSD NRNVH----L TEHGARKVEK ALGGI----- --DLYSEEHV GTTLTEVNVA LHAHVLLQRD VHYIVRDDAV HLINASRGRI
MS SecA1 DV-------- ---HYEVDLR KRTVGVHVGV HELGVEFVED QLGID----- --NLYEAANS -PLVSYLNNA LKAKELFQRD KDYIVRNGEV LIVDEFTGRV
MS SecA2 K--------- ---HYDTDAE SRNVH----L TEAGARVMEA KLGGI----- --DLYSEEHV GTTLTEINVA LHAHVLLQRD VHYIVRDDAV HLINASRGRI
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....|....| .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . |
E. coli SecA ---------- -- - - MLIKLLTKVF GSRNDRT RR MRKVV IINA MEPEMEKLSD EELKGKTAEF RARLE EVL
B. subtilis SecA ---------- -- - - MLGILNKMF DP TKRT R YEKIANDIDA IRGDYENLSD DALKHKTIEF KERLE GA T
B. anthracis SecA1 ---------- -- - - MIGILKKVF DV NQRQI R MQKTVE IDA LESSIKPLTD EQ KGKTLEF KERLT E V
B. anthracis SecA2 ---------- -- - - MLNSVKKLL GDSQKRKL YEQLV EINN LEEKLSDLSD EE RH TITF KDMLRDG V
S. aureus SecA1 ---------- -- - - -MGFLSKIL DG NNKEIKQ GKLADKVIA LEEKTAILTD EEIRN KQF QT LADIDNV
S. aureus SecA2 ---------- -- - - - MKHKLD VTINELRLKS IRKIVKRINT WSDEVKSYSD DALKQKTIEF KERLASGVDT
TB SecA1 ---------- -- - - - MLSKLL RLGEGR VKR KKVADYVGT LSDDVEKLTD AE RAKTDEF KRRLADQ NP
TB SecA2 MNVHGCPRIA ACRCTDTH GRPAFAYRWF VPKTTRAQPG RLSSRFW LL ASTEKNRS SLADV ASAE YDKE ADLSD KLR A GL NLDD AES D
MS SecA1 ---------- -- - - - MLSKLL RLGEGR VKR RKVADYVNA LSDDVEKLSD E RAKT EF KKRVADG---
MS SecA2 ---------- -- MANE SWRTSAYRKR VPKTSSAKPG LSS FWKLL ASTERNQAR SLSEVKGAAD FEKKAADLDD EQLT A KL KL D AG SD
110 120 130 140 150 160 170 180 190 200
....|....| .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . |
E. coli SecA -------ENL IPEAFAVVR ASKRVFGMRH FDVQLLGGMV LNERCIAEMR TGEGKTLT T LPAYLNALTG KGVHVVTVND YLAQRDAENN RPLFEFLGLT
B. subtilis SecA -------DDL LVEAFAVVRE ASRRVTGMFP FKVQLMGGVA LHDGNIAEMK TGEGKTLTST LPVYLNALTG KGVH VTVNE YLASRDAEQM GKIFEFLGLT
B. anthracis SecA1 -------DDL LPEAFAVVRE AATRVLGMRP YGVQLMGGIA LHE NISEMK TGEGKTLT T LPVYLNALTG KGVH VTVNE YLAQRDANEM GQLHEFLGLT
B. anthracis SecA2 -------DDI KVEAFAVVRE AA RVLGLRH YDVQLIGGLV LLEGNIAEMP TGEGKTLVSS LP YVRALEG KGVHVITVND YLAKRDKELI GQVHEFLGLK
S. aureus SecA1 KKQNDYLDKI LPEAYALVRE GSKRVFNMTP YKVQIMGGIA IHKGDIAEMR TGEG TLT T MP YLNALAG RGVHVITVNE YLSS QSEEM AELYNFLGLT
S. aureus SecA2 ------LDTL LPEAYAVARE ASWRVLGMYP KEVQLIGAIV LHEGNIAEMQ TGEGKTLT T MPLYLNALSG KGTY ITTND YLAKRDFEEM QPLYEWLGLT
TB SecA1 ----ETLDDL LPEAFAVARE AAWRVLDQRP FDVQVMGAAA LHLGNVAEMK TGEGKTLTCV LPAYLNALAG NGVHIVTVND YLAKRDSEWM GRVHRFLGLQ
TB SecA2 ---------- IPQFLAIARE AAERRTGLRP FDVQLLGALR MLAGDVIEM TGEGKTLAGA IAAAGYALAG RHVHVVTIND YLARRDAEWM GPL DAMGLT
MS SecA1 ----EDLDDL LPEAFAVARE AAWRVLNQRH FDVQVMGGAA LH GNVAEMK TGEGKTLT V LPSYLNALSG KGVHVVTVND YLARRDSEWM GRVHRFLGLD
MS SecA2 ---------- ITQFLAIARE AAERTTGLRP FDVQLLAALR MLAGDVVEM TGEGKTLAGA IAAAGYALGG RRVHVITIND YLA RDAEWM GPL KALGLT
210 220 230 240 25 260 270 280 290 300
....|....| .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . |
E. coli SecA VGINLPGMP- ----APAKRE AYAADITYGT NNE GF YLR DNMAFSPEER VQRKLHYALV DE DSI IDE ARTPLIISGP AEDSSEMYKR VNKIIPHLIR
B. subtilis SecA VGLNLNSMS- ----KDEKRE AYAADITYST NNELGF YLR DNMVLYKEQM VQRPLHFAVI DE DSI IDE ARTPLIISGQ AAKS K YVQ AN FVR LKA
B. anthracis SecA1 VGINLN MS- ----REEKQE AYAADITYST NNELGF YLR DNMVLYKEQC VQRPLHFAII DE DSI VDE ARTPLIISGQ AQKS E YMF AN FVR LEN
B. anthracis SecA2 VGLNIPQID- ----PSEKKL AYEADITYGI GTEFGF YLR DNMAASKNEQ VQRPYHFAII DEIDSVLIDE AKTPLIIAGK KSSSSD HYL CA VIK FQD
S. aureus SecA1 VGLNLNSKT- ----TEEKRE AYAQDI YST NNELGF YLR DNMVNYSE R VMRPLHFAII DE DSI IDE ARTPLIISGE AEKS S YTQ ANVFAKMLKQ
S. aureus SecA2 ASLGFVDIVD YEYQK EKRN IYEHDIIYTT GRLGF YLI DNLADSAEGK FLPQ NYGII DEVDSIILDA AQTPLVISGA PRL SN FHI VKEFVDTLIE
TB SecA1 VGVILATMT- ----PDERRV AYNADITYGT NNEFGF YLR DNMAHSLD L VQRGHHYAIV DE DSILIDE ARTPLIISGP ADGASNWYTE FARLAPLMEK
TB SecA2 VGWITADST- ----PDERRT AYDRDVTYAS VNEIGF LR DQLVTDVN L VSPNPDVALI DEADSVLVDE ALVPLVLAGT THRET RLEI IRLVA LVGD
MS SecA1 VGVILSGMT- ----PDERRA AYAADITYGT NNEFGF YLR DNMAHSVD M VQRGHNFAIV DE DSILIDE ARTPLIISGP ADGASHWYQE FARIVPMMEK
MS SecA2 VGWITADST- ----ADERRE AYQCDVTYAS VNEIGF LR DQLVTDVA L VSPNPDVALI DEADSVLVDE ALVPLVLAGT SHREQ R EI IRMVG LEAG
310 320 330 340 350 360 370 380 390 400
....|....| .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . | .. | . |
E. coli SecA QEKEDSETFQ GEGHFSVD K SRQVN----L TERGL LIEE LVKE IMDE GES YSPANI -MLMHHVTA LRAHALFTRD VDYIVKDGEV II EHTGRT
B. subtilis SecA EK-------- ---DYTYDIK TKAVQ----L TEEGMTKAEK AFGID----- --NLFDVKHV ALNHHINQA LKAHVAMQKD VDYVVEDGQV VI SFTGRL
B. anthracis SecA1 EK-------- ---DYSFDVK TKNVM----L TEDGITKAEK AFHIE----- --NLFDLKHV ALLHHINQA LRAHVVM RD TDYVVQEGEI VIV QFTGRL
B. anthracis SecA2 TL-------- ---HYTYDAE SKSAS----F TEDGITKIED LFDI ----- --NLYDLEHQ TLYHYMIQA LRAHVAFQCD VDYIV DEKI LL IFTGRV
S. aureus SecA1 DE-------- ---DYKYDEK TKAVH----L TEQG DKAER MFKVE----- --NLYDVQNV DVISHINTA LRAH TLQRD VDYMVVDGEV LI QFTGRT
S. aureus SecA2 DV-------- ---HFKMKKT KKEIW----L LNQGIEAAQS YFNVE----- --DLYS QAM VLVRNINLA LRAQYLFES VDYFVYNGDI VLI RITGRM
TB SecA1 DV-------- ---HYEVDLR KRTVG----V HE GVEFVED QLGID----- --N YEAANS PLVSYLNN LKAKELFSRD KDYIVRDGEV LIV EFTGRV
TB SecA2 KDADE----- ---YFATDSD NRNVH----L TEHGARKVEK ALGGI----- --D YSEEHV GTTLTEVNVA LHAHV LQRD VHYIVRDDAV HLINASRGRI
MS SecA1 DV-------- ---HYEVDLR KRTVGVHVGV HELGVEF ED QLGID----- --N YEAANS PLVSYLNN LKAKELFQRD KDYIVRNGEV LIV EFTGRV
MS SecA2 K--------- ---HYDTDAE SRNVH----L TEAGARVMEA KLGGI----- --D YSEEHV GTTLTEINVA LHAHV LQRD VHYIVRDDAV HLINASRGRI
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| | | | | | | | | | .| ...| ...|
E. coli SecA ---------- ---------- ---------- ---- MLIKLLTKVF GSRNDRTLRR MR VVNIINA MEPEMEKLSD EELKGKTAEF RA L GEVL
B. subtilis SecA ---------- ---------- ---------- ---- MLGILNKMF DP TKRTLNR YEK A DIDA IRGDYENLSD DALKH TIEF KERL KGATT
B. anthracis SecA1 ---------- ---------- ---------- ---- MIGILKKVF DV NQRQIKR QKTVEQIDA LESSIKPLTD EQLKGKTLEF KERLTKGETV
B. anthracis SecA2 ---------- ---------- ---------- ---- MLNSVKKLL GDSQKRKLKK YEQL QEINN LEE L DLSD E RH TITF KDM R GKTV
S. aureus SecA1 ---------- ---------- ---------- ---- MGFLSKIL DG NNKEIKQ LGKLAD VIA LEEKTA LTD EEIR TKQF QTEL DIDNV
S. aureus SecA2 ---------- ---------- ---------- ---- MKHKLD VTINELRLKS IRKIVKRINT WSD VKSY D DALKQKTIEF KE LA GV T
TB SecA1 ---------- ---------- ---------- ---- MLSKLL RLGEGRMVKR LKKVADYVGT SDDVEKLTD AE RAKTDEF KRRLADQKNP
TB SecA2 MNVHGCPRIA ACRCTDTHPR GRPAFAYRWF VPK TRAQPG LSSRFWRLL GAS EKNRSR SLADV ASAE YDK AADLSD EKLRK AGLL NLDDLAE AD
MS SecA1 ---------- ---------- ---------- ---- MLSKLL RLGEGRMVKR LRKVADYVNA SDDVEKLSD AE RAKTEEF KK ADG---
MS SecA2 ---------- ------MANE SWRTSAYRKR VPKTSS KPG RLS KFW LL GASTERNQAR SL EVKG AD FEKKAADLDD EQLT A KLL KLEDLAGASD
110 120 130 140 150 160 170 180 190 2 0
....|....| ....|....| ....|....| ....|....| | | | | | | | | | .| ...| ...|
E. coli SecA -------ENL IPEAFAVVRE ASKRVFGMRH FDVQLLGGMV LNERCI EM TGEGKTLTAT LPAYLNALTG KGVHVV VND YLAQRDAENN RPLFEFLGLT
B. subtilis SecA -------DDL LVEAFAVVRE ASRRVTGMFP FKVQLMGGVA LHDGNI EMK TGEGKTLTST LPVYLNALTG KGVHVV VNE YLASRDAEQM KIFEFLGLT
B. anthracis SecA1 -------DDL LPEAFAVVRE AATRVLGMRP YGVQLMGGIA LHEGNISEMK TGEGKT TST LPVYLNALTG KGVHVV VNE YLAQRDANEM QLHEFLGLT
B. anthracis SecA2 -------DDI KVEAFAVVRE AAKRVLGLRH YDVQLIGGLV LLEGNI EMP TGEGKT VSS PTYVRALEG KGVHVITVND YLAK DK LI QVHEFLGLK
S. aureus SecA1 KKQNDYLDKI LPEAYALVRE GSKRVFNMTP YKVQIMGGIA IHKGDI EM T EGKTLT MPTYLNALAG RGVHVI VNE YLSSVQSEEM AELYNFLGLT
S. aureus SecA2 ------LDTL LPEAYAVARE ASWRVLGMYP KEVQLIGAIV LHEGNI EMQ TGEGKT TAT MPLYLNALSG KGTYLI TND Y AKRDFEEM QPLYEWLGLT
TB SecA1 ----ETLDDL LPEAFAVARE AAWRVLDQRP FDVQVMGAAA LHLGNV EMK TGEGKT TCV LPAYLNAL G NGVHIV VND YLAKRDSEWM RVHRFLGLQ
TB SecA2 ---------- IPQFLAIARE AAERRTGLRP FDVQLLGALR MLAGDVIEMA TGEGKTLAGA I AAGYAL G RHVHVVT ND YL RRDAEWM GPLLDAMGLT
MS SecA1 ----EDLDDL LPEAFAVARE AAWRVLNQRH FDVQVMGGAA LHFGNV EMK TGEGKT T V LPSYLNALSG KGVHVV VND YLARRDSEWM RVHRFLGLD
MS SecA2 ---------- ITQFLAIARE AAERTTGLRP FDVQLL ALR MLAGDVVEMA TGEGK LAGA I AAGYALGG RRVHVITIND YL RRDAEWM GPLLKALGLT
210 220 230 240 250 260 270 280 290 3 0
....|....| ....|....| ....|....| ....|....| | | | | | | | | | .| ...| ...|
E. coli SecA VGINLPGMP- ----APAKRE AYAADITYGT NNEYGFDYLR DNMAFS EE VQRKLH ALV DEVD ILIDE A TPLIISGP AE SEM KR VNKI PHLIR
B. subtilis SecA VGLNLNSMS- ----KDEKRE AYAADITYST NNELGFDYLR DNMVLYK QM VQRPLHFAVI DE DSILIDE A TPLIISG AAK TKLYVQ ANAFVRTLKA
B. anthracis SecA1 VGINLNSMS- ----REEKQE AYAADITYST NNELGFDYLR DNMVLYK QC VQRPLHFAII DE DSILVDE A TPLIISG AQK TELYMF ANAFVRTLEN
B. anthracis SecA2 VGLNIPQID- ----PSEKKL AYEADITYGI GTEFGFDY R DNMAASKNEQ VQRPYHFAII DEID VLIDE AKTPLIIAGK KSS SDLHYL CAKV KSFQD
S. aureus SecA1 VGLNLNSKT- ----TEEKRE AYAQDITYST NNELGFDYLR DNMVNYS D VMRPLHFAII DE DSILIDE A TPLII GE AEK TSLYTQ ANVFAKMLKQ
S. aureus SecA2 ASLGFVDIVD YEYQKGEKRN IYEHDIIYTT NGRL DYLI DNLADSA GK FLPQLN G I DEV IILDA AQTPLVISGA PR QSN FH VK F DTLIE
TB SecA1 VGVILATMT- ----PDERRV AYNADITYGT NNEFGFDYLR D MAHSLDDL VQR HH AIV DEVD ILIDE A TPLIISGP ADGASNW TE FAR APLMEK
TB SecA2 VGWITADST- ----PDERRT AYDRDVTYAS VNEIGFDVLR DQLVTDVNDL VSPNP ALI DEADS LVDE ALV L LAGT THRET RL I IRLVAELVGD
MS SecA1 VGVILSGMT- ----PDERRA AYAADITYGT NNEFGFDYLR DNMAHSVDDM VQR HNFAIV DEVD ILIDE A TPLIISGP ADGAS WYQE FARIVPMMEK
MS SecA2 VGWITADST- ----ADERRE AYQCDVTYAS VNEIGFDVLR D LVTDV DL VSPNP ALI DEADS LVDE ALV L LAGT SHREQ R I IRMVGELEAG
310 320 330 340 350 360 370 380 390 4 0
....|....| ....|....| ....|....| ....|....| | | | | | | | | | .| ...| ...|
E. coli SecA QEKEDSETFQ GEGHFSVDEK SRQVN----L TERGL LIEE LL KEGIM GES YSPANI -MLMHH TAA LRAHALFTR VDYIVKDGEV IIVDEH GRT
B. subtilis SecA EK-------- ---DYTYDIK TKAVQ----L TEEGMTKAEK AFGI -- --NLFDVKHV -ALNHHINQA LKAHVAMQKD VDYVVE GQV VIVDSFTGRL
B. anthracis SecA1 EK-------- ---DYSFDVK TKNVM----L TEDGITKAEK AFHIE -- --NLFDLKHV -ALLHHINQA LRA VVM RD TDYVVQEGEI VIVDQFTGRL
B. anthracis SecA2 TL-------- ---HYTYDAE SKSAS----F TEDGITKI D LFDID -- --NLYDL HQ - LYHYMIQA LRAHVAFQCD VD IVH EKI LLVDI TGRV
S. aureus SecA1 DE-------- ---DYKYDEK TKAVH----L TEQGADKAER MFKVE -- --NLYDVQNV -D ISHINTA LRAH TLQRD VDYMVV GEV LIVDQFTGRT
S. aureus SecA2 DV-------- ---HFKMKKT KKEIW----L LNQGIEAAQS YFNVE -- --DLYSE AM -VLVRNINLA LRAQYLFESN DYFV GDI VLIDRITGRM
TB SecA1 DV-------- ---HYEVDLR KRTVG----V HEKGVEFVED QLGID -- --NLYEAANS -PLVSYLNNA LKAK LFSRD KDYIVRDGEV LIVDE TGRV
TB SecA2 KDADE----- ---YFATDSD NRNVH----L TEHG RKVEK ALGGI -- --DLYSE HV G TLTEVN A LHAHVLLQRD VHYIVRDD V LINASRGRI
MS SecA1 DV-------- ---HYEVDLR KRTVGVHVGV HELGVEFVED QLGID----- --NLYEAANS -PLVSYLNNA LKAK LFQRD KDYIVR GEV LIVDE TGRV
MS SecA2 K--------- ---HYDTDAE SRNVH----L TEAGARVM A KLGGI -- --DLYSE HV G TLTEINVA LHAHVLLQRD VHYIVRDD V LINASRGRI
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA ---------- ---------- ---------- ---------- MLIKLLTKVF GSRNDRTLRR MRKVVNIINA MEPEMEKLSD EELKGKTAEF RARLEKGEVL
B. subtilis SecA ---------- ---------- ---------- ---------- -MLGILNKMF DP-TKRTLNR YEKIANDIDA IRGDYENLSD DALKHKTIEF KERLEKGATT
B. anthracis SecA1 ---------- ---------- ---------- ---------- -MIGILKKVF DV-NQRQIKR MQKTVEQIDA LESSIKPLTD EQLKGKTLEF KERLTKGETV
B. anthracis SecA2 ---------- ---------- ---------- ---------- -MLNSVKKLL GDSQKRKLKK YEQLVQEINN LEEKLSDLSD EELRHKTITF KDMLRDGKTV
S. aureus SecA1 ---------- ---------- ---------- ---------- --MGFLSKIL DG-NNKEIKQ LGKLADKVIA LEEKTAILTD EEIRNKTKQF QTELADIDNV
S. aureus SecA2 ---------- ---------- ---------- ---------- ----MKHKLD VTINELRLKS IRKIVKRINT WSDEVKSYSD DALKQKTIEF KERLASGVDT
TB SecA1 ---------- ---------- ---------- ---------- ----MLSKLL RLGEGRMVKR LKKVADYVGT LSDDVEKLTD AELRAKTDEF KRRLADQKNP
TB SecA2 MNVHGCPRIA ACRCTDTHPR GRPAFAYRWF VPKTTRAQPG RLSSRFWRLL GASTEKNRSR SLADVTASAE YDKEAADLSD EKLRKAAGLL NLDDLAESAD
MS SecA1 ---------- ---------- ---------- ---------- ----MLSKLL RLGEGRMVKR LRKVADYVNA LSDDVEKLSD AELRAKTEEF KKRVADG---
MS SecA2 ---------- ------MANE SWRTSAYRKR VPKTSSAKPG RLSSKFWKLL GASTERNQAR SLSEVKGAAD FEKKAADLDD EQLTKAAKLL KLEDLAGASD
110 120 130 14 15 160 170 180 190 200
|. ..| ..|....| ....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA -------ENL IPEAFA VRE ASKRVFGMRH FDVQLLGGMV LNERCIAEMR TGEGKTLTAT LPAYLNALTG KGVHVVTVND YLAQRDAENN RPLFEFLGLT
B. subtilis SecA - -----DDL LVEAF VVRE ASRRVTGMFP FKVQLMGGVA LHDGNIAEMK TGEGKTLTST LPVYLNALTG KGVHVVTVNE YLASRDAEQM GKIFEFLGLT
B. anthracis SecA1 - -----DDL LPEAFAV RE AATRV GMRP YGVQLMGGIA LHEGNISEMK TGEGKTLTST LPVYLNALTG KGVHVVTVNE YLAQRDANEM GQLHEFLGLT
B. anthracis SecA2 -------DDI KVEAFAV RE AAKRVLG RH YDVQLIGGLV LLEGNIAEMP TGEGKTLVSS LPTYVRALEG KGVHVITVND YLAKRDKELI GQVHEFLGLK
S. aureus SecA1 KKQ DYLDKI LPEAYAL RE GSKRVFNM P YKVQ MGGIA IHKGDIAEMR TGEGKTLTAT MPTYLNALAG RGVHVITVNE YLSSVQSEEM AELYNFLGLT
S. aureus SecA2 ------LDTL LPEAYAVARE A WR LGMYP KEVQLIGAIV LHEGNIAEMQ TGEGKTLTAT MPLYLNALSG KGTYLITTND YLAKRDFEEM QPLYEWLGLT
TB SecA1 ----ETLDDL LPEAFAVARE AAWR LDQRP FDVQVMGAAA LHLGNVAEMK TGEGKTLTCV LPAYLNALAG NGVHIVTVND YLAKRDSEWM GRVHRFLGLQ
TB SecA2 ---------- IPQFLAIAR AAERRTG RP F VQLLGALR MLAGDVIEM TGEGKTLAGA IAAAGYALAG RHVHVVTIND YLARRDAEWM GPLLDAMGLT
MS SecA1 ----EDLDDL LPEAFAVARE AAWR LNQRH FDVQVMGGAA LHFGNVAEMK TGEGKTLTAV LPSYLNALSG KGVHVVTVND YLARRDSEWM GRVHRFLGLD
MS SecA2 ---------- ITQFL IARE AAERTTG RP F VQLL ALR MLAGDVVEMA TGEGKTLAGA IAAAGYALGG RRVHVITIND YLARRDAEWM GPLLKALGLT
210 22 23 240 25 260 270 280 290 300
|. ..| ..|....| ....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA VGIN P MP- ----APAKRE AYAADI YGT NN YGFDYLR DNMAFSPEER VQRKLHYALV DEVDSILIDE ARTPLIISGP AEDSSEMYKR VNKIIPHLIR
B. subtilis SecA VGLN NS S- ----KDEKRE AYAADI YST NN LGFDYLR DNMVLYKEQM VQRPLHFAVI DEVDSILIDE ARTPLIISGQ AAKSTKLYVQ ANAFVRTLKA
B. anthracis SecA1 VGIN S S- ----REEKQE AYAADI YST NN LGFDYLR DNMVLYKEQC VQRPLHFAII DEVDSILVDE ARTPLIISGQ AQKSTELYMF ANAFVRTLEN
B. anthracis SecA2 VGLNIPQ D- ----PSE KL AYEAD YGI GT GFDYLR DNMAASKNEQ VQRPYHFAII DEIDSVLIDE AKTPLIIAGK KSSSSDLHYL CAKVIKSFQD
S. aureus SecA1 VGLN NSKT- ----TEEKRE AYA D YST NNELGFDYLR DNMVNYSEDR VMRPLHFAII DEVDSILIDE ARTPLIISGE AEKSTSLYTQ ANVFAKMLKQ
S. aureus SecA2 SLG VDIVD YEYQK EKRN IYEHD IYTT NGRLGFDYLI DNLADSAEGK FLPQLNYGII DEVDSIILDA AQTPLVISGA PRLQSNLFHI VKEFVDTLIE
TB Sec 1 VGVI T T- ----PDERRV AYNADI YGT NNE GFDYLR DNMAHSLDD VQRGHHYAIV DEVDSILIDE ARTPLIISGP ADGASNWYTE FARLAPLMEK
TB SecA2 V WI DST- ----PDERRT AYDRD YAS VNEIGFDVLR DQLVTDVND VSPNPDVALI DEADSVLVDE ALVPLVLAGT THRETPRLEI IRLVAELVGD
MS Sec 1 VGVI T- ----PDERRA AYAADI YGT NNE GFDYLR DNMAHSVDDM VQRGHNFAIV DEVDSILIDE ARTPLIISGP ADGASHWYQE FARIVPMMEK
MS SecA2 V WI ADST- ----ADERRE AYQCDV YAS VNEIGFDVLR DQLVTDVAD VSPNPDVALI DEADSVLVDE ALVPLVLAGT SHREQPRVEI IRMVGELEAG
310 32 33 340 35 360 370 380 390 400
|. ..| ..|....| ....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli Sec E DS TFQ GEGHFSVDEK S QVN----L T RGLVLIEE LLVKEGIMDE GESLYSPANI -MLMHHVTAA LRAHALFTRD VDYIVKDGEV IIVDEHTGRT
B. subtilis SecA EK-------- ---DYTYDIK TKAVQ----L TEEGMT EK AFGID----- --NLFDVKHV -ALNHHINQA LKAHVAMQKD VDYVVEDGQV VIVDSFTGRL
B. anthracis SecA1 EK-------- ---DYSFDVK TKNVM----L TEDGITKAEK AFHIE----- --NLFDLKHV -ALLHHINQA LRAHVVMHRD TDYVVQEGEI VIVDQFTGRL
B. anthracis ecA2 TL-------- ---HYTY A S AS----F TEDGITKIED LFDID----- --NLYDLEHQ -TLYHYMIQA LRAHVAFQCD VDYIVHDEKI LLVDIFTGRV
S. aureus Sec 1 E-------- ---DYKYDEK TKAVH----L T QGAD AER MFKVE----- --NLYDVQNV -DVISHINTA LRAHVTLQRD VDYMVVDGEV LIVDQFTGRT
S. aureus SecA2 V-------- ---HFKMKKT KKEIW----L LNQGIEAAQS YFNVE----- --DLYSEQAM -VLVRNINLA LRAQYLFESN VDYFVYNGDI VLIDRITGRM
TB SecA1 V-------- ---HYEVDLR K VG----V HEKGVEFVED QLGID----- --NLYEAANS -PLVSYLNNA LKAKELFSRD KDYIVRDGEV LIVDEFTGRV
TB SecA2 KDADE----- ---YFAT SD NRNVH----L EHGARKVEK ALGGI----- --DLYSEEHV GTTLTEVNVA LHAHVLLQRD VHYIVRDDAV HLINASRGRI
MS SecA1 V-------- ---HYEVDLR K VGVHV V HELGVEFVED QLGID----- --NLYEAANS -PLVSYLNNA LKAKELFQRD KDYIVRNGEV LIVDEFTGRV
MS SecA2 K--------- ---HYDTDA SRNVH----L TEAGARVMEA KLGGI----- --DLYSEEHV GTTLTEINVA LHAHVLLQRD VHYIVRDDAV HLINASRGRI
410 420 430 440 450 460 470 480 490 500
|.. .| ....|....| ....| | | | |....| ....|....| .| .|....| ....|....| ....| .|
E. coli SecA MQGR WSDGL HQAVEAKEGV QIQNENQTLA SI FQNYFR YEK GMTGT ADTEAFEFSS IYKLDTVVVP TNRPMIRKDL PDLVYMTEAE KIQAIIEDIK
B. subtilis SecA MKGRR SEGL HQAIEAKEGL EIQNESMTLA I FQNYFRM YEK GMTGT AKTEEEEFRN IYN QVVTIP TNRPVVRDDR PDLIYRTMEG KFKAVAEDVA
B. anthracis SecA1 MKGRR SEGL HQAIEAKEGV EIQNESMTLA I F NYFRM YEK SGMTGT AKTEEEEFRN IYN NVIVIP TNKPIIRDDR ADLIFKSMKG KFNAVVEDIV
B. anthracis SecA2 MDGRSLSDGL HQALEAKEGL EITEENQTQA S TI NFFRM YPA SGMTGT AKTEEKEFN VYNMEVMPIP TNRPIIREDK KDVVYVTADA KYKAVREDVL
S. aureus SecA1 M GRRFSEGL HQAIEAKEGV QIQNESKTMA SI FQN FRM YNK AGMTGT AKTEEEEFRN IYN TVTQIP TNKPVQRNDK SDLIYISQKG KFDAVVEDVV
S. aureus SecA2 L GTKL GL HQAIEAKEGM EVSTDKSVMA I FQN FK FESFSGMTAT GKLGESEFFD LYSKIVVQVP TDKAIQRIDE PDKVFRSVDE KNIAMIHDI
TB Sec 1 LIGRR NEG HQAIEAKEHV EI AENQTLA ITLQNYFR YDK GMTGT AQTEAAELHE IYKLGVVSIP TNMPMIREDQ SDLIYKTEEA KYIAVVDDVA
TB Sec 2 Q QRWPDGL QA VEAKEGI ETTE VLD TITVQ INR Y TVCGMTGT ALAAGEQL Q FYQLGVSPIP PNKPNIREDE ADRVYITTAA KNDGIVEHIT
MS Sec 1 LMGRR NEG HQAIEAKERV EI AENQTLA ITLQNYFR Y K SGMTGT AETEAAELHE IYKLGVVPIP TNKPMVRQDQ SDLIYKTEEA KFLAVVDDVA
S Sec 2 S QRWPDGL QA VEAKEGI ETTE VLD TITVQ NR YPRVCGMTGT ALAAGEQL Q FYKLGVSPIP PNTPNIRKDE PDRVYITAAA KIDAIVEHIA
510 520 530 540 550 560 570 580 590 600
|.. .| ....|....| ....| | | | |....| ....|....| .| .|....| ....|....| ....| .|
E. coli SecA ERTAKGQ VL VGTI IEKSE LVSNELT AG IKHNVLNAKF HAN AAIVAQ AGYPAAVTIA TNMAGRGTD V GG------ ---------S WQ EVA LEN
B. subtilis Sec QRY TGQPVL VGTVAVET E LISKLLKNKG IPHQVLNAKN HEREAQIIEE AGQKGAVTIA TNMAGRGTDI K G------- ---------- ----------
B. anthracis SecA1 NRHKQGQPVL VGTVAIETSE LISKMLTRKG VRHNILNAKN HAREADIIAE AGMKGAVTIA TN AGRGTDI K G------- ---------- ----------
B. anthracis SecA2 KH KQGRPIL IGTMSILQSE TVARYLDEAN ITYQLLNA AEQEADLIAT AGQKGQITIA TNMAGRGTD LLG------- ---------- ----------
S. aureus SecA1 EKHKAGQPVL LGTVAVETSE YISNLLKKRG IRHDVLN N HER AEIVAG AGQKGAVTIA TNMAGRGTDI K G------- ---------- ----------
S. aureus SecA2 ELH TGRPVL LITRTAEAAE YFSK F MD IPNNLLIAQN VAKEAQMIAE AGQIGSMTVA TSMAGRGTDI K G------- ---------- ----------
TB SecA1 ERYAKGQPVL IGTTSVERSE YLSRQFTKRR IPHNVLN KY HEQEATIIAV AGRRGGVTVA TNMAGRGTDI VLGGNVDFLT DQRLRERGLD PVETPEEY A
TB SecA2 EVHQRGQPVL VGTRDVAESE ELHERLVRRG VP V N KN DA EARVIAE AGKYGAVTVS TQMAGRGTDI RL GS----- ---------- ----------
MS SecA1 ERHAKGQPVL IGTTSVERSE YLSKMLTKRR VPHNVLNAKY HEQEANIIAE AGRRGAVTVA TNMAGRGTDI VLGGNVDFLA DKRLRERGLD PVETPEEY A
MS SecA2 EVHKTGQPVL VGTHDVAESE ELHEKLLKAG VP V LNAKN DA EAAVIAE AGKLGAVTVS TQMAGRGTDI RLG SD---- ---------- ----------
610 620 630 640 650 660 670 680 690 700
|.. .| ....|....| ....| | | | |....| ....|....| .| .|....| ....|....| ....|....|
E. coli SecA PTAEQIEKIK ADWQVRHDAV LAAG L IIG TERHESRRID NQLRGRSGRQ GDAGSSRFYL SM DALMRIF ASDRVSGMMR KLGMKPGEAI EH----PWVT
B. subtilis SecA - --- -------EGV KELGGLAVVG TERHESRRID LRGRSGRQ GDPGITQFYL SMEDELMRRF GAERTMAMLD RFGMDDSTPI QS----KMVS
B. anthracis SecA1 - --- -------DDI KNIG AV G TERHESRRID LRGRAGRQ GDPGVTQFYL SM DELMRRF GSDNMKAMMD RLGMDDSQPI ES----KMVS
B. anthracis SecA2 - --- -------EGV HELGGL VIG TERHESRRVD N LKGRAGRQ GDPGSSQFFL SLEDEM KRF AQEEVEKLTK SLKTDETGLI LT----SKVH
S. aureus SecA1 - --- -------EGV EELGGLAV G TERHESRRID QLRGRSGRQ GDKGDSRFYL SLQDE MIRF GSERLQKMMS RLGLDDSTPI ES----KMVS
S. aureus SecA2 - --- -------EGV EALGGLAV I HEHMENS VD QLRGRSGRQ GDPGSSCIYI SL DYLVKRW SDSNLAENNQ LYSLDAQRLS QSNLFNRKVK
TB SecA1 AWHS LPIVK EEASKEAKEV IEAGGLYV G TERHESRRID QLRGRSGRQ GDPGESRFYL SLGDE MRRF N AALETLLT RLNLPDDVPI EA----KMVT
TB Sec 2 ----- --DEADHDRV AELGG HV G TGR H ER D QLRGRAGRQ GDPGSSVFFS SWEDDVVAAN LDHNKLPMAT D---ENGRIV SP-----RTG
MS SecA1 AWHEV PQVK AECAKEAEQV IEAGGLYV G TERHESRRID QLRGRSGRQ GDPGESRFYL SLGDE MRRF N ATLETLLT RLNLPDDVPI EA----KMVS
MS SecA2 ----- V GDDDAEKKKV AELGG HVVG TGR H ER D QLRGRAGRQ GDPGSSVFFS SWEDDVVAAH LE SKLPMET DPDAGDGRII AP-----RAA
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
E. coli SecA KAIANAQRKV ESRNFDIRKQ LLEYDDVAND QRRAIYSQRN ELLDVS-DVS ETINSIREDV FKATID-AYI PPQSLEEMWD IPGLQERLKN DFDL-----D
B. subtilis SecA RAVESSQKRV EGNNFDSRKQ LLQYDDVLRQ QREVIYKQRF EVIDSE-NLR EIVENMIKSS LERAIA-AYT PREELPEEWK LDGLVDLINT TYLD-----E
B. anthracis SecA1 RAVESAQKRV EGNNYDARKQ LLQYDDVLRQ QREVIYKQRQ EVMESE-NLR GIIEGMMKST VERAVA-LHT -QEEIEEDWN IKGLVDYLNT NLLQ-----E
B. anthracis SecA2 DFVNRTQLIC EGSHFSMREY NLKLDDVIND QRNVIYKLRN NLLQEDTNMI EIIIPMIDHA VEAISK-QYL VEGMLPEEWD FASLTASLNE ILSV------
S. aureus SecA1 RAVESAQKRV EGNNFDARKR ILEYDEVLRK QREIIYNERN SIIDEE-DSS QVVDAMLRST LQRSIN-YYI NTADDEPEYQ P--FIDYIND IFLQ-----E
S. aureus SecA2 QIVVKAQRIS EEQGVKAREM ANEFEKSISI QRDLVYEERN RVLEIDDAEN QDFKALAKDV FEMFVNEEKV LTKSRVVEYI YQNLSFQFNK DVAC------
TB SecA1 RAIKSAQTQV EQQNFEVRKN VLKYDEVMNQ QRKVIYAERR RILEGE-NLK DQALDMVRDV ITAYVD-GAT -GEGYAEDWD LDALWTALKT LYPVGITADS
TB SecA2 SLLDHAQRVA EGRLLDVHAN TWRYNQLIAQ QRAIIVERRN TLLRTV---- ---------- ---------- ---------- ---------- ----------
MS SecA1 RAIKSAQTQV EQQNFEVRKN VLKYDEVMNQ QRKVIYAERR RILEGE-NLA EQAHKMLVDV ITAYVD-GAT -AEGYAEDWD LETLWTALKT LYPVGIDHRD
MS SecA2 SLLDHAQRVA EGRLLDVHAN TWRYNQLIAQ QRAIIVERRE TLLRTD---- ---------- ---------- ---------- ---------- ----------
410 420 430 440 450 460 470 480 490 500
. .|....| ....|....| . | . .| ....|....| ....| .| .|....| ....|....| ....|....|
E. coli SecA MQGRRWSDGL HQAVEAKEGV QIQNENQTLA SITFQNYF L YEKLAGMTGT ADTEAF FSS IYKLDTVVVP NRPMIRKDL PDLVYMTEAE KIQAIIEDIK
B. subtilis SecA MKGRRYSEGL HQAIEAKEGL EIQNESMT A TITFQNYFRM YEKLAGMTGT AKTEEEEFRN IYNMQVVTIP NRPVVRDDR PDLIYRTMEG KFKAVAEDVA
B. anthracis SecA1 MKGRRYSEGL HQAIEAKEGV EIQNESMTLA TITFQNYFRM YEKLSGMTGT AKTEEE FRN IYNMNVIVIP NKPIIRDDR ADLIFKSMKG KFNAVVEDIV
B. anthracis SecA2 MDGRSLSDGL HQALEAKEGL EITEENQTQA SITIQNFFRM YPALSGMTGT AKTEEK FNR VYNMEVMPIP NRPIIREDK KDVVYVTADA KYKAVREDVL
S. aureus SecA1 MPGRRFSEGL HQAIEAKEGV QIQNESKT A SITFQNYFRM YNKLAGMTGT AKTEEE FRN YNMTVTQIP NKPVQRNDK SDLIYISQKG KFDAVVEDVV
S. aureus SecA2 LPGTKLQAGL HQAIEAKEGM EVSTDKSVMA TITFQNLFKL FESFSGMTAT GKLGESEFFD L KIVVQVP DKAIQRIDE PDKVFRSVDE KNIAMIHDIV
TB SecA1 LIGRRYNEGM HQAIEAKEHV EIKAENQTLA TIT QNYFRL YDKLAGMTGT AQTEAAELHE IYKLGVVSIP NMPMIREDQ SDLIYKTEEA KYIAVVDDVA
TB SecA2 AQLQRWPDGL QAAVEAKEGI ETTETGEVLD TITVQALINR YATVCGMTGT AL AGEQLRQ FYQLGVSPIP PNKPNIREDE ADRVYITTAA KNDGIVEHIT
MS SecA1 LMGRRYNEGM HQAIEAKERV EIKAENQTLA TIT QNYFRL YDKLSGMTGT AETEAAELHE IYKLGVVPIP NKPMVRQDQ SDLIYKTEEA KFLAVVDDVA
MS SecA2 ASLQRWPDGL QAAVEAKEGI ETTETGEVLD TITVQALINR YPRVCGMTGT AL AGEQLRQ FYKLGVSPIP PNTPNIRKDE PDRVYITAAA KIDAIVEHIA
510 520 530 540 550 560 570 580 590 600
.|....| ....|....| . | . .| ....|....| ....| .| .|....| ....|....| ....|....|
E. coli Sec ERTAKGQPVL VGTISIEKSE VSNELTKAG KHNVLNAKF HANEAAIVAQ AGYPAAVTIA NMAGRGTDI VLGG------ ---------S WQAEVAALEN
B. subtilis SecA QRYMTGQPVL VGTVAVETSE LISKLLKNK PHQVLNAKN HEREAQIIEE AGQKGAVTIA NMAGRGTDI KLG------- ---------- ----------
B. anthracis SecA1 NRHKQGQPVL VGTVAIETSE LISKMLTRK VRHNILNAKN HAREADIIAE AGMKGAVTIA NMAGRGTDI KLG------- ---------- ----------
B. anthracis SecA2 KHNKQGRPIL GTMSILQSE TVARYLDEAN TYQLLNAKS AEQEADLIAT AGQKGQITIA NMAGRGTDI LLG------- ---------- ----------
S. aureus SecA1 EKHKAGQPVL LGTVAVETSE YISNLLKKR RHDVLNAKN HEREAEIVAG AGQKGAVTIA NMAGRGTDI KLG------- ---------- ----------
. aureus SecA2 ELHETGRPVL LITRTAEAAE YFSK LFQMD PNNLLIAQN VAKEAQMIAE AGQIGSM VA SMAGRGTDI KLG------- ---------- ----------
B Sec 1 ERY KGQPVL IGTTSVERSE YLSRQFTKRR IPHNVLNAKY HEQEATIIAV AGRRGGVTVA NMAGRGTDI VLGGNVDFLT DQRLRERGLD PVETPEEYEA
TB SecA2 VHQ GQPVL VGTRDVAESE ELHE LVRR PAVVLNAKN DAEEARVIAE AGKYGAVTVS QMAGRGTDI RLGGS----- ---------- ----------
MS Sec 1 ERH KGQPVL IGTTSVERSE YLSKMLTKRR PHNVLNAKY HEQEANIIAE AGRRGAVTVA NMAGRGTDI VLGGNVDFLA DKRLRERGLD PVETPEEYEA
MS SecA2 EVHKTGQPVL VGTHDVAESE ELHEKLLK PAVVLNAKN DAEEAAVIAE AGKLGAVTVS QMAGRGTDI RLGGSD---- ---------- ----------
610 620 630 640 650 66 670 680 690 700
.|.. | .. | . | . | . .| .. |. | . | .| .|....| ....|....| ....|....|
. coli SecA PT QIEKIK ADWQVRHDAV LAAGGLHIIG TERHESRRID NQLRGRSGRQ GDAGSS FY SMEDALMRIF ASD VSGMMR KLGMKPGEAI EH----PWVT
B. subtilis SecA ---------- ------- GV KELGGLAVVG TERHESRRID NQLRGRSGRQ GDPGITQFY SMEDELMRRF GAERTMAMLD RFGMDDSTPI QS----KMVS
B. anthracis ecA1 ---------- -------DDI KN G-LAVIG TERHESRRID NQLRGRAGRQ GDPGVTQFY SMEDELMRRF GSDNMKAMMD RLGMDDSQPI ES----KMVS
B. anthracis SecA2 ---------- -------EGV HELGGLHVIG TERHESRRVD NQLKGRAGRQ GDPGSSQFF SLEDEMLKRF AQEEVEKLTK SLKTDETGLI LT----SKVH
S. aureus SecA1 ---------- ------- GV EELGGLAVIG TERHESRRID DQLRGRSGRQ GDKGDS FY SLQDELMIRF GSERLQKMMS RLGLDDSTPI ES----KMVS
S. aureus ecA2 ---------- -------EGV EA GGLAVII HEHMENSRVD RQLRGRSGRQ GDPGSSCIY SLDDYLVKRW SDSNLAENNQ LYSLDAQRLS QSNLFNRKVK
TB SecA1 AWHSE PIVK E SK K V IEAGGLYVLG TERHESRRID NQLRGRSGRQ GDPGES FY SL DELMRRF NGAALETLLT RLNLPDDVPI EA----KMVT
TB SecA2 ---------- --DE DHDRV AELGGLHVVG TGRHHTERLD NQL GRAGRQ GDPGSS FFS SWEDDVVAAN LDHNKLPMAT D---ENGRIV SP-----RTG
MS SecA1 AWHEV PQVK AECAK EQV IEAGGLYVLG TERHESRRID NQLRGRSGRQ GDPGES FY SL DELMRRF NGATLETLLT RLNLPDDVPI EA----KMVS
MS SecA2 ---------V GDDD EKKKV AELGGLHVVG TGRHHTERLD NQL GRAGRQ GDPGSS FFS SWEDDVVAAH LERSKLPMET DPDAGDGRII AP-----RAA
710 720 730 740 750 7 770 780 790 800
.|.. | .. | . | . | . .| .. |. | . | .| .|....| ....|....| ....|....|
. coli SecA KA AQRK ES NFDIRKQ L EYDDVAND QRRAIYSQRN ELLDVS DVS ETINSI EDV KATID-AYI PPQSLEEMWD IPGLQERLKN DFDL-----D
B. subtilis SecA RAV SSQKRV GNNFDSRKQ LLQYDDVLRQ QREVIYKQRF EVIDSE NLR EIVENMIKSS LERAIA-AYT PREELPEEWK LDGLVDLINT TYLD-----E
B. anthracis Sec 1 RAVESAQKRV GNNYDARKQ LLQYDDVLRQ QREVIYKQRQ EVMESE NLR GIIEGMMKST VE AVA-LHT -Q EIEEDWN IKGLVDYLNT NLLQ-----E
B. anthracis SecA2 D VNRTQLIC EGSHFSMREY NLKL DVIND QRNVIYKLRN NLLQEDTNMI EIIIPMID A VEAISK-QYL V GMLPEEWD FASLTASLNE ILSV------
S. aureus Sec 1 RAV SAQKR EGNNFDARKR ILEYDEVLRK QREIIYNERN SIIDEE DSS QVVDAMLRST SIN- YI NTADDEPEYQ P--FIDYIND IFLQ-----E
S. aureus Sec 2 QI V AQRIS EQ AREM NEFEKSISI QRDLVYEERN RVLEIDDAEN QDFKA AKDV MFVNEEK LTKSRVVEYI YQNLSFQFNK DVAC------
TB Sec 1 RAI SAQ QV EQQN EVR N VLKY EVMNQ QRKVIYAERR RILEGE-NLK DQALDMVRDV ITAYVD-GAT - GYAEDWD LDALWTALKT LYPVGITADS
TB SecA2 SLL HAQ A GRLLDVHAN TWRYNQLIAQ QRAIIVERRN TLLRTV - ---------- ---------- ---------- ----------
MS Sec 1 RAI SAQTQV QN EVRKN VLKY EVMNQ QRKVIYAERR RILEGE-NLA EQAHKMLVDV ITAYVD-GAT -A GYAEDWD LETLWTALKT LYPVGIDHRD
MS ecA2 SLL HAQR A GRLLDVH N TWRYNQLIAQ QRAIIVERRE TLLRTD - ---------- ---------- ---------- ----------
410 420 430 440 450 460 47 480 490 500
| | | | . |. | . .| .|
E. coli SecA QGRRWSDGL HQAVEA EG QIQNENQ A SITFQNYFRL YE LAGMTGT DTEAFEFSS IYKLDTVVVP NRPMIRKDL PDLVYMTEAE KIQ IIEDIK
B. subtilis SecA K RRYSEGL HQAIEAKEGL IQNESM A TITFQ YFRM YE LAGMTGT AKTEEEEFRN IYNMQVVTIP NRPVVRDDR PDLIYRTME KFK AEDVA
B. anthracis SecA1 K RRYSEGL HQA EAKEG IQN SMTLA TITFQNYFRM YE L GMTG AKTEEEEFRN IYNM IVIP N PIIRDDR ADLIFKS KFN VEDIV
B. anthracis SecA2 DGRSLSDGL HQA EAKEG ITEENQTQA SITIQNFFRM YP LSGM GT AKTEEKEFNR VYN EVMPI NRPIIREDK KDVVYVTADA KYK VREDVL
S. aureus SecA1 MP RRFSEGL HQAIE KEGV QIQNES TMA SITFQNYFRM YNKLAGMTG AKTEEEEFRN YNMTVTQIP N PVQRNDK SDLIYIS KFD VVEDVV
S. aureus SecA2 LPGT LQAGL HQAIEA EGM E STD SVMA T TFQNLFKL FE FSGMTAT G LGESEFFD YSKIVVQ P DKAIQRIDE PDKVFRSVDE KNI MIHDIV
TB SecA1 IGRRYNE M HQAIEA EHV EIK NQ A TITLQNYFRL YDKLAGMTG AQTEA ELH IYKLG VSIP NMPMIREDQ SDLIYKTEEA KYI VDDVA
TB SecA2 AQLQR PDGL QAAVE KEGI TTE GEV D TITVQA N Y TVCGMTGT ALAAG QLRQ FYQLG SPIP PN PNIR DE ADRV ITTAA KNDGIVEHIT
MS SecA1 MGRRYNEGM HQAIEA E V EIK NQT A TITLQNYFRL YDKLSGMTGT AETEA ELH IY LG VPIP N PMVR DQ SDLIYKTEEA KFL VDDVA
MS SecA2 A LQR PDGL QAAVE KEGI TTE EV D TITVQA N YPRVCGMTGT ALAAG QLRQ FYKLG SPIP PNTPNIRKDE PDRV ITAAA KIDA VEHIA
1 52 530 540 550 560 57 580 590 600
| | | | . |. | . . .|
E. coli SecA E TAKGQPVL V TISIEKSE LVSNE KAG IK N F H NE VAQ GYPAAVTIA T GRGTDI LGG------ --------- WQAEVAALEN
B. subtilis SecA Q YMTGQPVL V TVA ETS LI K K KG IP Q N HERE Q IEE AGQKGAVTIA T AGRGTDI KLG------- ---------- ----------
B. anthracis SecA1 N HK GQPVL V TVAIETS LI KM RKG VR NI N H RE IAE AGMKGAVTIA T AGRGTDI KLG------- ---------- ----------
B. anthracis SecA2 KHNK GRPI I TMS LQ E TV RYLD AN TYQLLN KS AEQ LIA A QKGQITIA T GRGTDI LLG------- ---------- ----------
S. aureus SecA1 E HKAGQPVL L TVAVET I N LKKRG IR DV HEREAE VAG AGQKGAVTIA AGRGT I KLG------- ---------- ----------
S. aureus SecA2 ELHETGRPVL L R AE AE FS L QMD I NL I QN V AQM AE AGQIGSMTVA TSM GRGTDI K G------- ---------- ----------
TB SecA1 E YAKGQPVL I TTS ERSE SRQF KRR IP N KY HEQE T IAV GRRGGVTVA T G GT I LG NVDF T DQ LRERGLD PVETPEEYEA
TB SecA2 EVHQRGQPV VGTRD ESE E H VRR LN KN D EEAR IAE AGKYG VTVS T MAGR T I RLGGS----- ---------- ----------
MS SecA1 E HAKGQPVL I TTS ERSE SKM KRR VP N KY HEQE N IAE GRRGAVTVA T G GT I LG NVDF A DK LRERG D PVETPEEYEA
MS SecA2 EVHKTGQPV VGT DV ESE E H K K VLN KN D EEA IAE AGK G VTVS T MAGR T I RLGGS ---- ---------- ----------
61 2 630 640 650 660 67 680 690 700
| | | | . |. | . . .|
E. coli SecA PT KIK WQVRHDAV LAAGG I G TERHE RR NQLRGRSG Q GDAG RF L SME ALM IF ASDRV GMMR KLGMKPGE I EH----PWVT
B. subtilis SecA ---------- -------E V KE GG AV G TERHE RR NQLRGRSGR DPG QF L SMEDELMRRF GAERTMAMLD RFGMDDSTPI QS --KMVS
B. anthracis SecA1 ---------- -------DDI KNIG AVIG TERHE RRI NQLRGRAGRQ DPGV QF L SMED LMRRF GSDNMKA MD RLGMDDS PI ES --KMVS
B. anthracis SecA2 ---------- -------E V HE GG V G TERHE RRV NQLKGRAGR DPG QFFL SLE EMLKRF AQEEVEK TK SLKTD TGLI LT --SKVH
S. aureus SecA1 ---------- -------E V GG AV G TERHE RR DQLRGRSGR DKGDSRF L S QD LMIRF GSERLQKMMS RLGLDDS PI ES --KMVS
S. aureus SecA2 ---------- -------E V A GG AV HEHMEN R QLRGRSGR DPGS CIYI LDDYLVKRW SDS LAENNQ LYSLDAQRLS QSNLFNRKVK
TB SecA1 AWHSE P VK EEASKE KEV IEAG YVLG TE HE RR NQLRGRSGRQ DP E RF L S DELMRRF NGAAL T LT RLN P D PI ----KMVT
TB SecA2 ---------- --DEADHDRV AE GG H G TGRHHTERL NQ RG AGRQ DPGS VFFS SWED VV AN LDH KLPMA D NGRIV SP - TG
MS SecA1 AWH VLPQVK ECAKE EQV IEAG YVLG TE HE RR NQLRGRSGRQ DP E RF L S DELMRRF NGATL T LT RLN PDD PI ----KMVS
MS SecA2 --------- G DDAEKKKV AE GG H G TGRHHTERL NQ RG AGRQ DPGS VFFS SWED VV AH LE SKLPME DPDAGDGRII AP - AA
710 720 730 740 750 760 770 780 790 800
... |. ..| ....|....| ....|....| ....|....| ....|....| . |....| ....|....| ....|... | . | ..|....|
E. coli SecA KAIANAQRKV RNFDIRKQ L YDDV ND QRR IYSQRN E LDVS-D S ETINSIREDV FKAT D-AYI PPQSLEEMWD IPGLQERLKN DFDL-----D
B. subtilis Sec R V SSQ RV EGNNF R Q L QYDDVLRQ QRE IYKQRF EVIDSE-NLR EIVENMIKSS LERAIA-AYT PREELPEEWK LDGLVDLINT TYLD-----E
B. anthracis SecA1 R V SAQ RV EGNNYDARKQ L QYDDV RQ QRE IYKQR EVMES -NL GIIEGMMKST VERAVA-LHT -QEEIEEDWN IKGLVDYLNT NLLQ-----E
B. anthracis SecA2 DFVNRTQL C EGS FSMREY N KLDDVIND QRN IYKLRN N LQE TNMI EIIIPMI HA VEAISK-QYL VEGMLPEEWD FAS TASLNE ILS ------
S. aureus SecA1 RAVESAQKRV EGNNFDARKR ILEYDEVLRK QREIIYNERN SIIDEE-DSS QVVDAMLRST LQRSIN-YYI NTADDEPEYQ P--F DYIND IFLQ-----E
S. aureus SecA2 QIVVKAQRIS EEQGVKAREM ANEFEKSISI QRDLVYEERN RVLEIDDAEN QDFKALAKDV FEMFVNEEKV LTKSRVVEYI Y N F F K DVAC------
TB SecA1 RAIKSAQTQV EQQNFEVRKN VLK DEVMNQ QRKVIYAERR RILEGE-NLK DQALDMVRDV ITAYVD-GAT -GEGYAEDWD L ALWTALKT LYP GITADS
TB SecA2 SLLDHAQRVA EGRLLDVHAN TWRYNQLIAQ QRAIIVERRN TLLRTV---- ---------- ---------- ------- -------- --------
MS SecA1 RAIKSAQTQV EQQNFEVRKN VLK DEVMNQ QRKVIYAERR RILEGE-NLA QAHKMLVDV ITAYVD-GAT -AEGYAEDWD LETLWTALKT LYP GIDHRD
MS SecA2 SLLDHAQRVA EGRLLDVHAN TWRYNQLIAQ QRAIIVERRE TLLRTD---- ---------- ---------- ---------- -------- --------
41 42 43 4 0 450 460 470 480 490 50
....|....| ....|....| ....|....| ....| . | ....|....| . . . ..| | . | . | ....
ecA MQGRRWSDGL HQAVE KEGV QIQNE QTLA SITFQNYFRL YEKLAG T T ADT AFEF IY LDTV P T RPMIRKDL PDLVYMTEAE KIQAI EDIK
is SecA MKGRRYSEGL HQAIEAKEGL EIQNESMTLA TITFQNYFR YEKLAGM T AK E FRN IY MQV TIP RPV RD R PDLIYRTMEG KFKA AEDV
cis SecA1 MKGRRYSEGL HQAIEAKEGV EIQNESMTLA TITFQNYFRM YEKL GMT T AK E FRN IYNMNV VIP T KPI RD R ADLIFKSMKG KFNA EDIV
cis SecA2 MDGRSLSDGL HQALEAKEGL EITEENQTQA SITI N RM YP LSGMT T AKT KEFN VYNMEVMPIP T RPI R DK KDV YVTADA KYKA REDVL
 SecA1 MP RRFSEGL HQAIEAKEGV QIQNESKTMA SITFQN FRM YNKLAGMTGT AK FR IYNMTVTQ P T KPVQRNDK SDLIYISQKG KFDA EDVV
 SecA2 LPGTKLQAGL HQAIEAKEGM EVS DKSVMA TITFQNLFKL FESFSGMTAT GKLG SE D YSKIV QVP DKAIQRID PDKVFRSVDE KNIAM HDIV
LIGRRYNEGM HQAIEAKEHV EIKAENQTLA TITLQNYFRL YDKLAGMTG AQT A E HE IY V SIP T MPMIR DQ SDLIYKTE A KYIAV D V
AQ QRWPDGL QAAVEAKEGI ETTETG VLD TITV A INR YAT CGM T ALA GEQ RQ FYQ VS IP P KP IRED ADRVYIT A KNDGI EHIT
LMGRRYNEGM HQAIEAKERV EIKAENQTLA TITLQNYFRL YDKLSGMTG A T A E H IY L IP T KPMVRQDQ SDLIYKTE A KFLA D V
A QRWPDGL QAAVEA EGI ETTETG VLD TITV A INR YPR CGM T ALA GEQ RQ FY VS IP P TP IRKD PDRVYITA KIDAIVEHI
5 0 520 530 540 5 0 560 570 580 590 60
....|....| . | ..| ..|....| ....| . | ....|... | ..| | . | ... . | ....
ecA ERT KGQPVL GTISIEKS LVS LTKAG IKHNVLNAKF HANE I AG P VT A TNMA RGTDI VLG - - S WQAEVA L N
is SecA QRYMTGQPVL VGTVAVETS LISKLL NKG IPHQ LNAKN HERE QI E AGQKGAVT A TNMA RGTDI KLG- - - --
cis SecA1 NRHKQGQPVL VGTVAIET LISK LTRKG VRHNILNAKN HARE DI E AGMKGAVT A T MA RGTDI KLG- - - --
cis SecA2 KHNKQGRPIL IGTMSILQS VARYLDEAN ITYQL NAKS AEQEADL T AGQKGQITIA TNMA RGTDI L G- - - --
 SecA1 EKHKAGQPVL LGTVAVETS YISNLL KRG IRHDVLNAKN HE E EIV G AGQKGA T A TNMA RGTDI KLG- - - --
 SecA2 ELHETGRPVL L TRTAE YFS VLFQMD IPNN IAQN VA EAQM AE AGQIGSMTVA TSMAGRGTDI KLG- - - --
ERY KGQPVL IGTTSVERS YLSR FTKRR IPHNVLNAKY HEQEAT AGR G VTVA TNMA RGT I VLG NVDF T DQRLRERGLD P ETPE YEA
EVHQRGQPVL VGTRDVAES ELHERLVRRG VPAVVLNAKN DAE A I KYGAVTVS TQMA RGTDI RLG S- - - --
ERHAKGQPVL IGTTSVERS YLSKMLTKRR PHNVLNAKY HE E NI AGR GAVTVA TNMA RGT I VLG NVD A DKRLRERGLD P ETPE YEA
EVHKTGQPVL VGTHDVAES ELHEKL KAG VPAVVLNAKN DAE A E GAVTVS TQMA RGTDI RLG SD- - - --
61 620 630 640 650 6 0 670 680 690 70
....|....| . | ..| ..|....| ....| . | ....|... | ..| | . | ... . | ....
ecA PTAEQIEKIK ADWQVRHDAV LAAGGLHIIG TERHESR I N L GRSGRQ GD GS RFYL SMEDALM IF A D VSGM R KLGMKPGEAI EH- PWV
is SecA ---------- ------- GV KE GGLAVVG TERHESR I N L GRS RQ GDPGITQFYL SMEDELM F GAE TMAML RFGMD STPI QS KMVS
cis SecA1 ---------- -------DDI KNIG-LAVIG TERHESR I N L GRA RQ GDPGVTQFYL SMEDELM F GSD MKAM D RLGMD SQPI ES KMVS
cis SecA2 ---------- ------- GV HELGGLHVIG TERHESR D N GRA RQ GDPG QF S E EML R AQE VEK TK SLKTDETGL LT SKVH
 SecA1 ---------- ------- GV EE GGLAVIG TERHESR I D L GRS RQ GDKGD RFYL SLQDELMIRF GS QKM S RLGLD STPI ES KMV
 SecA2 ---------- ------- GV EALGGLAVI HEHMEN RVD R LRGRSGRQ GD GS CIYI SLD YL KRW SDSN AEN Q LYSLDA RLS QSNLFNRKVK
AWHSELPIVK EEASKEAKEV IEAGGLYVLG TERHESR N L GRSGRQ GDPGESRFYL SLGDE M F NGA ETL T RL P VPI EA- KMVT
---------- -- E DH RV A LGGLHV G TGRH TER D N L GRA Q GDPGS VF S SWED A N LDHNKLPMAT D- ENGRIV SP RTG
AWHEVLPQVK AECAKEA QV IEAGGLYVLG TERHESR N L GRSGRQ GDPGESRFYL SLGDELM F NGAT ETL T RL P VPI EA- KMVS
--------- GD D KKKV A LGGLHV G TGRH TER N L GRA Q GDPGS VF S SWED A H L SKLPM T PDAGDGRI AP RAA
710 720 730 740 750 760 7 0 780 790 800
....|....| . | ..| ..|....| ....|. | . |. | | | |. | . |. | ....|. | . |....|
ecA KAIANAQRKV SRNF IRKQ LLEYDDVAND QR AIYSQRN EL DVS-DVS ETINS RE V FKATI -AYI P QSLE MWD IP LQERLKN DFDL- -D
is SecA RAVESSQKRV EGNNFDSRKQ LQYDD LRQ QREVIYKQRF EVIDSE-NLR E ENMIK L RAIA- Y RE LPE WK LDGLVDLINT TYLD- -E
cis SecA1 RAVESAQKRV EGNNY ARKQ LLQYDDVLRQ QREVIYKQRQ EVMESE-NLR I EGM K T V RA A-LHT -QE IE DWN IKGLVDYLNT NL Q- -E
cis SecA2 DFVNRTQLIC EGSHFSMREY NLK DDVIND QRNVIYKLRN NLLQEDTNMI EI PMIDHA V AISK-QYL VEGMLPE WD FASLTAS NE IL V- --
 SecA1 RAVESAQKRV EGNNFDARKR ILEYDEVLRK QREI YNERN SI DE -DS QV DAM R T LQRS N-Y I NTAD EPEYQ P- FIDYIND IFLQ- -E
 SecA2 QIVVKAQRIS EEQGVKAREM ANEFEKS SI QRDLVYE RN RVLEID AEN QDFKALAKDV FEMFVNE KV LTKSRV EYI YQNLSFQFNK DVAC- --
RAIKSAQTQV EQQNFEVRKN VLKYDEVMNQ QRKVIYAER RILEGE-NLK DQALDMVRDV ITAYVD-GAT -GEGYAEDWD LDALWTALKT LYPVGITADS
SLLDHAQRVA EGRLL VHAN TWRYNQLIAQ QRAI VER N TL RTV- - - - -- - --
RAIKSAQTQV EQQNF VRKN VLKYDEVMNQ QRKVIYAER RILEGE-NLA EQAHKM VDV ITAYVD-GAT -AEGYAEDWD LETLWTALKT LYPVGIDHRD
SLLDHAQRVA EGRLLDVHAN TWRYNQLIAQ QRAI VER E TL RTD- - - - - --
410 420 430 440 450 460 470 480 490 500
. | .| . | .| .| .| | ..| | . | | . | ....|.. | . |....| .. | . | ....|....|
. coli ecA MQG RWSDGL HQ V AKEGV QIQNENQT A SITFQNYFR YEKLAGMTGT DT AFEFSS IYKLDTVVVP TNRPMIRKDL PDLVYMTE E KIQAIIEDIK
B. subtilis SecA MKG RYSEGL HQAIEAKEG IQNESM LA TITFQNYFRM Y KLAGMTGT KT E F N IYNMQVVTIP TNRPVVRDDR PDLIYRTMEG KFKAVAEDVA
B. anthracis SecA1 MKG RYSEGL HQAI AKEGV IQNESM LA T TFQNYFRM Y L GMTGT KT E F N IYNMNVIVIP TNKPIIRDDR ADLIFKSMKG KFNAVVEDIV
B. anthracis SecA2 MDG SLSDGL HQA EAKEG ITEENQ QA S TIQNFFRM YPALSGMTGT KT KEFNR VYNMEVMPIP TNRPIIREDK KDVVYVTADA KYKAVREDVL
S. aureus Sec 1 MPG RFSEGL HQA EAKEGV QIQNESKTMA SITFQNYFR YNKLAGMTGT KT E F N IYNMTVTQIP TNKPVQRNDK SDLIYISQKG KFDAVVEDVV
S. aureus SecA2 LPGTKLQAGL HQAIEAKEGM VSTDKSVMA T TFQNLFKL F SF GMTAT GKLGESEFFD LYSKIVV VP TDKAIQRIDE PDKVFRSVDE KNIAMIHDIV
TB Sec 1 LIG RYNEGM HQ IEAKEHV EIK ENQTLA TITLQNYFR YD LAGMT T QTEAAELHE IYKLGVVSIP TNMPMIREDQ SDLIYKT A KYIAVVDDVA
B ecA2 Q QRWPDGL QA V AK GI ETTETGEVLD TITVQ LINR YATVCGMTGT ALAAGEQL Q FYQLGVSPIP PNKPNIREDE ADRVYITTAA KNDGIVEHIT
MS Sec 1 LMG RYNEGM HQ IEAKERV EIK ENQTLA TITL NYFR YD LSGMTGT ETEAAELHE IYKLGVVPIP TNKPMVRQDQ SDLIYKT A KFLAVVDDVA
MS Sec 2 S QRWPDGL QA V AK GI ETTET EVLD TITVQ LINR YPRVCGMTGT LAAGEQL Q FYKLGVSPIP PNTPNIRKDE PDRVYITAAA KIDAIVEHIA
510 520 530 540 550 560 570 580 590 600
| | .| .| | ..| . | | | . | ....|.. | . |....| .. | . | ....|....|
. coli Sec ER KGQP L VGTISIEKSE L SNE TKAG I HNVLNAKF H NEA IV GYP AVTIA TNMAGRGTDI VLGG------ ---- -S WQAEVAALEN
B. subtilis Sec Q YM GQPVL V TVAVETSE L SKL KNKG I HQVLNAKN H REAQI EE AGQKGAVTI TNMAGRGTDI KLG------- ---- -- ----------
B. anthracis SecA1 N HKQGQPVL VGTVAIETSE L SKM TRKG VRHNILNAKN HAREADII E AGMKGAVTIA TNMAGRGTDI KLG------- ---- -- ----------
B. anthracis SecA2 KHNKQGRPIL I TMSI QSE T RY DEAN IT QLLNAKS AEQEADLI T AGQKGQITIA TNMAGRGTDI LLG------- ---- -- ----------
. aureus SecA1 KHKAGQPVL L TVAVETSE Y S L K RG IRHDVLNAKN HEREAEIV G AGQKGAVTIA TNMAGRGTDI KLG------- ---- -- ----------
. aureus SecA2 ELHE GRPVL L TRT EAAE YFSKV FQMD IPN LL AQN AKEAQMI E AGQ GSMTVA TSMAGRGTDI KLG------- ---------- ----------
TB ecA1 RY KGQPVL IGTTSVERSE Y S QFTKRR IP NVLNAKY H Q AT I AGRRG VTVA TNMAGRGTDI VLGGNVDFLT DQRLRERGLD PVETPEEYEA
TB SecA2 VHQ GQPVL VGTRDVAESE E HERLVRRG VPAV LNAKN D EEARVI E AGKYGAVT S TQMAGRGTDI RLGGS----- ---- - ----------
S ec 1 RH KGQPVL IGTTSVERSE Y SKM T RR VP VLN KY H Q ANII E AGRRGAVTVA TNMAGRGTDI LGGNVDFLA DKRLRERGLD PVETPEEYEA
MS SecA2 VHK GQPVL VGTHDVAESE E HEK LKAG VPAV LNAKN D EEAAVI E AGK GAVT S TQMAGRGTDI RLGGSD---- ---- - ----------
610 620 630 640 650 660 670 680 690 700
| | .| .| | ..| . | | | . | ....|.. | . |....| .. | . | ....|....|
. coli SecA PTAE IEKIK DWQ RHDAV AAGGLH I TERHES ID NQLR RSGRQ GDAGSSRFYL SMEDALMR F ASDRVSGMMR KLGMKPGEAI EH----PWVT
B. subtilis ecA ---------- ------- GV KELGGLAVVG TERHESRRID NQLRGRSGR GDPGITQFYL SMEDELMRRF GAERTMAM D RFGMD STPI QS----KMVS
B. anthracis ecA1 ---------- -------D I KN G-LAVIG TERHESRRID NQLRGRA RQ GDPGVTQFYL SMEDELMRRF GSDNMKAMMD RLGMDDSQPI S----KMVS
B. anthracis ecA2 ---------- ------- GV HELGG HVIG TERHESRRVD NQLK RAGRQ GDPG SQFFL S EDEMLKRF AQEEVEKLTK SLKTDETGLI LT----SKVH
. aureus SecA1 ---------- ------- GV EELGGLAVIG TERHESRRID DQLRGRSGRQ GDKGDSRFYL SLQDELMIRF GSERLQKMMS RLGLDDSTPI S----KMVS
. aureus SecA2 ---------- -------EGV EALGGLAVII HEHM NSRV RQLRG GR GDPGS CIYI SLDDYLVKRW SDSNLAENNQ LYSLDAQRLS QSNLFNRKVK
B SecA1 AWHS LPIVK EASK AK V IEAGG YVLG TERHESRRID QLRGRSGRQ GDPGESRFYL SLGDELMRRF NGAALETLLT RLNL DDVPI EA----KMVT
TB SecA2 ---------- --DEADHDRV AELGG HVVG TGRHHTERL NQLR AGRQ GDPGSSVFFS SWEDDVVAAN LDHNKLPMAT D- ENGRIV SP-----RTG
M  SecA1 AWHEVLP VK ECAK A QV IEAGGLYVLG ERHESRRID QLRGRSGRQ GDPGESRFYL SLGDELMRRF NGATLETLLT RLNL DDVPI EA----KMVS
MS SecA2 ---------V GDDDAEKKKV AEL G HVVG TGRHHTERL NQLR AGRQ GDPGSSVFFS SWEDDVVAAH LE SKLPMET DPDAGDGRII AP-----RAA
710 720 730 740 750 760 770 780 790 800
. | .|....| ....|... .|... | . | | | ..| ....|....| ....|....| ....|....| ....|....|
E. coli Sec KAIANAQRKV ESRNFDIRKQ LLEYDDVAND QRRAIYSQRN E LDVS DVS ETINSIREDV FKATID-AYI PPQSLEEMWD IPGLQERLKN DFDL-----D
B. subtilis Se A AV SSQKRV EG NFDSRKQ LLQYDDVL Q QREVIY QRF E SE NLR EIVENMIKSS LERAIA-AYT PREELPEEWK LDGLVDLINT TYLD-----E
B. anthracis SecA1 V SAQKRV EGNNYDARKQ LLQYDDVLRQ QR VIYKQRQ E MESE NLR GIIEGMMKST VERAVA-LHT -QEEIEEDWN IKGLVDYLNT NLLQ-----E
B. anthracis SecA2 DFVNR QLIC EGSHFSMREY NLKLDDVIND QRNVIYKLRN N LQEDTNM EIIIPMIDHA VEAISK-QYL VEGMLPEEWD FASLTASLNE ILSV------
. aureus ecA1 AV SAQKRV EGNNFDARKR LEYDEVL K QR II NERN S E SS VDAMLRST LQRSIN-YYI NTADDEPEYQ P--FIDYIND IFLQ-----E
S. aureus SecA2 QIVVK QRIS EEQGVKAREM ANEFEKSISI Q DLV EERN RVLEIDDAE QDFKALAKDV FEMFVNEEKV LTKSRVVEYI YQNLSFQFNK DVAC------
TB SecA1 AIKSAQTQV EQQNFEVRKN VLKYDEVMNQ QRKVIYAERR RILEGE N K DQALDMVRDV ITAYVD-GAT -GEGYAEDWD LDALWTALKT LYPVGITADS
B ecA2 S LDHAQRVA EGRLLDVHAN TWRYNQLIAQ QR IIVERRN TLLRTV -- ---------- ---------- ---------- ----------
MS SecA1 AIKSAQTQV EQQNFEVRKN VLKYDEVMNQ QRKVIYAERR RILEGE N A EQAHKMLVDV ITAYVD-GAT -AEGYAEDWD LETLWTALKT LYPVGIDHRD
MS ecA2 S L HAQRVA EGRLLDVHAN TWRYNQLIAQ QRAIIVERRE TLLRTD -- ---------- ---------- ---------- ----------
41 2 3 44 45 46 470 480 490 500
.| |. ...| ... | . | . | | ....|
Q RRWSDGL HQAVEAKEG QIQNENQTLA SITFQNYFRL YEKLAGMTGT ADTEAFEFSS IYKLDT VVP TNRPMIRKDL P VYMTE KIQAI EDIK
ec M RRYSEGL HQAI AKEG EIQNESM LA I FQNYF M YEKLAGMTGT A TEEEEFRN IYNMQVVTIP TNRPVVRDDR P LIYRTMEG KFKAVAEDVA
SecA1 M RRYSEGL HQAI AKEGV EIQ ESMTLA I FQNYF M YEKLSGMTGT A TEEEEFRN IYNMNVIVIP TNKPIIRDDR A LIFKSMKG KFNAVVEDIV
SecA2 MDGRSLSDGL H AL AKEGL EIT NQT A SIT QNFFRM Y ALSGMTGT A TEEKEF R VYNMEV PIP TNRPIIREDK K VVYVTADA KYKAVREDVL
1 M GRRFSEGL HQAI AKEGV QIQNESKT A SITF NYFRM YNKLAGMTGT A TEEEEFRN IYNMTVTQIP TNKPVQRNDK S LIYISQKG KFDAVVEDVV
A2 GTK QAGL HQ I AKEGM EV TDK A I F N FKL FESF GMTAT G LGESEFF LYSK VVQ P TDKAIQRIDE P KVFRS DE KNIAMIHDIV
IGRRYNEGM HQAIEAKE V EI AENQTLA I LQNYFRL YDKLAGMTGT AQTEAA LH IYKLGV SIP TNMPMIREDQ S LIYKTE A KYIAVVDDVA
AQLQRWPDGL Q V AKEGI ETTETGEVLD I VQA INR Y TVCGMTGT ALAA EQLR FYQLGVSPIP PNKPNIREDE A RVYITTAA KNDGIVEHIT
MGRRYNEGM HQAIEAKERV EIKAENQTLA I LQNYFRL YDKLSGMTGT AETEAA LH IYKLGV PIP TNKPMVRQDQ S LIYKTE A KFLAVVDDVA
ASLQRWPDGL Q V AKEGI ETT TGEVLD I VQA INR YPRVCGMT T ALAAGEQLR FYKLGVSPIP PNTPNIRKDE P RVYITAAA KIDAIVEHIA
510 2 3 54 5 5 570 580 590 600
| |. ...| ... | . | . | | ....|
RTAKGQPVL VGTI IEKSE LVSNEL KAG IKHNVLN KF HANEAAIVAQ GY AAVTIA TNMAGRGT I VLGG------ - S WQAEVAALEN
ec QRYMTG PVL VGT SE LISK L NKG IPHQVLN KN H REAQI E GQKGAVTIA TNMAGR TDI KLG------- - - ----
SecA1 NRHKQGQPVL VGTV IE SE LISKML KG HNILN KN HAREADIIA GMKGAVTIA TNMAGR T I LG------- - - ----
SecA2 HNKQGRPIL IGTMS LQSE RYLDEAN TYQLLN KS A Q AD AT GQKG TIA TNMAGRGTDI LLG------- - - ----
S A1 EKHKAGQPVL GT V SE YISNLLKKRG I HDVLN KN H R AEIVAG GQKGAVTIA TNMAGR TDI KLG------- - - ----
A2 ELHETGRPV ITRTAEA E YFSK LFQ D PNN LIAQN VAKEAQMIAE GQIGSMTV TSMAGRGTDI KLG------- - - ----
ERYAKGQPVL IGT S RSE LSRQF KRR IPH LN KY H QEATI AV GRRGGVTVA TNMAGRGTDI VLGGNVDFLT QRLRE GLD PVET EEYEA
EVHQRGQPVL VGTRD AE E ELHE L RG PAVVLN KN AEEARVIA GKYGAVTVS TQM GRGTDI RLGGS-- - - ----
E HAKGQPVL IGT S RSE LSKML KRR PH LN KY H QEANI A GRRGAVTVA TNMAGRGTDI VLGGNVDFLA KRLRE GLD PVET EEYEA
EVHKT QPVL VGTHD AE E ELHEKLLKAG PAVVLN KN AEEAAVIA GKLGAVTVS TQM GRGTDI RLGGSD---- - - ----
610 64 65 66 670 680 690 700
| |. ...| ... | . | . | | ....|
PTA QIEKIK DW V HDAV AGG H T HE RRID NQ RGRSGRQ GD GSSRFYL SMEDALMRIF ASDRVSGMMR KLGM P EAI H --PWVT
Sec ---- - EGV K LGG AV T HESRRID NQ RGRSGRQ GDPGITQFYL SMEDELM RF GA RTMAMLD RFGMDDSTPI QS --KMVS
ecA1 ---- - D I KNIG- AVI TE HESRRID NQ RGRAGRQ GDPG TQFYL SMEDELMRRF GS NMKAMMD RLGMDDSQPI ES --KMVS
ec 2 ---- - EGV H LGG HVI T H SRRVD NQ KGRAGRQ GDPGSSQFFL S EDEMLKRF AQ EVEKLTK SL TDETGLI LT -SKVH
A1 ---- - GV EELGG AV T HESRRID Q RGRSGRQ GDKGDSRFYL S QDELMIRF GS RLQKMMS RLGL DSTPI ES --KMVS
A2 ---- - GV EALGG AVI H MENSRVD RQ RGRSGRQ GDPGSSCIYI SLDDYLVKRW SDSNLAEN Q LYSLDAQRLS QSNLFNRKVK
WHSELPIVK E ASK A V IEAGG Y T H SRRID NQ RGRSGRQ GDPG SRFYL S DELMRRF NGAALETLLT R NLPDDV I EA----KMVT
---- - DE DHDRV L GLHV TG HHT RLD NQLRGRAGRQ GD GSSVFFS SWEDDVVAAN LDHNKLPMAT D ENGRIV SP --RTG
S WHEVLP VK A CAK AEQV IEAGG Y T H SRRID NQ RGRSGRQ GDPG SRFYL S DELMRRF NGATLETLLT R NLPDDV I EA----KMVS
---- V D AEK V A LGGLHVV TG HHTERLD NQLRGRAGRQ GD GSSVFFS SWEDDVVAAH LERSKLPMET DPDAGDGRII AP --RAA
710 2 3 740 750 76 770 780 790 800
. |. | . |. | . | ....|....| ... |. | .. | . | ....|....| . ..| .| ..|....|
KAIANAQRKV E NFDIRKQ L EY V N QRRAIYSQRN EL DVS-DVS ETINS REDV FKATID-AYI PPQSLEEMWD IPGLQER KN DFDL-----D
ecA RA S KR EGN FDSRKQ QY DVLRQ VIYKQRF EVIDSE-NLR EIVENMIKSS LERAIA-AYT PREELPEEWK LDGLV LINT TYLD-----E
SecA1 RAVESAQKRV EGN DARKQ L QYDDV RQ R V YKQR EVMESE-NLR GIIEGMMKST VERAVA-LHT -QEEIEEDWN IKGLVDY NT NLLQ-----E
SecA2 DFVN TQLIC EGSH SMREY NLKLDDVIND QRNVIYKLRN L QEDTNMI E IIPM DHA VEAISK-QYL VEGMLPEEWD FASLT NE ILSV------
A1 RAVESAQKRV EGN FDA KR ILEYDEVLRK QREIIYNERN SIIDEE-DSS QVVDAMLRST LQRSIN-YYI NTADDEPEYQ P--FIDYIN FLQ-----E
A2 QIVVKAQRIS E QGVK REM ANE EKSISI QRDL Y ERN RV EIDDAEN Q FKALAKDV FEM VNEEKV LTKSRVVEYI YQNLSFQFNK DVAC------
RAIKSAQTQV Q NFE KN VLK EVMNQ RKVIYAERR I EGE-NLK DQALDMVRD ITAYVD-GAT -GEGYAEDWD LDALWT K YPVGITADS
SLLDHAQRVA EGRL DVHAN TWRYNQLIAQ RAIIVERRN TLLRTV---- --- - ---------- - - ----
RAIKSAQTQV Q NFE RKN VLK EVMNQ RKVIYAERR I EGE-NLA EQAHKMLVDV ITAYVD-GAT -AEGYAEDWD LETLWTA K YPVGIDHRD
SLLDHAQRVA EGRL DVHAN TWRYNQLIAQ RAIIVERRE TLLRTD---- --- - ---------- - - ----
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ..| | | .. | . | . | . | . | .. .| .. |
E. coli SecA ---------- ---------- ---------- ---------- MLIKLLTKVF GSRNDRTLRR M KVVNIINA M PEMEKLSD E LKGKTAEF RARLEKGEVL
B. subtilis SecA ---------- ---------- ---------- ---------- -MLGILNKMF DP TKRTLNR YEKIANDIDA RGDYENLSD DALKHKT EF KERLEKGATT
B. anthracis SecA1 ---------- ---------- ---------- ---------- -MIGILKKVF DV NQRQIKR MQKTVEQIDA L SSIKPLTD EQLKGKTLEF KERLTKGETV
B. anthracis SecA2 ---------- ---------- ---------- ---------- -MLNSVKKLL GDSQKRKLKK YEQLVQEINN E LSDLSD LRHKTITF KDMLRDGKTV
S. aureus SecA1 ---------- ---------- ---------- ---------- --MGFLSKIL DG NNKEIKQ LGKLADKVIA L E TAILTD E IRNKTKQF QTELADIDNV
S. aureus SecA2 ---------- ---------- ---------- ---------- ----MKHKLD VTINELRLKS IRKIVKRINT WSDEVKSYSD DALKQKTIEF KER ASGVDT
TB SecA1 ---------- ---------- ---------- ---------- ----MLSKLL RLGEGRMVKR LKKVADYVGT LSDDVEKLTD LRAKTDEF KRRLADQKNP
TB SecA2 MNVHGCPRIA ACRCTDTHPR GRPAFAYRWF VPKTTRAQPG RL SRFWRLL GASTEKNRSR SLADVTASAE YDKEAADLSD KL KAAGLL NLDDLAESAD
MS SecA1 ---------- ---------- ---------- ---------- ----MLSKLL RLGEGRMVKR L KVADYVNA LSDDVEKLSD LRAKTEEF KKRVADG---
MS SecA2 ---------- ------MANE SWRTSAYRKR VPKTSSAKPG RL SKFWKLL GASTERNQ R SLSEVKGAAD F K AADLDD QLTKAA LL KLEDLAGASD
110 120 130 140 150 160 170 180 190 200
...|....| ....|....| .. | . | .. | . | .. | . | | | | . | | | | | . .| .. |
E. oli SecA -------ENL IPEAFAVV E ASKRVFGMRH FDV LLGGMV LNERCIAEMR TGEGKTLTAT PAYLN LT K V V T ND YLA RDAEN RP FEFLGLT
B. ubtilis SecA -------DDL LVEAFAVV E ASRRVTGMFP FKV LMGGVA HDGNIAE K TGEGKTLTST LPVYLN LT K V TVNE Y ASR AEQM GKIFEFLGLT
B. anthracis SecA1 -------DDL LPEAFAVV E AATRVLGMRP YGV LMGGIA LH GNISE K TGEGKTLTST LPVYLNALT K V V TVNE YLAQ DA M GQ HEFLGLT
B. anthracis SecA2 -------DDI KVEAFAVV E AAKRVLG RH YDV LIGGLV L GNIAEMP TGEG TLVSS LPTYVRALE K V VITVND Y AKRDK LI G VHEFLGLK
S. aureus SecA1 KKQNDYLDKI LPEAYALVR GSKRVFNMTP YKV IMGGIA IHKGDIAEMR TGEGKTLTAT PTYL LA R VITVNE Y SSV SE M AE YNFLGLT
S. aureus SecA2 ------LDTL PEAYAVARE ASWRVLGMYP KEV L G IV LH GNIAEMQ TGEGKTLTAT MPLY NALSG K TY ITTN YLAKRDFEEM QP YEWLGLT
TB SecA1 ----ETLDDL PEAFAVA E AAWRVLDQRP FDV VMG AA LHLGNV EMK TGEGKTLTCV PAY N LA N I T ND YLAKRDSEWM GRVHRFLGLQ
TB Sec 2 ---------- IPQFLAIARE AAERRTGLRP FDVQLLG LR MLAGDVIEMA TGEGKT G IAA GY LA H HV TIND YLAR DA WM GP LDAMGLT
MS SecA1 ----EDLDDL PEAFAVA E AAWRVLNQRH FDV VMGGAA LHFGNV EMK TGEGKTLTAV PSY NALS K T ND YLARRDSEWM GRVHRFLGLD
M  Sec 2 ---------- ITQFLAIA E AAERTTGLRP FDVQLLA LR MLAGDVVEMA TGEGK IAA GY LG RR HVITIND YLARRDA WM GP LKALGLT
210 220 23 24 250 260 270 280 290 300
...|....| ....|....| .. | . | . | | | | | | . | | | . | . |
E. oli SecA VGINLPGMP- ---- PA RE AYAADITY T NNEYGFDYLR DNMAFSPEER VQ HYA V DEVDS LIDE A TPLI P A DSSEMYKR VNK P IR
B. ubtilis SecA GLNLNSMS- ----KDE RE AYAADI YST NNELGFDYLR DNMVLYKEQM VQR LHFAVI DEVD ILIDE ARTPLIIS Q AAKSTKLYVQ ANAFVRTLKA
B. anthracis Sec 1 VGINLNSMS- ----R E QE AYAADITYST NNELGFDYLR DNMVLYKEQC VQRP FAII DEVDSILVD ARTPLI S Q AQKSTELY F ANAF TLEN
B. anthracis Sec 2 VGLNIPQID- ----PSE KL AYEADITY I GTEFGFDY R DNMA SK EQ VQRP FAII DEIDSVLIDE AKTPLIIA K K SSSDLH L C KV KSFQD
S. aureus SecA1 VGLNLNSKT- ----T E RE AYAQDITYST NNELGFDYLR DNMVNYSEDR VMRP HFAII DEVD ILID ARTP IIS A KST LY Q AN FAKMLK
S. aureus SecA2 ASLGFVDIVD YEYQKGE RN IY HDIIYTT NGRLGFDYLI DNLA SAEGK FLPQ G I DE DSIILDA A TP VIS PR QSNLF I VKEFVDTLIE
TB SecA1 VGVILATMT- ----PDERRV AYNADITY T NNEFGFDYL DNM HSL DL VQRG YAIV DSILID ARTPLII P ADGASNWY FA LA LMEK
TB SecA2 VGWI D T- ----PDERRT AYDRDVTYAS VNEIGF LR DQLVTDVNDL VSPNPD LI DEADS LVDE A VPLV A T THR TPRLEI I LVA LVGD
MS SecA1 VGVIL MT- ----PDERRA AYAADITY T NNEFGFDYL DNM HS DM VQRG FAIV EVDSILID RTPLII P ADGASHWYQ FA I MMEK
MS SecA2 VGWIT D T- ----ADERRE AYQCDV YAS VNEIGF LR DQLVTDVADL VSPNPD I DEADS LVDE A VPLV A T SHR PRVEI IRMVGEL AG
310 320 33 34 350 360 370 380 390 400
...|....| ....|....| .. | . | . | | | | | | . | | | . | . |
E. oli SecA QEK DSETFQ GEGHFSVDEK SRQVN---- TERGLVLIE LVK IM E ESLYSPANI -MLMHH TAA LRAH LFTRD V YIVK E I VDEHTGRT
B. ubtilis SecA EK-------- ---DYTYDIK TKAVQ TEEGMTKAEK AFGID- NLFD HV -ALNHH NQA LKAHVAMQKD V Y V D V VDSFTGRL
B. anthracis SecA1 EK-------- ---DYSFDVK TKNVM TEDGITKAEK AFHIE- NLFDL HV -ALLHH NQA LRAHV MHRD T Y VQE EI VD FTGRL
B. anthracis SecA2 TL-------- ---HYTYDAE SKSAS F TEDGITKIED LFDID- NLYDLEHQ -TLYHYMIQA LR H AFQCD V YIVH EKI LLVDIFTGRV
S. aureus SecA1 DE-------- ---DYKYDEK TKAVH TEQG DKAER MFKVE- NLYDVQ V -DVI HINTA LRAHVTLQRD V Y VVD EV L VDQFTGRT
S. aureus Sec 2 DV-------- ---HFKMKKT KKEIW NQGIEA QS NVE- DLYS AM -VLV N NLA LRAQYLFES VDYFVYN DI L DRITG M
TB SecA1 DV-------- ---HYEVDLR KRTVG----V HEKGVEFVED Q GID- NLYE ANS -PLVSYLNNA L K LF RD Y VRD E L VD TG V
TB SecA2 KDA E----- ---YFATDSD NRNVH TEHGARKVEK A GGI---- DLYSE H GTTLTEVNVA HAH LLQ VHYIVRDDAV HLINAS GRI
MS SecA1 DV-------- ---HYEVDLR KRTVGVHVGV HELGVEFVED Q GID- NLYEAANS -PLVSYLNNA L K FQRD K Y VRN E L VD TG V
MS SecA2 K--------- ---HYDTDAE SRNVH TEAGARVMEA K GGI- DLYSE HV TTLTE NVA HAH LLQ D VHYIVRDDAV HLINAS GRI
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|. | . |. | . |. | | | | . | | | | .|
E. coli SecA ---------- ------- - - MLIKL TKVF GSRNDRTLR M KV NI NA MEPEM KLSD E LKGKT EF RARLEKGEVL
B. subtilis SecA ---------- ------- - - -MLGILNKMF DP TKRTLNR YEKIANDIDA IRGDY N SD DALKHKTIEF ERLEKGAT
B. anthracis SecA1 ---------- ------- - - -MIGILK VF DV NQRQIKR MQKTV QIDA LES IKPLTD EQLKGKTLEF ERLTKGETV
B. anthracis SecA2 ---------- ------- - - -MLNSVK L GD QKRKLK YEQ VQEIN LE KLSD SD E LRHKTITF DMLR GKTV
S. aureus SecA1 ---------- ------- - - - MGFLSKIL DG N KEIKQ LGKLADKVIA LE KTAILTD E IRNKTKQF QTELADID V
S. aureus SecA2 ---------- ------- - - - MKHKLD VTINELRLKS IR IVKRINT WSDEVKSYSD DAL QKTIEF ERLASGVDT
TB SecA1 ---------- ------- - - - MLSKL RLGEGRMVKR LK VADYVGT LSD V KLTD AELRAKTDEF R LADQKNP
TB SecA2 MNVHGCPRIA ACRCTDTHPR GRPAFAYRWF VPKT RAQPG RLS RFWRL GASTEKN SR SLADVTASAE YDKEA DLSD EKLRKA GL N D ESAD
MS SecA1 ---------- ------- - - - MLSKL RLGEGRMVKR L KVADYVNA LSD V KLSD AELRAKTE F RVAD -
MS SecA2 ---------- ------MANE SWRTSAYRKR VPKTS AKPG RLS KFWKL GASTERNQAR SLS VK A D FEK A DLD EQLTKA KL ED GASD
1 0 120 130 140 150 160 170 180 190 200
| | .. |....| ....|.. .| . .|.. .| . .|.. . .| | | | .| . | |
E. oli SecA ENL IPEAF V RE ASKRVFGMRH DVQL G MV LNE CIA MR TGEGK T T LPA LNA TG K VHV ND YLAQRD EN R LFEFL L
B. ubtilis SecA DDL LVEAFAV RE ASR VTGMFP KVQLMG VA LHDGN MK TGEGK TST LPV LNA TG K VHV VN YL SRDAE M GKIFEFL L
B. anthracis SecA1 DDL LPEAFAV RE A TRVLGMRP YGVQLMG IA LHEGNIS MK TGEGK ST LPV LNA TG K VHV VN YL QRDA M GQLHEFL L
B. anthracis SecA2 DDI KVEAFAV RE A KRVLGLRH YDVQLIG LV L EGNIA MP GEGK LVS LPT VRA EG K VHVI VND Y AKRDK L G VHEFL LK
S. aureus SecA1 KKQNDYLDKI LPEAYALVRE GSKRVFNMTP YKVQIMG IA IHK D MR TGEGK T T MPT LNA AG R VHVI VN YLS V SE M AELY FL L
S. aureus SecA2 LDTL LPEAYAV RE ASWRVLGMYP KE QLIGAIV LHEGN AEMQ TGEGK T T MPLYLNA SG K YLIT ND YLAKRDFE M YEWL L
TB SecA1 E LDDL LPEAFAVARE A WRVLDQRP FDVQVM A LHLGN MK TGEGK TCV L A LNA AG VHIV VND YL KRDSEWM GR HRFL LQ
TB SecA2 ---------- I QFLAI RE A ER TGLR FDV L G L MLAGDVIEM TGEGK LAGA GYA AG RHVHV TIND Y AR D WM G L D M L
MS SecA1 EDLDDL LPEAFAVARE A WRVLNQRH FDVQVM LHFGN MK TGEG T V LPS LNA SG K VHVV VND YL R DSEWM GR HRFL LD
MS SecA2 - ITQFLAIARE A ERT GLR F V L A LR LAGDV EMA TGEGK LAGA GYA R VHVITIND Y AR D EWM G L K L L
210 2 0 230 2 0 250 260 27 28 290 3 0
| | .. |....| ....|. .| . |. | ....|.. . .| | .| . | |
E. oli SecA VGINL GMP- ---- PAKRE AYA DITY T N EY FDY R DNMAF PE R VQRKL YA V D VDSILIDE R PLI S P EDS E YK VNKI P LIR
B. ubtilis SecA VG N NSMS- ----KDEKRE YA ITYST N EL FDY R DNMV EQM VQRPL AVI D VDSILIDE R PLI S Q A KS KLYVQ ANAF TLKA
B. anthracis Sec 1 VGIN NSMS- ----REEKQE YA DITY T N EL FDY R DNMV EQC VQRPL FAI D VD ILV E R PLI S Q AQKS ELY F ANAF TLE
B. anthracis Sec 2 VGLNIPQID- ----PSEKK AYEADITY I GTEF FDY R DNMA S NEQ VQRPYHFAI DEID VLI E PL A K K DLH C KVIKSFQD
S. aureus SecA1 VGLN NSKT- ----TEEKRE YAQDITY T N E FDY R DN VN EDR V RPL FAI DEVDSILIDE R PLI S AEKS SLYTQ ANVFAKMLKQ
S. aureus SecA2 AS GFVDIVD YEYQKGEKRN I E DI YT N R FDY I DNLAD AE K FLP L GI D VD LDA QTPLV S PRLQ FHI VK FVDTLIE
TB SecA1 VGVI ATMT- ----PDE V YNADITY T N EF FDY R DNMAH D L VQRGH YAIV DEVDS LIDE R PL S P D AS WYTE FA LA LMEK
TB SecA2 VGWITADST- ----PD AYDRDVTYAS NEI FD R DQLVTDVN L V PN D A I DEA S LVDE PL LA T H PRLEI I LVAE G
MS SecA1 VGVI SGMT- ----PDE A YA DITY T N EF FDY DNMAH VD M VQRGHNFAIV D D ILIDE R PL S P D ASHWYQE FA I M EK
MS SecA2 VGWITADST- ---- D E AYQCDVTYA NEI FD R DQLVTDVA L V PN D A I DEA S L DE PL LA T SH PR EI IRMVGE EAG
310 320 3 0 340 3 0 360 37 38 390 4 0
| | .. |....| ....|. .| . |. | ....|.. . .| | .| . | |
E. oli SecA QEKEDSETFQ GEGHFSVDEK SRQVN- T RGLV IE L K GIMDE GESLYSPANI -MLMH VT LRAH LF RD V YI K V VDEHTGRT
B. ubtilis SecA K - -- ---DYTYDIK TKAVQ T GM KAEK AFGID- NLFDVKHV - L H NQA LKAHV M KD VDY QV IVDSFTGRL
B. anthracis SecA1 K - -- ---DYSFDVK TKNV T DGI KAEK AFHIE- NLFDLKHV - L H NQ LRAHV MHRD YV Q I VDQFTGRL
B. anthracis SecA2 TL - -- ---HYTYD E S SAS F T DGI KIED LF ID- NLYDL Q -TLYHYM Q LRAHVAFQCD VDYI KI L VDIFTGRV
S. aureus SecA1 DE - -- ---DYKYDEK TKAVH T QGADKAER MFKV - NLYDVQNV - VISH NTA LRAHVTLQR VDYM V L VDQFTGRT
S. aureus Sec 2 D -------- ---HFKMK T K EIW L LNQGIE QS YFNVE- DLYSEQAM - LVRN NLA LRAQYLFE N VDYFVY DI IDRITGRM
TB SecA1 DV - -- ---HYEVDLR KR VG- H KGVEFV D QLG - NLYEA NS -P VSYLN A LKA LF RD DYI R V LIVDEFTGRV
TB SecA2 KD DE -- ---YFATDSD NRNVH T HGARKV K ALG I- DLYSE HV T LTE NV LHAH L QR HYIVR A HL NAS GRI
MS SecA1 DV - -- ---HYEVDLR KR VGV G H LGVEFV D LG - NLYEA NS -P VSYLN A LKA ELFQRD DYI R V LIVDEF GRV
MS SecA2 K- - -- ---HYDTDAE SRNVH T A AR M LG I- DLYSE V GT LTEINV LHAH L QRD VHYIVR A HL NAS GRI
10 20 30 40 50 60 70 80 90 100
....| .. | | . .| . |....| .| .| .| . ..|. . . .| . | . | . |.. | ....|. |
E. coli SecA --- - --- - ---- - ML KLLTKVF GSRN RT RR MRKVVNIINA MEP MEKLSD EELKGKTA F RARLEKG L
B. subtilis SecA --- - - - ---- - -M GILNKMF DP-TKRT NR YEKIANDI A IRGDYENLSD DAL HKT EF KERLEKG T
B. anthracis SecA1 --- - - - ---- - -M GILKKVF D -NQR I R MQK VEQI A LESS PLTD EQL GKT F KERLTKGETV
B. anthracis SecA2 --- - - - ---- - -M NSVKKLL GD QKRK KK YEQLVQEINN LEE SDLSD EELRHKTITF KDMLRDGKTV
S. aureus SecA1 --- - - ---- - --MGFLSKIL DG-NNK KQ L ADKVIA LEEKTAILTD EEIRNKTKQF QTELADIDNV
S. aureus SecA2 --- - - ---- - -- MKHKLD VTINELR IRKIVKRIN WSD V YSD DAL QKTIEF KERLASG DT
TB SecA1 --- - - ---- - -- MLSKLL R G GRMVK KKVADYVGT LSD EKLTD AELRAKTDEF KRRLADQKNP
TB Sec 2 MNVHGCPRIA AC CTDTHPR GRPAFAYRWF VPKT A G RL RFWRLL GA TEKNRS LADV ASAE YD EAADLSD EKLRK AGLL NLDD A AD
MS SecA1 --- - - ---- - -- MLSKLL R G GRMVK RKVADYVNA LSD EKLSD AELRAKTEEF KKRVADG---
MS SecA2 ---------- ------MANE SWRTSAYRKR VPKTS AKPG RLS KFW LL GASTERN A LSEVKGAA F KKA DLDD EQLTK AKLL KLED AGASD
1 12 130 140 50 160 170 180 190 200
| |.. | | | | . .| | | |.. | ....|. |
E - ENL IPEAFA VR A RVFGM H FDVQLLGGMV CIAEMR G T T PAYLNA KGVHVV VN L QRD ENN RPLFEFL LT
B - DDL VEAF VVRE SRRV GMFP FKVQLMGG NIAEM G G T T T LPVYLNA KG HVV VNE L SRDAEQM GKIF FL LT
B - DDL PEAF VVR AATRVLGMRP YGVQLMGGIA HE NISEM G T TS LPVYLNA KGVHVV VNE YL QRDANEM GQLH FL LT
B - D I KVEAFA VR AAKRVLG RH D QLIGGLV L E NIAEMP G G T SS LPTYVRALE KGVH ITVN L KR KELI GQVHEFL L
S KKQ DYLD I LPEAY VRE GS RVFN TP YKVQ MGGIA IH D AEMR G G T TAT PTYLN L RGVHVI VNE L VQSEEM A LYNFL LT
S LDTL PE YA AR WRV G YP EVQ IG IV LH NI EMQ G T T T PLYL ALS KG YLI TN YL KR FEEM QPLYEWL LT
T ETLD L LPE F VARE AAWRVLDQRP FDVQ MG LH NVAEMK G G T TCV PAYLNA NGVHIVTVN L K DSEWM GRVHRFL LQ
T ---------- IPQF AIARE RRTGLRP FDVQ LG LR M DVIEM G T GA I A Y A RH HVVTIN L RRD EWM GPLL AM LT
M E LD L LPEAF VARE AAWRVL QRH FDVQ MGGAA LHF NVAEM G G T T V PSYLNA S KG HVVTVN L R DSEWM GRVHRFL L
M ---------- ITQF AIARE A RTTGLRP FDVQ LA LR M DVVEM G T GA I A YA G RR HVITIN L RRD EWM PLLKAL LT
2 0 2 23 240 250 60 270 280 290 300
.| | . | | | | . .| | | |.. | ....|. |
E VGIN PGMP- ----AP KRE AA I Y N YGF YLR DNM FS EER VQRKLH V DEVDSI IDE ARTP IISGP DSS MYKR VNKIIPHLIR
B VGL SMS- ----KDEKRE A AA I Y NN GF YLR DN LYK QM VQ PLHF VI DE DSI IDE ARTP I SGQ AAKST LYV NAFVRTL
B VGI SMS- ----R EKQE A AA I Y N GF YLR DNM LYK QC VQ PLHF II DEVDSI VDE ARTP SGQ QKST LYMF ANAFVRTLEN
B VGL PQ D- ----PSEKK A A TYG GT GF YLR D MAASK E VQRPYHF II EIDSV IDE AKTP AGK KSSSSDLHYL CAKVIKSFQD
S VGLN SKT- ----T EKRE A AQDITYS NNE GF YLR DNM NYSEDR VM PLHF II DEVDSI IDE ARTP SGE AEKSTSLYT AN FAKML Q
S AS GFVDIVD Y YQK EKR I H IIYT GRLGF YLI DN S GK FLPQLN II DEVDSIIL A AQTP V SGA PRLQSNLFHI VKEFVDTLIE
T VGVI MT- ----PDERRV NA ITYG N E GF LR DNMAHSLD L VQR HH IV DEVDSI IDE ARTP ISGP AD ASNWYTE FARL P EK
T GWI D T- ----PD RRT YD TY S VNEIGF VLR DQ TDV L VSPNPD A I D A S VDE AL P VLAG THRETPRLEI IRLVAEL GD
M VGVI GMT- ----PDERRA A A ITYG E GF LR DNMAHS D M VQ GHNF IV DEVDSI IDE ARTP ISGP AD ASHWYQE F RIVPM EK
M GWIT D T- ----AD RRE YQC VTY S VNEIGF VLR DQ TDV L VSPNPD A I D A SV VDE AL P VLAG SHREQPRVEI IRMVGELE G
310 32 33 340 350 360 70 380 390 400
.| | . | | | | . .| | | |.. | ....|. |
E Q DS TFQ EGHF VD K SRQVN----L T RGLVLI LL K IMDE E YSP N -MLM VTAA AH LFTR VDYIVKD V IIVDEHTGRT
B EK - DYTYDIK T AVQ ---L TE GM EK AF ID -- --N D H -ALNHHINQA K HVAMQKD V YV D V VIVD FTGRL
B E - DY F VK T NVM ---L TEDGITK EK AFHIE -- --N H -ALLHHI QA HVVMH D T YVV E I VIVDQF GRL
B TL - HYTYD E K AS ---F TEDGI KIED F D -- --NLYD EHQ -TLYHYM QA AHVAFQCD V Y VHDEKI LLVD FTGRV
S - DYKYD T AVH ---L TE G D A R MFKV -- --NLYD QN - VISHIN A AHVTLQ V YM VD V LIVDQFTGRT
S V - HFKMKKT KKE W ---L LN GIEA QS YF VE -- --DLYS Q M - LV N NLA QYLFESN V YFVYN I VLIDRITGRM
T V- ---- ---H V R KR VG --- H KGV FVE Q ID -- --NLYEAAN -PL S N KAKE FS D YI R EV LIVDEFTGRV
T KD E - --YF TDS N N ----L T HGA KVEK AL GI -- --DLYS EH TTLTE NVA A V LQRD VHYI RDDAV HLINASRGR
M V-------- ---HY R KR VG H H LGV FVE Q ID----- --NLY AAN -PL S N KAKE FQ D K YI RN EV LIVDEFTGRV
M K -- ---HYDTDAE S N ---L T AGA VME KL GI -- --DLYS EH TTLT INVA A V LQR VHYI RDD V HLIN SRGR
10 30 40 50 60 70 8 9 100
.| ..| ....|. . | | | | .. | . .| ....|... | ..|
E. coli SecA -- --- ------- - ML KLLTK F GSRNDRTLRR MRKVVNII A MEPEM K SD EELKGKTAEF RARLEKGEV
B. subt lis SecA -- --- ------- - - -MLG LNKMF DP-TKRTLNR YEKIANDIDA IRGDYEN SD DALKHKT EF K RLEKGATT
B. anthracis SecA1 -- --- ------- - - -MIG LKKVF DV-NQR IKR MQKTVEQIDA LESSIKPLTD E LKGKTLEF K RLT GE V
B. anthracis SecA2 -- --- ------- - - -MLNSVKK L GDSQKR L K YEQLVQEINN LEEKLSD SD E LRHKT F DML DGKTV
S. aureus SecA1 -- --- ------- -- - - MGFLSK L DG-NNKEIKQ LGKLADKVIA LEEKTAILTD EEIRNKT QF QT LAD D V
S. aureus SecA2 -- --- ------- -- - - MKHKL TINELR KS IRKIVKRINT WSDEVKSYSD DALKQ T EF K RLASGVDT
TB SecA1 -- --- ------- -- - - MLSK L RLGE RMVKR LKKVADYVGT LSD VEKLTD AELR KTDEF KRRLADQKNP
TB SecA2 MNVHGCPRI ACRCT AYRWF VP T AQPG RLS R WRLL GASTEKNRS SLADVTASAE Y KEAADL D EKLRKA GLL N DDL ESA
M  SecA1 -- --- ------- -- - - MLSK L RLGE RMVKR LRKVADYVNA LSD VEKLSD AELR KT EF KKRVADG---
M  SecA2 -- ----- AYRKR VPKTS AKPG RLSSKFWKLL GASTERNQAR SLSEVKGAAD FEKKA DLDD EQLTKA KLL EDL GAS
10 13 14 1 1 170 8 9 2
. | | | | | ..|
. coli SecA ENL I F V FGM H FDV L G MV E CIAEMR TG TL LP Y A TG K VHV TVND L QRD ENN RPLFE LGLT
B. subt lis SecA DL LVEAF GM P F LMG A HD NIA MK TG TL S LPVY A T K VHVVTVNE LASRD E M IF FLGLT
B. anthracis Sec 1 DL LPEAF LGMRP YGV LMG IA HE NI MK TG TL S LPVY A T K VHV TVNE LAQRD NEM QL FLGLT
B. anthracis Sec 2 DDI KVEAF V LG RH YD QLIG V L E NIAE P TG TLVSS LP Y ALE K VHV T ND L KRDKELI Q FLGLK
S. aureus SecA1 QN YLDKI LPEAY FN P Y V MG I IHK DIA MR TG KTL A MP Y A AG R VHVITVNE LSSVQSEEM LYNFLGLT
S. aureus SecA2 L LP AY V G YP LIGAIV HE NIAEMQ TGE TL A MPLY NA G K Y IT ND YLA RDFEEM QP WLGLT
TB ecA1 ET DDL LPEAFA L QRP F VMGA H NVA MK TG KTL C LPAY A A N VHI TVND L KRDSEWM R RFLGLQ
TB SecA2 -- IPQF T RP F L G L ML GD IEMA TGE KTL A IAAA Y LA RHVHV T D L RD EWM PLLD M L
M  ecA1 ED DDL LPEAFA L QRH F VMG HF NVA MK TG KTL A LPSYL A S K VHVVTVND LARRDSEWM R RFLGL
M  SecA2 -- I QF TG RP FD L L ML GD VEMA TGE KTL A IAAA Y LG RRVHVIT D L RD EWM PLLK L LT
21 230 240 2 2 270 8 9 3
. | | | | | |
E. coli Sec VGIN MP- ----A I Y T N E GFD L FSPEER QRKLHY LV E D ILIDE ART I SGP A DS MYKR VNKI PH R
B. subt lis SecA V LN NSMS- ----K I Y T N ELGF L N VLYK QM RPLHF VI DE D I IDE RT IISGQ AAKSTK YVQ NAF RTLK
B. anthracis Sec 1 V IN NSMS- ----R I Y T N ELGFD LR LYKEQC QRPLHF I DEVD ILVDE RT I SGQ AQKSTE YMF NAFVRTL N
B. anthracis Sec 2 V LNI Q D- ----P TYGI GTE GFD LR N SKNEQ V RPYHFA I DEIDSVLI AKT II GK KSSS H L CAKVIK F
. a reus SecA1 V LNLNSKT- ----T ITYS N ELGFD L N VNYSED VMRPLHF I DEVD I IDE ART II GE A KSTS Y Q NVFAKM KQ
S. a reus SecA2 ASL FVDIVD YE QKG N IIYTT NGRL FDYLI N S EGK F PQLNYGII DE D II A A T V SG P LQ N FH VKEFVDT IE
B SecA1 V IL TMT- ----P ITYG N E GF L N HSLDD VQ HYAIV DE D ILIDE ART II GP A A NWYT FA LA LM K
TB Sec 2 V WIT DST- ----P TYA NE GF VL Q T VND SPN D LI DE DSVLVDE AL L GT THR P LEI RLVAE V
 SecA1 V ILS MT- ----P ITYG N E GF L N HSVDDM VQ NFAIV DE D ILIDE ART LII GP A A HWYQ FA I MM K
M  Sec 2 V WIT DST- ----A VTYA NE GF VL Q SPN D LI DE DSV VDE AL L GT SHR P EI RMV E E G
31 0 340 3 3 370 8 9 4
. | | | | | |
. coli SecA Q KEDS TFQ GEG ----L ER LV E L K G MDE ESLY PA I - LMHHVTAA LRA ALF R VDYI D V I HTG
B. subt lis Sec K DY L E GM K K FG D NLF VKH - NHHINQA LKA VAMQK VDYV E V V D FTG
B. anthracis SecA1 K DY L E G K K F E NLF LKHV - LLHHINQA LRA VVMH TDYVVQE EI VIVDQFTG
B. anthracis SecA2 TL Y F E G TKI D LFD D NLY L Q -T YHYMIQA LRA V FQC VDYI HDEK VDIFTGR
S. a reus SecA1 DE DY L EQG D A MF E NLYDVQ -DVISH NTA LRA VTL V YM V E I DQFTG T
S. a reus SecA2 D HF L NQG EA QS YF VE D Y EQA - VRNIN A RAQ LFE N VD F YN DI VL RITGRM
TB SecA1 D - -- --- E T V H KGVEF D G D- -- -NLYE A S -PLVSYLNNA LKAKELF KDYIV EV I FTG
TB SecA2 KDA E --YF H L TE GARKVEK G I LY EE TT TE N A LH VLLQR VHYI DDAV HLINA RG I
M  SecA1 D -- ---HYE T VHV V H GVEF D G D---- -NLYE A S -PLVSYLNNA LKAKELFQ KDYIV N EV I FTG
M  SecA2 K -- ---HY H L TEA AR ME K G I -DLY EE TTLTEIN LH VLLQR VHYI DAV HLINA RG I
EcSecA
BsSecA
BaSecA1
BaSecA2
SaSecA1
SaSecA2
MtbSecA1
MtbSecA2
MsSecA1
MsSecA2
C-terminal
Motifs Q I Ia GG Ib II III IV V VI
NBD1 NBD2
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vestigate their ATPase and GTPase activities. To determine whether SecA1 and SecA2 could 
interact with membrane in the same way as EcSecA, the ATPase activity of SecA homologues 
were investigated in presence of liposomes; proteolysis assay was used to identify specific 
transmembrane domain of MtbSecA1; transmission electron microscopy (TEM) and atomic 
force microscopy (AFM) were used to investigated whether SecA1 and SecA2 could change 
structure in presence of liposomes; the subcellular localization of MsSecA1 and MsSecA2 were 
investigated. 
SecA homologues were used to develop and optimize three structurally different classes 
of potential SecA inhibitors developed from three different approaches: 1) RB and RB analogs 
derived from systematical dissection RB and SAR study; 2) pyrimidine analogs derived from 
virtual screening based on ATP binding pocket of EcSecA and SAR study [80-81]; 3) bistriazole 
analogs derived from random screening and SAR study. This project is in collaboration with Dr. 
Binghe Wang‟s lab. SecA inhibitors were screened and optimized based on the Structure-
Activity relationship study. The in vitro inhibition effects of inhibitors against the ATPase activi-
ty of SecA homologues were investigated as well as the antimicrobial activities against B. subti-
lis 168, S. aureus 6538, B. anthracis Sterne, E. coli NR698, and S. aureus Mu50. Several potent 
SecA inhibitors were subjected to killing assay to investigate their bactericidal effects. 
In E. coli and B. subtilis Sec system, SecYEG complex form the translocation core chan-
nel in membrane, while SecA undergo cycles of membrane insertion and dissociation, guiding 
and pushing pre-protein export through transmembrane channel formed by SecYEG [38, 91]. 
However, SecY and SecE are not required for protein translocation in some in vitro assay [92-
93]; and in activated state, some domain of SecA is exposed to the surface of E. coli inner mem-
brane [94-95]. Previous studies of our lab demonstrated that EcSecA exists as soluble form and 
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membrane form [96-97]; SecA alone could form ring-like structures upon interaction with anio-
nic phospholipids [38-39]; and EcSecA is sufficient to export preOmpA across liposomes (Shieh 
et al, 2012),  suggesting that SecA might be involved in forming a protein conducting-channel 
that spans the entire membrane. Thus, drugs targeting SecA might be directly accessible from the 
extracellular matrix and exert their effects without entering the cell, and bypassing the negative 
effect of efflux transporters in bacteria, which is a major mechanism for the development of cur-
rent drug-resistance [72-76, 98-99]. S. aureus Mu50 and S. aureus N315 are resistant to QacA 
efflux-mediated antibiotics [100]. NorA and MepA are two S. aureus efflux pumps, belong to the 
major facilitator superfamily (MFS) or the multidrug and toxic compound extrusion (MATE) 
family [98, 101]. In this study, we further investigated whether our inhibitors have antimicrobial 
activities against S. aureus Mu50 and S. aureus N315, and whether NorA and MepA could affect 
the antimicrobial activities of our SecA inhibitors.  
Sec system is not only responsible for the secretion of many essential proteins, but also 
responsible for the secretion of many toxins and virulence factors [33-35]. Because both SecA1 
and SecA2 are involved in secretion of virulence factors, dual targeting inhibition on these two 
SecA homologues would dramatically reduce virulence. Virulence target-based therapies are not 
sufficient to combat infection, but targeting SecA homologues is not only reduces virulence but 
also decreases viability, dramatically increasing the chance of control bacterial infection and re-
ducing the occurrence of drug resistance. To determine whether inhibitors could inhibit the in 
vivo function of SecA and whether inhibitors could reduce virulence of bacteria pathogen, we 
investigated the inhibition effect of SecA inhibitors on the secretion of three S. aureus toxins and 
three B. anthracis toxins, in which precursors contain N-terminal signal peptide required for se-
cretion through Sec-pathway [34-35].  
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To validate SecA as the target of those inhibitors developed in our study, we investigated 
inhibition on in vivo function of SecA and interaction between SecA and inhibitors. And two dif-
ferent target identification assays were used to determine whether inhibitors could specifically 
bind with SecA at whole cell level.  
In this research, we study the biochemistry properties of SecA homologues, develop nov-
el SecA inhibitors, and further demonstrate that SecA is a real target of those inhibitors. The dis-
sertation is composed of three parts: 1) Comparative characterization of SecA1 and SecA2 of 
Gram-positive bacteria. 2) Development and optimization of novel SecA inhibitors. 3) Valida-
tion of SecA as a real target.  
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CHAPTER 1 COMPARATIVE CHARACTERIZATION OF SECA1 AND SECA2 OF 
GRAM POSITIVE PATHOGENS 
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Summary 
Although majority of bacteria contain only one SecA homologue, two SecA homologues 
are indentified in some important Gram-positive pathogenic bacteria. SecA1 is involved in gen-
eral protein secretion and essential for viability, whereas SecA2 contribute to the virulence of 
some important Gram positive pathogen by playing a role in a specialized secretion pathway. 
The biochemical properties of SecA1 and SecA2 from Gram-positive bacterial pathogens have 
not been well characterized. Alignment showed that nine motifs of DEAD helicase are highly 
conserved in all SecA homologues. In EcSecA, these nine motifs form two nucleotide binding 
domains (NBD); NBD1 acts as the ATPase catalytic machinery; NBD2 is a regulator of ATP 
hydrolysis at NBD1. The conservation of these motifs suggested that SecA1 and SecA2 might be 
ATPase and have direct role on translocation. In this study, four different species of SecA1 and 
SecA2 were cloned, over-expressed in E. coli, and purified. All these SecA homologues possess 
ATPase activity, suggesting that they could be molecular motor. The ATPase activity of SecA1 
can be stimulated by liposomes, while the ATPase activity of SecA2 cannot be stimulated by li-
posomes. The optimal temperature for ATPase activity is varied in different SecA proteins. Only 
mycobacteria SecA1 showed high ATPase activity at 0
o
C. The ATPase activity of MsSecA1 
could be obviously stimulated by BA13 membrane and the preOmpA of E. coli, while other Se-
cA homologues do not show similar response. Because the membrane and precursor were from 
E. coli, they might not be recognized by translocase from other species. Mycobacteria SecA1 
and SecA2 failed to complement the temperature-sensitive defect EcSecA, suggesting that inte-
raction between secretion factors of Sec system might be specific for different organisms. Major-
ity of MsSecA1 are located on membrane, while majority of MsSecA2 are located in cytosol. 
Liposomes could induce conformational change of MtbSecA1 and form ring-like structures un-
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der TEM and AFM. All these results suggest that mycobacteria SecA1 might interact with mem-
brane in the same way as EcSecA and might be involved in forming transmembrane channel. 
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Introduction 
Bacterial exported proteins play important roles in bacterial physiology, viability, or/and 
pathogenicity [11-13]. Some exported proteins function as essential proteins, required for bac-
terial growth, cell wall maintenance, and cell division [17-18]; moreover, some exported proteins 
function as toxins or virulence factors required for establishment of infection, invasion in human 
tissue, protection from host defense system, or inducing toxic syndrome [19-22] . Therefore, fur-
ther understanding of protein secretion mechanism may provide opportunities to target therapies 
or to create a vaccine candidate by interrupting components of the secretion pathway [23]. In 
both Gram
+
 bacteria and Gram
-
 bacteria, two major conserved protein export systems are respon-
sible for transporting proteins across cytoplasmic membrane [24-26]: General secretion (Sec) 
pathway and Twin-arginine translocation (Tat) pathway. In some bacteria, there are also specia-
lized export systems responsible for secretion specific virulence factors [28]. Sec system is not 
only responsible for the secretion of many essential proteins, and it is also responsible for the 
secretion of many toxins and virulence factors [33-34].  
The Sec pathway is well-characterized through studies with E. coli and B. subtilis. In 
these two model systems, an essential protein is the SecA ATPase, which interacts with virtually 
all the other components of the system, acting as a molecular chaperone, providing driving force 
for translocation, pushing preprotein export through transmembrane channel [36], and being in-
volved in forming protein conducting channel [38-39]. SecA is highly conserved in bacteria and 
essential for viability, moreover it has no counterpart in mammalian cell [40]. Thus SecA might 
be an ideal target for developing antimicrobial agents [13, 23]. It was long believed that all bac-
teria have a single SecA [41]. However, in recent 9 years, two SecA homologues are identified in 
some important Gram positive bacteria [28, 42-48]. Majority of these bacteria are human patho-
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gens, including some pathogens lethal to human or causing serious multi drug resistant problems. 
For those two SecA homologues, the one with the higher homology to EcSecA was named Se-
cA1, and the other one with lower homology to EcSecA was named SecA2. Previous genetic 
studies show that SecA1 essential for viability and might be involved in general secretion path-
way [28, 49-50]; while SecA2 is not essential, except in C. glutamicum [51] and C. difficile [52]. 
Although SecA2 is not essential for the viability but it is involved in secretion of specific pro-
teins related with virulence, such as protective enzyme, adhesion, autolysin [44-46, 48, 53-54]. 
SecA2 also plays a role in creating immune response. In MTB, SecA2 restricts maturing of anti-
gen specific CD8+ T cells and protection in vivo [56]; while in L. monocytogenes, SecA2 pro-
motes protective immune response [57]. 
Although the function of SecA is well studied in E. coli and B. subtilis, and the functions 
of SecA1 and SecA2 from Gram+ bacteria pathogen were studied with genetic methods, the bio-
chemical properties of SecA homologues not investigated. We don‟t know whether these pro-
teins have similar functions as EcSecA and BsSecA. Alignment result showed that nine motifs of 
DEAD helicase were highly conserved in all SecA homologues (Fig. 0.2). In EcSecA, these nine 
motifs form two nucleotide binding domains (NBD);  NBD1 has high affinity to nucleotide, and 
contains minimal ATPase catalytic machinery; NBD2 has low affinity to nucleotide, and acts as 
an activator of ATP hydrolysis by controlling ADP release and optimal ATP catalysis at NBD1 
[90, 102]. Thus, NBD1 and NBD2 are very important to the translocase activity of EcSecA. The 
conservation of these domains suggests SecA1 and SecA2 might have similar translocase activity 
as EcSecA. Thus, we hypothesize that SecA1 and SecA2 are ATPase that hydrolyses ATP to 
promote translocation of specific proteins. Moreover, drugs targeting NBD domains might have 
dual targets in those Gram-positive pathogen containing two SecA homologues. 
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In this study, SecA1 and SecA2 were cloned from M. tuberculosis H37Rv, M. smegmatis 
mc
2
155, S. aureus 35556, and B. anthracis Sterne, over-expressed in E. coli, and purified. The 
biochemical properties of these SecA homologues were comparatively characterized. 
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Materials and Methods 
Medium and Reagents: LB and TAG were used as liquid and solid (with1.5% agar) 
medium to grow bacteria.  1 liter TAG medium contain 10 g tryptone, 5 g NaCl, 10g glucose, 
40mM potassium phosphate buffer (pH7.0), 7.6 mM ammonium sulfate, and 1.6mM sodium ci-
trate. T4 DNA ligase (triple-master) was purchased from Eppendorf. Plasmid and Gel extraction 
kits were purchased from Qiagen. All other chemicals were purchased from Sigma-Aldrich. 
Middlebrook 7H9 broth with 0.2% glycerol, 1ADC (0.5% bovine serum albumin, fraction V, 
0.2% dextrose, 0.85% NaCl), and 0.1% Tween 80 was used to grow M. smegmatis Mc
2
155. 
Bacterial Strains: E. coli DH5α was used as host for cloning. E. coli BL21.19 and 
BL21λDE3 were used for overexpression. E. coli BL21.19 and BA13 were used for complemen-
tation assay. BL21.19: λDE3, SecA13(Am) supF(Ts) trp(AM) Zch::Tn10, recA::CAT 
claA319::KAN [103]. BA13: secA13(Am) supF(Ts) mutant of MC4100, secA(am), supF(ts), F
-
, 
lacU169, araD136, relA
-
, rps150, febB5301, deoC7, ptsF25thi [96, 104]. Genes from M. tuber-
culosis H37Rv, M. smegmatis mc
2
155, S. aureus 35556, and B. anthracis Sterne were used to 
clone SecA1 and SecA2. M. smegmatis mc
2
155 was from Dr. Miriam Braunstein at University of 
North Carolina at Chapel Hill. M. tuberculosis H37Rv gene was from TB vaccine testing and re-
search materials contract program of Colorado State University.  
Primers and Plasmids: The primers and plasmids used in this work were listed in Table 
1.1. 
Cloning: PCR amplification was carried out in Eppendorf Mastercycler using Triple 
master DNA polymerase of Eppendorf. 2-3% DMSO was added into amplification mixture when 
cloning SecA homologues from M. tuberculosis H37Rv, M. smegmatis mc
2
155. PCR products 
were purified by gel extraction; vector DNA and PCR product were double digested by restric-
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tion enzymes, then purified by gel extraction; then the digested DNA of vector and insert were 
ligated using T4 DNA ligase at 14°C overnight; ligation mixture were transformed into E. coli 
DH5α; positive cloning was selected and transform into BL21.19 or BL21λDE3. 
         Table 1.1 Plasmids and primers used for cloning secA1 and secA2 
Gene primer (5’-3’) 
Restric-
tion site 
plasmid 
MtbsecA1-1 (his-) 
5‟primer  GCGGGGACATACATATGCTGTCGAAG Nde I 
pET-20b (+) 
3‟primer  TCTGCAACCAAGCTTCTAACGCTT Hind III 
MtbsecA1-2 (his+) 
5‟primer  GCGGGGACATACATATGCTGTCGAAG Nde I 
pET-20b (+) 
3‟primer  GCAACCTACAAGCTTACGCTTCTT Hind III 
MtbsecA2-3 (his+) 
5‟primer  CGTCCAGCCCCATGGTGA ACGTG Nco I 
pET-33b (+) 
3‟primer  CTTACGCTGGAATTCTCAGCGGAA EcoR I 
MssecA1 (his+) 
5‟primer  ACTCATATGCTGTCGAAGTTGGTC Nde I 
pET-20b (+) 
3‟primer ATAGAGCTCGAGCCCTTGGGGTGC Sac I 
MssecA2 (his+) 
5‟primer ACTCATATGGCGAATGAGTCCTG Nde I 
pET-33b (+) 3‟primer ATAGAATTCGAGCGGAACACACCC EcoR I 
3‟primer  ATAAAGCTTGCGGAACACACCCGG Hind III 
SasecA1 (his+) 
5‟primer AGCGGCTAGCGGATTTTTATCAAAAATTC Nhe I 
pET-21d (+) 
3‟primer TCGCAAGCTTTTTTCCATGGCAATTTTTG Hind III 
SasecA2 (his+) 
5‟primer GAACCATGGGCAAACATAAACTAG Nco I 
pET-33b (+) 3‟primer TATGAATTCCCTGGAAAATGTATAAC EcoR I 
3‟primer TATGAGCTCCCTGGAAAATGTATAAC Sal I 
BasecA1 (his+) 
5‟primer TCTCCATATGATCGGTATTTTAAAAAAGGTG Nde I 
pET-20b (+) 3‟primer TATAGTCGACCTTCCCGATACCACAGCAG Sal I 
3‟primer TATAAAGCTTCTTCCCGATACCACAGCAG Hind III 
BasecA2 (his+) 
5‟primer TATACCATGGTGCTGAATTCGGTAAAAAAGC NcoI 
pET-33b (+) 
3‟primer TATAGTCGACTTGTACGTTTTCAGGAACACC Sal I 
 
Overexpression: BL21.19 or BL21λDE3 containing the respective plasmids were 
streaked on TAG medium plate and incubated at 30
o
C or 37
o
C overnight. Single colony was in-
oculated into 3 ml of TAG medium and shook at 30
o
C or 37
o
C overnight. Then, the overnight 
culture was diluted into 50 ml of the same medium and continued to grow at 30
o
C or 37
o
C until 
OD600 reached 1. The freshly grown-up culture was further diluted into 1.5 L of the same me-
dium and grew until OD600 reached 0.8, then the culture was cooled down in tap water and put 
back to shaker at 20
o
C. 0.1 mM to 0.5 mM IPTG was added to the culture and the cell culture 
continued to grow at 20
o
C overnight and the cells were collected by centrifugation. 
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ATPase Activity Assay: Malachite green colorimetric assay [105] was used to investi-
gate ATPase or GTPase activity of SecA homologues. For the intrinsic ATPase activity, appro-
priate amount of SecA was mixed with 2 mM ATP in reaction buffer (50 mM Tris-HCl, pH 7.6, 
20 mM KCl, 2 mM Mg(OAc)2 and 1 mM DTT). For the lipid ATPase activity, different amount 
of liposomes was added into the intrinsic ATPase assay. To make liposomes, E. coli total lipid 
was dried in a speed vacuum, resuspended in TK buffer (50 mM Tris-HCl, pH 7.5, 50 mM KCl), 
then sonicated for 10 min on ice. For membrane ATPase activity, E. coli BA13 membrane frac-
tion II (washed by 6 M Urea) was added into the intrinsic ATPase activity. For translocation 
ATPase activity, E. coli BA13 membrane fraction II (washed by 6M Urea) and proOmpA were 
added into the intrinsic ATPase assay. The components were mixed at 0
o
C, and incubated at dif-
ferent temperature for different time; the reactions were stopped by the subsequent addition of 
800 µl of color regent (0.045% malachite green mixed with 4.2% ammonium molybdate in 4N 
HCl at a ratio of 3:1, 0.1% Triton X-100 was added after filtration of the mixture) and 100 µl of 
34% sodium citrate; the mixture was incubated at room temperature for 40 min, then its absorp-
tion was measured at 660 nm. The specific activity was determined based on a standard curve 
which was prepared with phosphate salt.  
Complementation Test: Plasmids harboring different mycobacteria SecA homologues 
genes were transformed into BL21.19 strain or BA13, and grew on TAG/agar plates at 30
o
C 
overnight. The single colony was picked up and streaked on two new TAG/agar plates with dif-
ferent concentration of IPTG or arabinose, and incubated at 30
o
C and 42
o
C overnight respective-
ly. 
Subcellular distribution of mycobacteria SecA2 and SecA1: M. smegmatis Mc
2
155 
were grown in Middlebrook 7H9 broth with 0.2% glycerol, 1ADC (0.5% bovine serum albu-
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min, fraction V, 0.2% dextrose, 0.85% NaCl), and 0.1% Tween 80. The cell pellet was French 
pressed at 18,000 psi, and unbroken cells and large cellular debris are removed by centrifugation 
at 3,000  g. The supernatant of 3,000  g was centrifuged at 27,000  g for 1h to generate a 
fraction enriched in cell wall. The supernatant of 27,000  g was centrifuged at 258,000  g for 
1.5 hrs to sediment the remaining cytoplasmic membrane. 
Preparation of sample for TEM: 15-20 μl samples of protein (25-200 μg/ml) in 20 mM 
Tris-HCl buffer (pH 7.4) were added to small Teflon wells (4 mm in diameter and 0.5 mm deep) 
until the liquid surface bulged up. Add 0.5-1.0 μl of E. coli phospholipids (from Avanti Polar 
Lipids) solutions (1 mg/ml) in chloroform/methanol (3:1 vol/vol) with a syringe. The wells were 
incubated in a sealed humid atmosphere at 4
o
C for 24 hours. Then, the lipid monolayers at the 
air/liquid interfaces were picked off with hydrophobic carbon coated gold grids. After washing 
with several drops of incubation buffer, grids were negatively stained with uranyl acetate solu-
tion (0.5-1%  wt/vol). The grids were examined with TEM. 
Preparation of sample for AFM: To prepare lipid bilayers, extracted E. coli total lipid 
was vacuum dried, resuspended in TKM buffer (10 mM Tris-HCL, pH 8.0, containing 50 mM 
KCl and 2 mM MgCl2) and sonicated for 15 min in an ice bath. The mixture of SecA with or 
without lipid bilayer in 10 μl TKM buffer was vortaxed for 10 sec and applied to freshly cleaved 
mica, which were held at room temperature for 10-15 min, rinsed four times with deionized wa-
ter, and dried in a dessicator. Goat anti-rabbit IgG gold at concentration of 15 μg/ml in the same 
TKM buffer, was used as a reference for measuring the sizes.   
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Results 
Cloning, Expression, and Purification of SecA Homologues 
Cloning, Expression, and Purification of SecA Homologues of M.  tuberculosis H37Rv 
Cloning and Over-expression M.  tuberculosis secA1 (MtbsecA1) The MtbSecA1 gene 
was amplified from M. tuberculosis H37Rv, cloned into pET-20(+), and overexpressed in 
BL21.19. SecA1 can be expressed very well at 20
o
C for 4-6 hours induced by 0.5 mM IPTG, and 
in the supernatant of 50k rpm supernatant (Fig. 1.1).  
Purification of MtbSecA1 The PI/MW of MtbSecA1 (5.29/10.6 kDa) is very close to 
the PI/MW of EcSecA (5.4/10.2 kDa), causing difficulty to separate these two proteins. To im-
prove purity of MtbSecA1, EcSecA could be depleted by culturing BL21.19 at 41
o
C for more 
than three generation. However, our result showed that depletion EcSecA at 41
o
C will cause 
much lower expression of MtbSecA1-1 (Fig. 1.1). Therefore, instead of depletion, Nickle col-
umn was used to separate those two proteins (Fig. 1.2a).  The elution from Nickle column was 
load to SP-Sepherose column, and further purified by size column (Fig. 1.2b-1.2c).   
Cloning and Over-expression M.  tuberculosis secA2 (MtbsecA2) The MtbSecA2 gene 
were amplified from M. tuberculosis H37Rv, cloned into pET-33b with 6X his-tag at C-terminal, 
and overexpressed in E. coli BL21λDE3. MtbSecA2 was expressed at three temperature, differ-
ent time, and different concentration of IPTG. Our results showed that TAG medium was better 
than LB medium, and 37
o
C was better than 30
o
C and 18
o
C. However, at 30
o
C and 37
o
C, majority 
of MtbSecA2 formed inclusion body or aggregated; while at 18
o
C, MtbSecA2 expression was 
not very good, but majority of MtbSecA2 remained at the supernatant (Fig. 1.3a). To increase 
expression of MtbSecA2, rifampicin was used to shut down the expression of E. coli host protein. 
The cell was grown and expressed as Fig. 1.3b. When expressed at 30
o
C, the expression of 
41 
MtbSecA2 was very good (Fig. 1.3c), however there was no soluble MtbSecA2 (Fig. 1.3d). To 
induce enough T7 RNA polymerase, 1 mM IPTG was added 25 min earlier before adding rifam-
picin at 20
o
C. The results showed that the expression of MtbSecA2 at 20
o
C is not as good as ex-
pression at 30
o
C (Fig. 1.3e), but adding rifampicin at 20
o
C without up-regulate temperature, ma-
jority of MtbSecA2 are soluble (Fig. 1.3f). To enhance expression amount of soluble MtbSecA2, 
yeast extract or MgSO4 was added in TAG medium when adding IPTG to induce expression. 
However, the expression of Mtb SecA2 didn‟t affected by adding yeast extract and Mg2+ (data 
not shown).   To express MtbSecA2 at a large scale, MtbSecA2 was grown at 37
o
C in 1.5 L TAG 
with 6L bottle. When OD600 reach 0.9, cell culture was cooled down to 20
o
C, then added IPTG to 
1 mM; 25 min later adding 200 μg/ml rifampicin, then expressed at 20oC overnight or 5.5 hours. 
A lot of soluble MtbSecA2 remain in the supernatant of 50K rpm (Fig. 1.3g). 
Purification of MtbSecA2 Cell pellet was resuspended, and French pressed at 18k PSI, 
then centrifuged at 4k rpm, 8k rpm, and 37k rpm to remove unbroken cell, inclusion body, and 
membranes. The supernatant of 37k rpm were loaded to His-trap column and further washed 
with imidazole gradient by using FPLC. MtbSecA2 bound His-trap very well, and majority of 
MtbSecA2 was eluted out with 50 mM to 100 mM imidazole (Fig. 1.4a). To avoid denaturation, 
the eluents from His-trap column were directly loaded to Hisprep
TM 
26/10 desalting column in-
stead of dialysis. The eluted fraction of desalting column was loaded to Q-sepharose column. 
The result showed that Q-Sepharose column could further remove some junk protein and in-
crease purity of MtbSecA2 (Fig. 1.4b).  The appropriate fractions from Q-Sepharose column 
were concentrated with Amicon Ultra centrifugal filter, then, loaded to Superose-6 column. The 
column was washed with 100 mM NH4HCO3. The result showed the purity is very high, but 
there is some degradation (Fig. 1.4c).   
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Figure 1.1  Expression of MtbSecA1 
P: pellet of 50k rpm 30min; S: supernatant of 50k rpm 30 min 
   
 
 
  
Figure 1.2a Purification of MtbSecA1 with Ni-NTA resin 
lane 1: pellet of 4k rpm; lane 2: pellet of 36k rpm; lane 3: supernatant of 36k rpm; lane 4: unbinding sample; lane 5: 
buffer wash; lane 6: 20 mM imidazole; lane 7: 40 mM imidazole; lane 8: 60 mM imidazole; lane 9: 250 mM imida-
zole; lane 10: 500 mM imidazole. 
 
 
 
    
Figure 1.2b Purification of MtbSecA1 with SP-sepherase column 
Lane 1-2: fraction 40-41, confirmed to be EcSecA by western blot; lane 3-13: fraction 59-69. PBS buffer: pH 6.4. 
                                   Superose-6 column                                  S-300 column                   0 
 
 
Figure 1.2c Purification MtbSecA1 with size column 
Buffer: 100 mM NHHCO3; lane 1-14: different fraction from Superose-6 column; lane 15: loading sample of Super-
dex-300 column; lane 16-26: different eluent fraction from Superdex-300 column. 
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Figure 1.3a Expression of MtbSecA2  
P: pellet of 50k rpm; S: supernatant of 50k rpm 
 
 
     
Figure 1.3b Expression of MtbSecA2 with rifampicin at different temperature 
 
 
            
                        
 Figure 1.3c Expression of MtbSecA2 with rifampicin at 30
o
C  
 
 
 
Tb SecA2 
OD600=0.7 
TAG, 1mM MgSO4 37
o
C 
30oC, 0.5h, 1h, 
2h, 3h, 4h 
37oC, 10min 
0.2mg/ml Rephampicin 0.2mg/ml Rephampicin 
30oC, water bath 5min 20oC, water bath 5min 
1mM IPTG, 15min, 30oC 1mM IPTG, 25min, 20
oC 
20oC, 10min 37oC, 10min 20oC, 10min 
20oC, 0.5h, 1h, 
3h, 5h, O/N 
Temperature                                     30oC                           0              
Rephampicin             37oC 10min              30oC 10min               
Expression (hrs)  0.5  1   2    3    4    0.5   1    2    3    4    0        
                      30oC 1h    30oC 2h    37oC 0.5h    37oC 1h    18 oC O/N 
IPTG(mM)  0.5     1.0   0.5   1.0     0.5    1.0    0.5    1.0    0.5    1.0 
             M   P  S  P   S  P  S  P  S   P  S   P  S  P  S   P  S   P  S  P   S 
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Figure 1.3d Solubility of MtbSecA2 expressed at 30
o
C 
P: pellet of 50K rpm 30 min; S: supernatant of 50K rpm 30 min. 
 
 
 
            
                            
Figure 1.3e Expression of MtbSecA2 and rifampicin at 20
o
C  
o/n: overnight. 
 
 
 
 
                            
Figure 1.3f Solubility of MtbSecA2 expressed at 20
o
C  
P: pellet of 50K rpm 30 min; S: supernatant of 50K rpm 30 min 
 
 
 
 
                     
Figure 1.3g Expression of MtbSecA2 at large scale 
W: crude cell lysate; P is pellet; S is supernatant.  
Temperature                                                20oC                                    0               
Rephampicin                     37oC 10 min                       20oC 10 min            0        
Time (hrs)         1             3        5          o/n      1          3         5       o/n 
Pellet/sup        P   S       P   S   P   S     P   S    P   S    P   S   P   S    P   S   
 Rpm           4.5k     10k      50k 
              W  P    S   P   S     P   S   
               1   2    3   4    5    6    7 
  
Temperature                                20oC                0 
Rephampicin           37oC 10 min        20oC 10 min    
Expression (hrs)     1     3    5   o/n    1     3     5   o/n   0 
Temperature                                                   30oC                                                     0                     
Rephampicin                    37oC    10min             0                     30oC 10min                 0        
Time (hrs)       0.5       1         2       3          4         0 0.5       1        2          3        4             
Pellet/sup       P   S   P   S   P   S   P   S    P   S        P   S   P   S   P   S    P   S   P   S         
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Figure 1.4a Purification of MtbSecA2 with His-trap column 
Lane 1: 4k rpm pellet; lane 2: 4k rpm supernatant; lane 3-4: 8k rpm pellet; lane 5: 8k rpm supernatant; lane 6: 37k 
rpm pellet; lane 7: 37k rpm supernatant; lane 8: loading sample; lane 9: unbinding sample; lane 10-37: different elu-
ent fractions.  
 
 
 
Figure 1.4b Purification of MtbSecA2 with Q-sepharose column 
Buffer: PBS buffer pH 7.6; lane 1: loading sample; lane 2: unbinding sample; lane 3-28: different eluent fractions. 
 
 
 
Figure 1.4c Purification of MtbSecA2 with Superose-6 column 
Buffer: 100 mM NH4HCO3; lane 1-14: different eluent fractions. 
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Cloning, Expression, and Purification of SecA Homologues of M. smegmatis  
Cloning and overexpression of M. smegmatis secA1 (MssecA1) The gene of MsSecA1 
was amplified from M. smegmatis mc
2
155, cloned into pET-20b (+) with 6X his-tag at C-
terminal, and overexpressed well in E. coli BL21λDE3 at 20oC for 10 hours (Fig. 1.5). 
Purification of MsSecA1 The harvested cells were French pressed at 18,000 PSI and 
centrifuged at 5,000 g for 10 min and 36K rpm for 30 min. Then, the supernatant of 36k rpm was 
purified with His-trap column. MsSecA1 could bind with His-trap column very well (Fig. 1.6a).  
MsSecA1 could be washed out with 80 mM imidazole, and majority of the protein came out be-
tween 100 mM-250 mM imidazole. The elution from His-trap column was mixed and dialyzed 
over night with 25 mM potassium phosphate buffer (pH 6.4), then further purified with SP-
sepharose column (Fig.1.6b) and size column (Fig. 1.6c). The results of SP column and size col-
umn showed that there was some degradation.  
Cloning and overexpression of M. smegmatis secA2 (MssecA2) The gene of MsSecA2 
(His tag +) was amplified from M. smegmatis mc
2
155, cloned into pET-33b with 6X his-tag at 
C-terminal, and  overexpressed in E. coli BL21λDE3 at 20oC for 10 hours. The expression was 
very good (Fig. 1.5). The harvested cell was French pressed at 18,000 PSI and centrifuged at 
5,000 X g for 10 min and 36K rpm for 30 min. Then, the supernatant of 36k rpm was purified 
with His-trap column with 25 mM potassium phosphate buffer (pH 7.6) containing 0.5 M NaCl. 
MsSecA2 could bind with His-trap column, but MsSecA2 could be washed out with 10 mM im-
idazole, and majority of the protein came out between 20 mM-100 mM imidazole (Fig. 1. 7a). 
Some appropriate fraction of His-trap column was mixed and dialyzed over night with 25 mM 
potassium phosphate buffer (pH 8.0), then further purified with Q-Sepharose column (Fig. 1.7b) 
and Superdex-200 column (Fig. 1.7c).    
  
47 
 
 
 
       
Figure 1.5 Expression of MsSecA1 and MsSecA2 
Lane 1-6 and lane 8-13: different colonies.  
 
 
 
Figure 1.6a Purification of MsSecA1 with His-trap column  
Lane 1: the pellet of 36k rpm; lane 2: the supernatant of 36k rpm; lane 3: loading sample; lane 4: unbinding sample; 
lane 5-14 is different eluent fraction. 
 
 
 
  
Figure 1.6b Purification of MsSecA1 with SP-sepharose column  
Lane 1 is the precipitated pellet of dialysis; lane 2 is loading sample; lane 3 is unbinding sample; lane 4-28 are dif-
ferent eluent fraction. 
 
 
Figure 1.6c Purification of MsSecA1 with size column. 
Buffer: 100 mM NH4HCO3; lane 1-9: different fraction from Superose-6 column; lane 10-23: different eluent frac-
tion. 
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Figure 1.7a Purification of MsSecA2 with His-trap  
Lane 1: crude cell lysate; lane 2: the pellet of 4k rpm; lane 3: the pellet of 36k rpm; lane 4: the supernatant of 36k 
rpm; lane 5: loading sample; lane 6: unbinding sample; lane 7-28 is different eluent fraction. 
 
 
 
Figure 1.7b Purification of MsSecA2 with Q-sepharose column 
Lane 1: loading sample; lane 2: unbinding sample; lane 3-14: different eluent fractions. 
 
 
 
Figure 1.7c Purification of MsSecA2 with S-200 
Buffer: 100 mM NH4HCO3; lane 1-28: different eluent fractions. 
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Cloning, Expression, and Purification of SecA Homologues of S. aureus  
Cloning and expression of S. aureus secA1 (SasecA1) The SasecA1 gene was amplified 
from S. aureus ATCC35556, cloned into pET-21d with 6X his-tag at C-terminal (Fig. 1.8), then 
over-expressed in BL21λDE3 at 20oC or 37oC with 0.5 mM IPTG. The gel result showed that the 
expression of SaSecA1 at 20
o
C was better than at 37
o
C (Fig. 1.9).  
Purification of SaSecA1 Cell pellet was French pressed at 18,000 psi. The supernatant 
of 37k rpm was loaded onto 5 ml His-trap column, and washed with different imidazole gradient 
by FPLC.  The results show that SaSecA1 bind to His-trap column very well, and it could be 
eluted with >60 mM imidazole, and there were two peaks. The SDS-PAGE gel result showed the 
purity of some fraction was very high (Fig. 1.10a). The elution of his-trap column was concen-
trated with centrifugal filter to 10 mg/ml, then loaded to Superdex-200 column. The result of Su-
perdex-200 column showed that SaSecA1 was very big and had degradation (data not shown). 
Some appropriate fractions of His-trap column were mixed, and concentrated with centrifugal 
filter, then diluted and loaded to Q-Sepharose column. SaSecA1 was further purified by using Q-
Sepharose column (Fig. 1.10b). Then the fraction 59-71 were concentrated, and loaded to S-200 
column. The result of Superdex-200 column showed that the purity was very high and the protein 
was shown as dimers when compared with other previous data (Fig. 1.10c). This data were dif-
ferent with previous result of Superdex-200 column. The possible explanation is that when eluted 
fraction of his-trap column was concentrated, the protein was aggregated and formed large mole-
cule, which might be caused by high salt and high concentration of imidazole.  
Cloning and expression S. aureus secA2 (SasecA2) The SasecA2 gene had been cloned 
into pET-33b, and expressed in BL21λDE3 at 20oC overnight with 0.5 mM IPTG. The expres-
sion was very good (Fig. 1.11).   
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Purification of SaSecA2 Cell pellet was French pressed at 10,000 psi. The supernatant 
of 37k rpm was loaded onto 5 ml His-trap column, and washed with different imidazole gradient 
by FPLC.  The results showed that SaSecA2 bound to His-trap column very well, and it could be 
eluted with >50 mM imidazole. The SDS-PAGE gel result showed the purity of some fraction 
was very high (Fig. 1.12a).Some fractions were precipitated by ammonium sulfate, however after 
precipitation, the protein couldn‟t be re-solublized. Some fraction was concentrated to 10 mg/ml 
with centrifugal filter, but the concentrated protein precipitated very quickly during loading to 
sample loop at room temperature, while loading sample on ice prevents precipitation. The buffer 
for his-trap column was 25 mM K3PO4 pH 8.0 with 0.5 M NaCl, 1 mM DTT, and imidazole. We 
don‟t know why high concentration of NaCl and imidazole will cause non-recoverable protein 
precipitate at room temperature, however if the imidazole was removed by desalting column or 
Q-column, then concentrated SaSecA2 did not precipitate. Superose-6 column could further sep-
arate small proteins around 29 kDa from SaSecA2 (Fig. 1.12b).  
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Figure 1.8 Map of SaSecA1/pET-21d 
 
                                               20oC                                           37oC 
 
 
Figure 1.9 Expression of SaSecA1 
Lane 1-13: different colonies.  
 
  
Figure 1.10a Purification of SaSecA1 with His-trap column 
Lane 1: pellet of 4k rpm; lane 2: supernatant of 37k rpm; lane 3: pellet of the 37k rpm; lane 4: unbinding sample; 
lane 5-28: different eluent fraction of his-trap column.  
 
 
 
Figure 1.10b Purification of SaSecA1 with Q-sepharose column  
Lane 1: loading sample; lane 2: unbinding sample; lane 3-22: different eluent fractions. 
 
 
 
Figure 1.10c Purification of SaSecA1 with S-200 
Lane 1-14: different eluent fractions. 
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Figure 1.11 Expression of SaSecA2 
Lane 1-6 and 8-13: different colonies; lane 7: control without IPTG induction. 
 
 
 
Figure 1.12a Purification of SaSecA2 with His-trap column 
Lane 1: whole cell lysis; lane 2: pellet of 5k rpm; lane 3: supernatant of 5K rpm; lane 4: pellet of 37k rpm; lane 5: 
supernatant of 37k rpm; lane 6: loading sample; lane 7: unbinding sample; lane 8-28: different eluent fractions. 
                     
 
 
 
 
Figure 1.12b Purification SaSecA2 with Superos-6 column 
Buffer: 100 mM NH4HCO3; lane 1-9: different eluent fractions. 
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Cloning, Expression, and Purification of SecA Homologues of B. anthracis  
Cloning and expression of B. anthracis secA1 (BasecA1) The BasecA1 gene was ampli-
fied from B. anthracis Sterne, cloned into pET-20b (Fig. 1.13). Then, it was over-expressed in 
BL21λDE3 at 20oC or 37oC with 0.5 mM IPTG. The gel result showed that the expression of 
BaSecA1 was better at 20
o
C than at 37
o
C (Fig. 1.14).  
Purification of BaSecA1 Cell pellet was French pressed at 10,000 psi. The supernatant 
of 37k rpm was loaded onto 5 ml His-trap column, and washed with different imidazole gradient 
by FPLC.  BaSecA1 bind to His-trap column very well, and it could be eluted with >60 mM im-
idazole (Fig. 1.15a).  The eluent from His-trap column was desalted, then loaded to SP-sepharose 
column. The result showed that BaSecA1 was further purified by using SP-sepharose column 
(Fig. 1.15b). Some appropriate fraction were concentrated, and loaded to Superdex-200 column. 
The result of S-200 column showed that the purity was high, but there were some degradation 
(Fig. 1.15c). And the result of Superose-6 column was shown as dimmer when compared with 
other previous data (data not shown).  
Cloning and expression of B. anthracis secA2 (BasecA2) The secA2 gene of B. anthra-
cis was amplified from B. anthracis Sterne, cloned into pET-33b (Fig. 1.16). Then, it was over-
expressed in BL21λDE3 at 20oC or 37 oC with 0.5 mM IPTG. The gel result showed that the ex-
pression of BaSecA2 was good at 20
o
C and 37
 o
C (Fig. 1.17a), however majority of BaSecA2 
was in insoluble form (Fig. 1.17b). Thus, IPTG concentration was decrease to 0.05 mM, 0.075 
mM, or 0.1 mM to induce expression of BaSecA2. The result showed that 0.075 mM IPTG in-
duce very little amount of BaSecA2 expression, while 0.1 mM IPTG could induce a lot, but Ba-
SecA2 was become insoluble as soon as it was expressed (data not show).  
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Purification of BaSecA2 Cell pellet was French pressed at 18k PSI for three times, and 
centrifuged at 3.5K rpm twice and 8k rpm twice to separate unbroken cell and inclusion body. 
However, a lot inclusion body was centrifuged down in 3.5K rpm. The SDS-PAGE gel result 
showed that 4 preps had similar purity of BaSecA2, thus, 4 pellets were combined, washed with 
0.5 M and 1 M Urea, then was resuspended with 6 M urea (Fig. 1.18a-1.18b). The 90k rpm su-
pernatant of 6M urea suspension was slowly diluted to 20 times with Tris buffer. After dilution, 
BaSecA2 remained soluble and have ATPase activity. Then the 20 times diluted sample was 
loaded to His-trap column and washed with imidazole gradient. The result showed that renatured 
BaSecA2 could bind to the His-trap column, and the purity was very high (Fig. 1.19a). The some 
elution fractions of his-trap column were desalted with desalting column, then loaded to Q-
sepharose column. The result showed that BaSecA2 was further purified through Q column (Fig. 
1.19b). The some elution fractions were combined and concentrated, then loaded to Superdex-
200 column. The result showed that the purity of BaSecA2 was very high (Fig. 1.19c).  
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Figure 1.13 Map of BaSecA1/pET20b  
 
 
                                     
 
Figure 1.14 Expression of BaSecA1  
Lane 1-20: different colonies. 
 
 
 
Figure 1.15a Purification of BaSecA1 with His-trap column 
Lane 1: pellet of 4k rpm; lane 2; supernatant of 4k rpm; lane 3: pellet of 37k rpm; lane 4: supernatant of 37k rpm; 
lane 5-28: different eluent fractions.     
 
 
 
Figure 1.15b Purification of BaSecA1 with S-sepharose column 
Lane 1: loading sample; lane 2: unbinding sample; lane 3-14: different eluent fractions. 
 
 
Figure 1.15c Purification of BaSecA1 with S-200 column 
Buffer : 100 mM NH4HCO3. Lane 1-13: different eluent fractions. 
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Figure 1.16 Map of BaSecA2/pET20b 
 
                                  
               
Figure 1.17a Expression of BaSecA2  
Lane 1-12: different colonies.  
 
 
 
 
 
 
Figure 1.17b Over-expression of BaSecA2 with 0.5mM IPTG 
Lane 1: whole cell lysate; lane 2-3: first and second pellets of 3.5k rpm; lane 4-5: first and second pellets of 8k rpm; 
lane 6: the supernatant of 8k rpm.  
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Figure 1.18a Denature and renature of BaSecA2 
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Figure 1.18b Denature of BaSecA2  
S: supernatant; P: pellet; Lane 1:  8K rpm supernatant of 0.5M urea suspension; lane 2:  8K rpm supernatant of 1M 
urea suspension; lane 3-4:  first and second 8K rpm pellet of 6M urea suspension; lane 5: 8k rpm supernatant of 6M 
urea suspension; lane 6-7: 90k rpm pellet and supernatant of 6M urea suspension.  
 
 
 
 
 
Figure 1.19a Purification BaSecA2 with His-trap column 
Lane 1: loading sample; lane 2: unbinding sample; lane 3-28: different elution fraction. 
             
 
Figure 1.19b Purification of BaSecA2 with Q-sepharose column 
Lane 1: loading sample; lane 2: unbinding sample; lane 3-28: different elution fraction. 
 
 
Figure 1.19c Purification of BaSecA2 with Superdex-200 column 
Lane 1-13: different elution fraction.   
  
M  1  2  3  4  5  6  7  8  91011121314 M 15161718 192021 222324 2526 27 28  
Urea  0.5M 1M          6M       0 
              8K 8K     8K     90K 
                S   S   P   P S  P   S       
          M   1   2   3   4  5  6   7        
M  1  2  3  4  5  6  7   8 9 10 11121314   M 15161718 192021 222324 2526 27 28  
M  1   2   3   4   5   6   7    8   9  10 11 12 13 
 
58 
Immunospecificity of SecA homologues 
Making the Antibody of MtbSecA1 Purified MtbSecA1 was cut from SDS-PAGE Gel. 
At the first time, 1 mg MtbSecA1 mixed with Freund‟s complete adjuvant was injected into each 
of Rabbit No. 128 and No. 129. Two weeks later, 0.5 mg MtbSecA1 mixed with Freund‟s in-
complete adjuvant was injected into those two rabbits. Two weeks after second injection, 20 ml 
blood was collected from each rabbit and serum was separated, and 0.5 mg MtbSecA1 mixed 
with Freund‟s incomplete adjuvant was injected again. Injection was repeated 5 times for each 
rabbit. Antibody appeared from the first antiserum and the sensitivity was increasing with the 
injection times. Fig. 1.20a shows that even the first bleed can recognize 30 ng Mtb secA1 at 
5,000 times dilution. The forth bleed can recognize 30 ng MtbSecA1 at 10,000 times dilution. 
Making the Antibody MtbSecA2 To make of MtbSecA2 antibody, denatured MtbSe-
cA2-2 (his tag -) was purified from inclusion body and aggregated protein. MtbSecA2-2 cell pel-
let was French pressed at 18,000 psi., then centrifuged at 4K rpm, 12K rpm, 20K rpm, 50K rpm 
consecutively to separate unbroken cell, inclusion body, and membrane. The pellets of 12K rpm, 
20K rpm, 50K rpm were washed with 20 mM Tris-HCl buffer, then centrifuge at 12K rpm or 
20K rpm, repeat 4-5 times. The pellets were dissolved in 8 M urea, centrifuged at 38K rpm, and 
then the supernatant was loaded to Q sepharose column. Majority of MtbSecA2-2 didn‟t bind to 
Q-sepharose column, and the purity of MtbSecA2 was very high in the unbinding sample. Thus, 
MtbSecA2-2 band in unbinding sample was cut from SDS-PAGE, and injected into two rabbits. 
At the first time, 1 mg MtbSecA1 mixed with Freund‟s complete adjuvant was injected into each 
of Rabbit No. 120 and No. 121. Two weeks later, 0.5 mg MtbSecA2 mixed with Freund‟s in-
complete adjuvant was injected into those two rabbits. Two weeks after second injection, 20 ml 
blood was collected from each rabbit and serum was separated, and 0.5 mg MtbSecA2 mixed 
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with Freund‟s incomplete adjuvant was injected again. Injection was repeated 7 times for each 
rabbit. Antibody appeared from the first antiserum and the sensitivity was increasing with the 
injection times. 300 ng MtbSecA2 was detected out with 1:5000 dilution of the first and second 
bleed, with 1:10000 dilution of the third bleed, and with 1:20000 dilution of the 4
th
 bleed (data 
not shown). For the 5
th
 and 6
th
 bleed, 25ng MtbSecA2 can be detected with 1:10000 dilution of 
serum (Fig. 1.20b). The antibody sensitivity of rabbit No. 120 is higher than rabbit No. 121.  
Making the antibody of SaSecA2 Purified SaSecA2 protein was denatured and sepa-
rated by SDS-PAGE Gel, then corresponding protein band was cut out and mixed with adjuvant, 
then injected into two rabbits. At the first time, 1mg SaSecA2 mixed with Freund‟s complete ad-
juvant was injected into each of Rabbit No. 130 and No. 131. Two weeks later, 0.5 mg SaSecA2 
mixed with Freund‟s incomplete adjuvant was injected into those two rabbits. Two weeks after 
second injection, 20 ml blood was collected from each rabbit and serum was separated. And one 
week later, 0.5 mg MtbSecA1 mixed with Freund‟s incomplete adjuvant was injected again. In-
jection was repeated 4 times for each rabbit. Antibody appeared from the first antiserum and the 
sensitivity was increasing with the injection times. The Western blot result showed that those 
rabbit produce very good antibody (Fig. 1.20c). Ten thousand times diluted third serum could 
detect 100 ng of SaSecA2 in 3 min development. 
Specificity of SecA antibodies Western blot results demonstrated that 50ng MtbSecA1 
could be recognized by BsSecA antibody and EcSecA antibody at 5000 times dilution, and 
BsSecA antibody is more sensitive than EcSecA antibody (Fig. 1.21). The specificity of MtbSe-
cA2 antibody was checked by western blot with different SecA proteins. Although 300 ng of Se-
cA proteins were loaded to each lane, the SDS-PAGE gel result showed the actual amounts of 
those proteins were different (Fig. 1.22a). This result may caused by degradation. The western 
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blot result showed the specificity of MtbSecA2 is very high (Fig. 1.22a). We also investigated 
that specificity of EcSecA antibody, BsSecA antibody, MtbSecA1 antibody, and SaSecA2 anti-
body. EcSecA antibody showed high sensitivity to SaSecA1 and BaSecA2; it could cross react 
with BsSecA and BaSecA1, but not with SaSecA2 (Figure 1.22b). BsSecA antibody showed 
high sensitivity to BaSecA1 and SaSecA1, while it showed low sensitivity to EcSecA, SaSecA2, 
and BaSecA2 (Figure 1.22c). SaSecA2 antibody showed high sensitivity to SaSecA1, good sen-
sitivity to BaSecA1, low sensitivity to BaSecA2, EcSecA, and BsSecA (Figure 1.22d). MtbSe-
cA1 showed low sensitivity to EcSecA, BsSecA, BaSecA and BaSecA2 (Figure 1.22e). 
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Figure 1.20a Sensitivity of MtbSecA1 antibody 
Each lane contains 30 ng MtbSecA1. Lane 1-7: 1:5000 dilution; lane 8-9: 1:10000 dilution.  
 
 
 
 
Figure 1.20b Sensitivity of MtbSecA2 antibody 
Serum was diluted 1:10000 times.              
 
 
 
 
              
Figure 1.20c Sensitivity of SaSecA2 antibody  
Lane 1: preserium (1:500, 5min); lane 2: 1st bleeding (1:500, 5min); lane 3: 2nd bleeding (1:500, 5min); lane 4: 3rd 
bleeding (1:1000, 5min); lane 5: 3rd bleeding (1:2000, 5min); Lane 6: 3rd bleeding (1:10000, 3min). Each lane con-
tains 100ng. 
 
 
 
                               
Figure 1.21 Identification of MtbSecA1 with BsSecA antibody and EcSecA antibody 
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Figure 1.22a Specificity of MtbSecA2 antibody 
Lane 1: 300 ng MtbSecA2; lane 2: 300 ng MtbSecA1; lane 3: 300 ng EcSecA; lane 4: 300 ng BsSecA; Lane 5: 300 
ng PaSecA. 
 
 
 
 
Figure 1.22b Specificity of EcSecA antibody 
Serum was diluted 1:5000 times.              
 
 
 
Figure 1.22c Specificity of BsSecA antibody 
Serum was diluted 1:5000 times.              
 
 
 
Figure 1.22d Specificity of SaSecA2 antibody 
Serum was diluted 1:5000 times.              
 
 
 
 
 
 
Figure 1.22e Specificity of MtbSecA1 antibody 
Serum was diluted 1:5000 times.              
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The Intrinsic ATPase Activity of SecA1 and SecA2 
Although the function of SecA is well studied in E. coli and B. subtilis, and the functions 
of SecA1 and SecA2 from Gram-positive bacteria pathogen were studied with genetic methods, 
the biochemical properties of SecA homologues are not clear. Alignment result showed that nine 
motifs of DEAD helicase were highly conserved in all SecA homologues (Figure 0.2). In EcSe-
cA, these nine motifs form two nucleotide binding domains (NBD);  NBD1 has high affinity to 
nucleotide, acting as an ATPase catalytic machinery; NBD2 has low affinity to nucleotide, and 
acting as a an activator of ATP hydrolysis [90]. Thus, NBD1 and NBD2 are very important to 
the translocase activity of EcSecA. The conservation of these domains suggests SecA1 and Se-
cA2 might have similar ATPase activity as EcSecA. Thus, we hypothesize that SecA1 and Se-
cA2 are ATPases that hydrolyses ATP to promote translocation of specific proteins. To test 
our hypothesis, Malachite Green colorimetric assay was used to investigate the ATPase and 
GTPase activity of SecA1 and SecA2 from M. tuberculosis, M. smegmatis, S. aureus, and B. 
anthracis.  
Our results showed that the ATPase activity of MtbSecA1 was much higher than its 
GTPase activity (Fig. 1.23), indicating MtbSecA1 is an ATPase. Although two nucleotide bind-
ing domains were highly conserved in MtbSecA2, MtbSecA2 had low ATPase and GTPase ac-
tivity at 30
o
C, 37
o
C, and 42
o
C (Fig. 1.24). Similar to MtbSecA1, MsSecA1 and MsSecA2 had 
much higher ATPase activity than GTPase activity, suggesting they are ATPases (Fig. 1.25).  
For EcSecA, Mg
2+
 is required for its ATPase activity. To determine whether metal ions 
required for the activity of MtbSecA2 are different with ion required for the activity of MtbSe-
cA1 and EcSecA, NTPase activity of MtbSecA1 and MtbSecA2 was determined in presence of 
different metal ions. Our results showed that Mg
2+
 and Zinc
2+
 were required for ATPase activity 
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of MtbSecA1 (Fig. 1.26), which is similar to the result of EcSecA. At 30
o
C in presence of Mg
2+
 
and Zinc
2+
, liposomes could stimulate ATPase activity of MtbSecA1 up to 10 fold (Fig. 1.26); 
however, when Mg
2+
 and Zinc
2+
 were mixed together, the ATPase activity of MtbSecA1 was 
lower than with single metal ion (Fig. 1.26). These results might due to competition between 
these two ions on the binding sites. The NTPase activity of MtbSecA2 couldn‟t be significantly 
stimulated by Mg
2+
, Mn
2+
, Zn
2+
 and liposomes (Fig. 1.27a-1.27b).  MsSecA2 share more than 
80% homologue with MtbSecA2. However, Mg
2+
 could dramatically increase ATPase activity of 
MsSecA2 (Fig. 1.28). The alignment result show that SecA2 is highly conserved in mycobacte-
ria, the mainly different is located on N-terminal. Mycobacteria use GTG as start codon. There 
are three GTG located at N-terminal of MTB SecA2 gene. In our study, MtbsecA2 gene was 
cloned from the first GTG. In a paper published on JB 2008 [106], MtbsecA2 was cloned from 
the third GTG, because the protein sequence of the shorter MtbSecA2 more closely resemble Se-
cA2 from other mycobacteria (Fig. 1.29). The shorter MtbSecA2 have higher intrinsic ATPase 
activity than the full length MtbSecA2. In the genome sequence of M. tuberculosis, there is no 
obvious ribosome binding site in front of either first or third GTG. Both the full length and the 
shorter MtbSecA2 can complement secA2 mutant phenotypes in M. smegmatis and M. tuberculo-
sis [54, 106-107], suggesting that the full length MtbSecA2 function in vivo. We don‟t know why 
the N-terminal 30 amino acid could inhibit the ATPase activity of MtbSecA2. Three cystine re-
sidues in the N-terminal of MtbSecA2 might cause the protein very unstable.  
Similar to mycobacteria SecA1, SecA1 and SecA2 from S. aureus and B. anthracis have 
very high endogenous ATPase activity (Fig. 1.30-1.31), indicating that they are ATPase. The in-
trinsic ATPase activity of SaSecA2 and BaSecA2 are higher than SaSecA1 and BaSecA1 (Fig. 
1.30-1.31).    
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Figure 1.23 The intrinsic ATPase and GTPase activity of MtbSecA1  
30
o
C, 40 min, 2 mM ATP or GTP, 2 mM Mg
2+
. 
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Figure 1.24 The intrinsic ATPase and GTPase activity of MtbSecA2 
40 min, 2 mM ATP or GTP, 2 mM Mg
2+
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Figure 1.25 The intrinsic ATPase activities of MsSecA1and MsSecA2 
37
o
C, 40 min, 2 mM ATP or GTP, 2 mM Mg
2+
. 
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Figure 1.26 NTPase activity of MtbSecA1 with different metal ion 
30
o
C, 40 min, 2 mM ATP or GTP, 2 mM metal ion. 
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Figure 1.27a NTPase activity of MtbSecA2 with different metal ion  
37
o
C, 40 min, 2 mM ATP or GTP, 2 mM metal ion. 
MtbSecA2 ATPase activity of 30oC
Mg Mn zinc Mg+zinc Mn+zinc
0
20
40
60
80 0 to 1
1 to 1
2 to 1
4 to 1
8 to 1
P
i (
p
m
o
l/m
in
)
MtbSecA2 GTPase activity of 30oC
Mg Mn zinc Mg+zinc Mn+zinc
0
20
40
60
80 0 to 1
1 to 1
2 to 1
4 to 1
8 to 1
P
i (
p
m
o
l/m
in
)
 
Figure 1.27b NTPase activity of MtbSecA2 with different metal ion 
30
o
C, 40 min, 2 mM ATP or GTP, 2 mM metal ion. 
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Figure 1.28 ATPase activities of mycobacteria SecA2 with different metal ion  
30oC, 40 min, 2 mM ATP, 2 mM Ca
2+
, or  2 mM Mg
2+
, or 2 mM Mn
2+
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Figure 1.29 N-terminal alignment of mycobacteria SecA2 (Adapted from ) 
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Figure 1.30 The intrinsic ATPase activities of SaSecA1 and SaSecA2 
25
o
C, 40 min, 2 mM ATP or GTP, 2 mM Mg
2+
. 
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Figure 1.31 The intrinsic ATPase activities of BaSecA1 and BaSecA2 
30
o
C, 40 min, 2 mM ATP or GTP, 2 mM Mg
2+
. 
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The Lipid, Membrane, and Translocation ATPase Activity of SecA1 and SecA2  
In E. coli Sec-system, SecA undergo cycles of membrane insertion and dissociation, 
guiding and pushing preprotein export through transmembrane channel [38, 91]. And lipid could 
induce conformational change of EcSecA forming ring-like structure, indicating it might be in-
volved in forming transmembrane channel [38]. Interacting with anionic phospholipids, mem-
brane, and precursor protein could stimulate the ATPase activity of EcSecA (Fig. 1.36). To de-
termine whether SecA1 and SecA2 could interact with membrane in the same way as EcSecA, 
the ATPase activity of SecA homologues were investigated in presence of liposomes, membrane 
and precursor proteins. Our results showed that the ATPase activity of MtbSecA1, MsSecA1, 
SaSecA1, and BaSecA1 could be stimulated by liposomes (Fig. 1.32-1.35), however the ATPase 
activity of MtbSecA2, MsSecA2, SaSecA2, and BaSecA2 could not be stimulated by liposomes 
(Fig. 1.32-1.35). These results suggested that SecA1 might have similar function as EcSecA and 
SecA2 might have similar function as BsSecA. The ATPase activities of SecA1 and SecA2 were 
further investigated in presence of E. coli BA13 membrane washed with 6 M urea, or/and 
preOmpA of E. coli.  The ATPase activity of MsSecA1 could be stimulated by BA13 mem-
branes (Fig. 1.37a-c) and preOmpA (Fig. 1.38). However, the ATPase activities of MsSecA2, 
SaSecA1, SaSecA2, BaSecA1, and BaSecA2 were not obviously stimulated by BA13 membrane 
and preOmpA (Fig. 1.39-1.42). These results might due to specific interactions required for rec-
ognition between precursor and translocase. Because the membrane and precursor were from E. 
coli, they might not be recognized by translocase from other species. 
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Figure 1.32 The ATPase activities of MtbSecA1 and MtbSecA2 in presence of liposomes 
30
o
C, 40 min, 2 mM ATP, 2 mM Mg
2+
. 
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Figure 1.33 The ATPase activities of MsSecA1 and MsSecA2 in presence of liposomes 
30
o
C, 40 min, 2 mM ATP, 2 mM Mg
2+
. 
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Figure 1.34 The ATPase activities of SaSecA1 and SaSecA2 in presence of liposomes 
25
o
C, 40 min, 2 mM ATP, 2 mM Mg
2+
. SaSecA2: 1 μg. 
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Figure 1.35 The ATPase activities of BaSecA1 and BaSecA2 in presence of liposomes 
30
o
C, 40 min, 2 mM ATP, 2 mM Mg
2+
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Figure 1.36 Intrinsic, membrane, and translocation ATPase activities of EcSecA 
Intrinsic ATPase activity: EcSecA 5 μg; membrane ATPase activity: EcSecA 1 μg, membrane 3 μg; translocation 
ATPase activity: EcSecA 0.5 μg, membrane 1.5 μg , preOmpA 0.5 μg; membrane: 6M urea washed BA13 mem-
brane; 40
o
C 40 min; 2 mM Mg
2+
; 2 mM ATP. 
The ATPase activity of MsSecA1
7.5:0 2.5:2.5 2.5:5.0 2.5:7.5
0
5
10
15
20
25
40
o
C, 40 min
MsSecA1 (g): membrane (g)
P
i (
p
m
o
l/ 
g
/m
in
)
 
Figure 1.37a Stimulation of membrane on the ATPase activity of MsSecA1 at 40
o
C 
Membrane: 6M urea washed BA13 membrane; 40
o
C 40 min; 2 mM Mg
2+
; 2 mM ATP. 
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Figure 1.37b Stimulation of membrane on the ATPase activity of MsSecA1 at 30
o
C 
Membrane: 6M urea washed BA13 membrane; 30
o
C 40 min; 2 mM Mg
2+
; 2 mM ATP. 
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Figure 1.37c Simulation of membrane on the ATPase activity of MsSecA1 at 20
o
C 
Membrane: 6M urea washed BA13 membrane; 40
o
C 40 min; 2 mM Mg
2+
; 2 mM ATP. 
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Figure 1.38 Intrinsic, membrane, and translocation ATPase activities of MsSecA1 
Intrinsic ATPase activity: MsSecA1 5 μg; membrane ATPase activity: MsSecA1 2.5 μg, membrane 7.5 μg; translo-
cation ATPase activity: MsSecA1 2.5 μg, membrane 7.5 μg, preOmpA 0.5 μg. 40oC 40 min; 2 mM Mg2+; 2 mM 
ATP. 
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Figure 1.39 Intrinsic, membrane, and translocation ATPase activities of MsSecA2 
Intrinsic ATPase activity: MsSecA2 5 μg; membrane ATPase activity: MsSecA2 2.5 μg, membrane 7.5 μg; translo-
cation ATPase activity: MsSecA2 2.5 μg, membrane 7.5 μg, preOmpA 0.5 μg.  
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Figure 1.40 Intrinsic, membrane, and translocation ATPase activities of SaSecA1 
Intrinsic ATPase activity: SaSecA1 5 μg; membrane ATPase activity: SaSecA1 2.5 μg, membrane 7.5 μg; transloca-
tion ATPase activity: SaSecA1 2.5 μg, membrane 7.5 μg, preOmpA 0.5 μg.  
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Figure 1.41 Intrinsic, membrane, and translocation ATPase activities of SaSecA2 
Intrinsic ATPase activity: SaSecA2 2.5 μg; membrane ATPase activity: SaSecA2 1.25 μg, membrane 3.75 μg; trans-
location ATPase activity: SaSecA2 1.25 μg, membrane 3.75 μg, preOmpA 0.5 μg.  
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Figure 1.42 Intrinsic, membrane, and translocation ATPase activities of BaSecA1 
Intrinsic ATPase activity: BaSecA1 5 μg; membrane ATPase activity: BaSecA1 2.5 μg, membrane 7.5 μg; translo-
cation ATPase activity: BaSecA1 2.5 μg, membrane 7.5 μg, preOmpA 0.5 μg.  
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Temperature Effect on the ATPase Activity of SecA1 and SecA2  
To investigate whether temperature could affect the ATPase activity of mycobacteria Se-
cA homologues, the ATPase activity of SecA homologues was investigated at different tempera-
ture. The optimal temperature for the intrinsic ATPase activity of EcSecA is around 42
o
C, while 
for ATPase activity of EcSecA in presence of liposomes is around 30
o
C, which is good for the 
function of liposomes (Fig. 1.36). To our surprise, MtbSecA1 has highest ATPase activity at 0
o
C 
with or without liposomes (Fig. 1.37a).  To confirm whether the ATPase activity of MtbSecA1 at 
0
o
C was real, kinetic assay was carried at different temperature, and boiled MtbSecA1 was used 
at negative control. The result showed that the ATPase activity of MtbSecA1 is increasing with 
time, activity at 0
o
C is higher than that at 30
o
C, and the denatured boiled protein lose its activity 
(Fig. 1.37b). We don‟t know why and how these characteristics of MtbSecA1 could help for the 
growth or physiology of MTB. To investigate whether all SecA1 of mycobacteria have similar 
high ATPase activity at low temperature, the ATPase activity of MsSecA1 was investigated. The 
results showed that MsSecA1 has high ATPase activity at 0
o
C (Fig. 1.38a). The result of kinetic 
assay showed that its ATPase activity was increasing with time at 0
o
C (Fig. 1.38b). The intrinsic 
ATPase activity of MtbSecA2 at 37
o
C is higher than that at 30
o
C and 42
o
C (Fig. 1.24). To inves-
tigate whether temperature has similar effect on MsSecA2, its ATPase assay was carried at dif-
ferent temperatures. The results showed that MsSecA2 has highest intrinsic ATPase activity at 
around 33
o
C (Fig. 1.39). This result was different with the activity of mycobacteria SecA1. Does 
this result indicate SecA1 and SecA2 might have different functions at different growth condi-
tion of mycobacteria? The optimal temperatures for the ATPase activities of SaSecA1, SaSecA2, 
BaSecA1, and BaSecA2 are all between 20
o
C-30
o
C (Fig. 1.40-1.43), while the optimal tempera-
ture for BsSecA is above 40
o
C (Fig. 1.44).  
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Figure 1.43 Temperature effect on the ATPase activity of EcSecA  
40 min; 2 mM ATP; 2 mM Mg
2+
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Figure 1.44a Temperature effect on the ATPase activity of MtbSecA1 
40 min; 2 mM ATP; 2 mM Mg
2+
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Figure 1.44b Temperature effect on the ATPase activity of MtbSecA1 
0
o
C or 30
o
C; 2 mM ATP; 2 mM Mg
2+
. 
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Figure 1.45a Temperature effect on the ATPase activity of MsSecA1 
40 min; 2 mM ATP; 2 mM Mg
2+
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Figure 1.45b Temperature effect on the ATPase activity of MsSecA1 
0
o
C; 2 mM ATP; 2 mM Mg
2+
. 
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Figure 1.46 Temperature effect on the ATPase activity of MsSecA2 
40 min; 2 mM ATP; 2 mM Mg
2+
. 
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Figure 1.47 Temperature effect on the ATPase activity of SaSecA1 
40 min; 2 mM ATP; 2 mM Mg
2+
. 
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Figure 1.48 Temperature effect on the ATPase activity of SaSecA2 
40 min; 2 mM ATP; 2 mM Mg
2+
. 
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Figure 1.49 Temperature effect on the ATPase activity of BaSecA1 
40 min; 2 mM ATP; 2 mM Mg
2+
. 
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Figure 1.50 Temperature effect on the ATPase activity of BaSecA2 
40 min; 2 mM ATP; 2 mM Mg
2+
. 
 
Intrinsic ATPase activity of BsSecA
0
o
C 10
o
C 20
o
C 30
o
C 35
o
C 40
o
C
0
20
40
60
80
P
i 
(p
m
o
l/

g
/m
in
)
 
Figure 1.51 Temperature effect on the ATPase activity of BsSecA 
40 min; 2 mM ATP; 2 mM Mg
2+
. 
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Subcellular Distribution of Mycobacteria SecA2 and SecA1 
To determine the distribution of mycobacteria SecA homologues, M. smegmatis Mc
2
155 
were grown in Middlebrook 7H9 broth with 0.2% glycerol, 1ADC(0.5% bovine serum albumin, 
fraction V, 0.2% dextrose, 0.85% NaCl), and 0.1% Tween 80. The cell pellet was French pressed 
at 18,000 psi, and unbroken cells and large cellular debris are removed by centrifugation at 3,000 
 g. The supernatant of 3,000  g was centrifuged at 27,000  g for 1h to generate a fraction 
enriched in cell wall. The supernatant of 27,000  g was centrifuged at 258,000  g for 1.5 hrs to 
sediment the remaining cytoplasmic membrane. The remaining supernatant contains soluble 
components of the cytoplasm. Western blot was used to determine the distribution of M. smeg-
matis SecA1 and SecA2 by using the antibodies of MtbSecA1 and MtbSecA2. The results show 
that both SecA1 and SecA2 could be detected in the supernatant of 285,000  g and the pellet of 
258,000  g (Fig.1.52a). 80% of MtbSecA1 are in the pellet, while 60% of MtbSecA2 are in the 
supernatant, suggestion that MtbSecA2 are more soluble than MtbSecA1. To investigate whether 
SecA1 and SecA2 are real membrane protein, those two pellets were extracted with 1% OG, 1% 
Triton-100, 6 M urea. The result show that some of SecA1 and SecA2 in those pellets are real 
membrane protein, because they could be extracted with OG and Triton-100, but not be 6 M urea 
(Fig. 1.52b). Some of SecA1 and SecA2 in those pellets are aggregated, or big oligmer, or mem-
brane bounded, because they could be extracted by 6 M urea, but not be OG and Triton (Fig. 
1.52b). Our data suggested that mycobacteria SecA1 and SecA2 are both located on membrane 
and in cytosol, and SecA2 are more soluble than SecA1. These results are similar to the subcel-
luar distribution of EcSecA, suggesting mycobacteria SecA homologues might have similar 
working mechanism as EcSecA.  
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Figure 1.52a The distribution of SecA1 and SecA2 in M. smegmatis  
Lane 1 is the crude cell lysate; Lane 2 and lane 3 are the pellet and supernatant of 3,000 g for 10 min. Lane 4 and 
lane 5 are the pellet and supernatant of 27,000 g for 1 hour. Lane 6 and lane 7 are the pellet and supernatant of 
258,000 g for 1.5 hours. 
 
 
Figure 1.52b The distribution of SecA1 and SecA2 in M. smegmatis 
P: pellet; S: supernatant; OG: 0.1% octyl glucoside; Urea: 6 M urea. 
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Membrane Interaction of SecA1 and SecA2 
Trypsin digestion of MtbSecA1 In E. coli Sec-system, SecA undergo cycles of mem-
brane insertion and dissociation, guiding and pushing pre-protein export through transmembrane 
channel [38, 91]. Previous studies of our lab showed the EcSecA has soluble and membrane-
integral forms. It can form a ring-like pore structure in the presence of anionic phospholipids. 
These results indicated that EcSecA may form the central core of protein-conducting channels 
[38]. Our preliminary data show that MtbSecA1 was located on membrane and cytosol, and lipo-
somes could stimulate its ATPase activity up to 9 fold. These results suggest they might have 
similar function and working model as EcSecA. To determine whether mycobacteria SecA ho-
mologues could interact with membrane in the same way as EcSecA, proteolysis assay was used 
to identify specific transmembrane domain. MtbSecA1 was incubated with liposomes on ice for 
10 min, then, after adding trypsin, put on ice for 15 min. The result shows that the digestion pat-
tern of MtbSecA1 was not changed by liposomes, while liposomes can decrease 66 kDa frag-
ments and increase 45 kDa and 39 kDa fragments of EcSecA (Fig. 1.53a-b). To find whether the 
temperature could affect the correlation of SecA and liposomes, the mixture of SecA and lipo-
somes was pre-incubated on ice or 30
o
C, then, digested by trypsin for 15 min on ice. The result 
shows no change was caused by different pre-incubation temperature (Fig. 1.53c). Liposomes 
used in this study was made from E. coli Avanti polar lipid, which might be different with lipid 
in the membrane of M. tuberculosis. 
Study the structure of MtbSecA1 with TEM and AFM. The two-dimensional crystal-
lization technique was applied to MtbSecA1. Some ring-like structures were observed in MtbSe-
cA1‟s sample with around 11 nm outer diameter and 7 nm inner hole (Fig. 1.54). The ring-like 
structure is bigger than EcSecA which formed 8 nm outer diameter with a 2 nm inner hole [38]. 
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AFM results showed that MsSecA1 could form ring-like structure (Fig. 1.55), while MsSecA2 
didn‟t (Fig. 1.56). These results indicated that lipid could induce conformational change of my-
cobacteria SecA1, suggesting SecA1 might interact with membrane in the same way as EcSecA 
and it might be involved in forming transmembrane channel. 
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Figure 1.53a Trypsin resistance of MtbSecA1 with or without liposomes 
MtbSecA: 10 μg; EcSecA: 10 μg. 
 
 
  
Figure 1.53b Trypsin resistance of MtbSecA1  
MtbSecA: 10 μg; EcSecA: 10 μg. 
 
    
 
                              
Figure 1.53c Trypsin resistance of MtbSecA1  
MtbSecA: 10 μg; EcSecA: 10 μg. 
98KD 
66KD 
45KD 
29KD 
                                            Mtb secA1               EcSecA 
Protein:liposomes  1:0  1:1   1:2  1:4  1:8  1:16  1:0  1:2 
98KD 
66KD 
 45KD 
29KD 
18KD 
 
                                         0
o
C                        30
o
C              0 
                           EcSecA  MtbSecA1 EcSecA  MtbSecA1 
Liposomes            1:0   1:2   1:0   1:8   1:0   1:2   1:0   1:8 
Trypsin(ng/μl)      3       3     20    20     3      3     20     20  
18KD 
 
                                         MtbSecA1           EcSecA                  MtbSecA1                EcSecA         
Liposomes              ‒     ‒    ‒     ‒     ‒    ‒     ‒     ‒            +     +     +     +    +     +     +     +       
Trypsin(μg/ml)     0     1    3     6    10   30    0     6            0     1     3     6    10   30    0     6 
85 
 
 
Figure 1.54 TEM structure of MtbSecA1 in presence of liposomes 
 
 
 
Figure 1.55a AFM structure of MsSecA1 in pres-
ence of liposomes 
 
Figure 1.55b AFM structure of MsSecA1 without 
liposomes 
 
 
Figure 1.56a AFM structure of MsSecA2 in pres-
ence liposomes 
 
Figure 1.56b AFM structure of MsSecA2 without 
liposomes 
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Conclusions and Discussion 
SecA is the central component of Sec-dependent secretion pathway, which is responsible 
for the secretion of many essential proteins as well as some toxins and virulence factors. Two 
SecA homologues are indentified in some important Gram-positive pathogens. SecA1 is in-
volved in general protein secretion and essential for viability, whereas SecA2 contribute to secre-
tion of specific virulence factors. Alignment result showed that nine motifs of DEAD helicase 
were highly conserved in all SecA homologues (Fig. 0.2). In EcSecA, these nine motifs form two 
nucleotide binding domains (NBD);  NBD1 has high affinity to nucleotide, and contains minimal 
ATPase catalytic machinery; NBD2 has low affinity to nucleotide, and acts as an activator of 
ATP hydrolysis [90]. Thus, NBD1 and NBD2 are very important to the translocase activity of 
EcSecA. The conservation of these domains suggests SecA1 and SecA2 might have similar 
translocase activity as EcSecA.  
In this study, SecA1 and SecA2 from different four species were cloned, over-expressed, 
and purified (Table 1.2). The biochemistry properties of these SecA homologues were characte-
rized. The results were summarized in Table 1.3. All these SecA homologues had ATPase activi-
ty, suggesting that they could be molecular motor like EcSecA. SaSecA2 and BaSecA2 showed 
very high endogenous ATPase activity, while MtbSecA2 showed very low ATPase activity and 
low GTPase activity; Mg
2+
 and Zinc
2+
 are required for ATPase activity of MtbSecA1, which is 
similar to the result of EcSecA. The results confirmed that MtbSecA2 has low NTPase activity in 
presence of Mg
2+
 and Ca
2+
. The optimal temperature for ATPase activity is varied in different 
SecA proteins. Only mycobacteria SecA1 showed high ATPase activity at 0
o
C.  
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In E. coli Sec-system, SecA undergo cycles of membrane insertion and dissociation, 
guiding and pushing preprotein export through transmembrane channel [38, 91]. Interacting with 
lipid, membrane, and precursor protein could further stimulate the ATPase activity of EcSecA. 
And the previous data from our lab show that EcSecA can form ring-like structure in presence of 
lipid, indicating it might be involved in forming transmembrane channel [38]. To determine 
whether SecA1 and SecA2 could interact with membrane in the same way as EcSecA, the AT-
Pase activity of SecA homologues were investigated in presence of liposomes, membrane, and 
precursor. The ATPase activity of SecA1 could be stimulated by liposomes, while the ATPase 
activity of SecA2 couldn‟t be stimulated by liposomes, suggesting that SecA1 might have similar 
function as EcSecA and SecA2 might have similar function as BsSecA. The ATPase activity of 
MsSecA1 could be stimulated by BA13 membrane and the preOmpA, while other SecA homo-
logues didn‟t show similar response. Because the membrane and precursor were from E. coli, 
they might not be recognized by translocase from other species. The complementation assay re-
sults showed that mycobacteria SecA1 and SecA2 failed to complement the temperature-
sensitive defect of EcSecA (Table 1.4), suggesting that interaction between secretion factors of 
Sec system might be specific for different organisms.  
The subcellular distribution of M. smegmatis SecA1 and SecA2 were investigated by us-
ing the antibodies of MtbSecA1 and MtbSecA2. Our data suggested that mycobacteria SecA1 
and SecA2 are both located on membrane and in cytosol. These results are similar to the subcel-
luar distribution of EcSecA, suggesting mycobacteria SecA homologues might have similar 
working mechanism as EcSecA. Thus, proteolysis assay was used to identify specific transmem-
brane domain. However, liposomes didn‟t induce the formation of trypsin resistant fragment of 
MtbSecA1, while liposomes can decrease 66KD fragments and increase 45KD and 39KD frag-
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ments of EcSecA (Fig. 1.53a-b). TEM result and AFM result showed that liposomes could in-
duce conformational change of MtbSecA1 and form ring-like structures. Liposomes could stimu-
late the ATPase activity of MtbSecA1 and MsSecA1, and the ATPase activity of MsSecA1 could 
be stimulated by membrane and pre-protein. All these results suggest that mycobacteria SecA1 
might interact with membrane in the same way as EcSecA and might be involved in forming 
transmembrane channel.  
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Table 1.2 Summary of cloning, expression, and purification of SecA1 and SecA2 
Protein 
Homology 
to EcSecA 
Size 
(a.a.) 
Vector 
Expression 
(20
o
C) 
His- 
tag 
Purification 
Ni Ion Size 
MtbSecA1 44.7/59.9 949 pET-20b BL21.19 + Ni-NTA S S200 
MtbSecA2 31.8/45.6 808 pET-33b BL21λDE3 + His-trap Q Superose6 
MsSecA1 45.1/61.9 957 pET-20b BL21λDE3 + His-trap SP S200 or Superose6 
MsSecA2 32.8/45.1 789 pET-20b BL21λDE3 + His-trap Q S200 or Superose6 
SaSecA1 44.3/63.6 843 pET-20b BL21λDE3 + His-trap / S200 or S300 
SaSecA2 31.5/50.5 796 pET-33b BL21λDE3 + His-trap / S200 or Superose6 
BaSecA1 50.6/66.9 835 pET-21d BL21λDE3 + His-trap / S200 or S300 
BaSecA2 39.4/56.7 788 pET-33b BL21λDE3 + His-trap / S200 or S300 
Homology: identity/similarity; „+‟: with his-tag; „/‟: without; S200: Superdex 200; S300: Superdex 300.  
 
Table 1.3 ATPase activity of SecA1 and SecA2 
Protein 
Intrinsic 
ATPase 
Liposomes 
stimulation 
Membrane 
ATPase 
Translocation 
ATPase 
Optimal temperature 
Intrinsic With liposomes 
Ec SecA Pi ≈ 36 11 fold ↑ 4 fold ↑ 18.3 fold ↑ 42oC (Pi ≈ 36) 30oC (Pi ≈ 137) 
Bs SecA Pi ≈ 67 - ND ND 40oC (Pi ≈ 67) ND 
MtbSecA1 Pi ≈ 16 7 fold ↑ ND ND 0oC (Pi ≈ 16) 0
o
C (Pi ≈ 30) 
MtbSecA2 Pi ≈ 4 - ND ND 37
oC (Pi ≈ 16)  
MsSecA1 Pi ≈ 18 3 fold ↑ 3.3 fold ↑ 5.5 fold ↑ 0oC (Pi ≈ 18) 20
o
C (Pi ≈ 47) 
MsSecA2 Pi ≈ 12 - 1.4 fold 1.8 fold 30oC (Pi ≈ 9) ND 
SaSecA1 Pi ≈ 10 3.5 fold ↑ 1.3 fold 1.3 fold 25
o
C (Pi ≈ 10) 25oC (Pi ≈ 32) 
SaSecA2 Pi ≈ 120 - 1.1 fold 1.3 fold 25oC (Pi ≈ 120) ND 
BaSecA1 Pi ≈ 25 1.5 fold↑ 1 fold 1 fold 25
o
C (Pi ≈ 8) 20oC (Pi ≈ 28) 
BaSecA2 Pi ≈ 74.4 - ND ND 30oC (Pi ≈ 74) ND 
ATPase activity: Pi (pmol/μg/min); „↑‟: increase; „-‟: negative result; membrane: 6M urea washed E. coli BA13 
membrane; precursor: E. coli preOmpA; ND: not determined. 
Table 1.4 Complementation activity of mycobacteria SecA1 and SecA2 
Protein Vector E. Coli Strain TAG Plate Growth at 30
o
C Growth at 42
o
C 
MtbSecA1 pET-20b BL21.19 0.01 μM-1 mM IPTG +++ - 
MtbSecA2 pBAD BA13 0.00002‰-2‰ arabinose +++ - 
MsSecA1 pET-20b BL21.19 0.01 μM-1 mM IPTG +++ - 
MsSecA2 pET-20b BL21.19 0.01 μM-1 mM IPTG +++ - 
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CHAPTER 2 DEVELOPMENT AND OPTIMIZATION OF NOVEL SECA INHIBITORS 
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Summary 
Two SecA homologues are indentified in some important Gram-positive pathogens. Se-
cA1 is involved in general protein secretion and essential for viability, whereas SecA2 contribute 
to secretion of specific virulence factors. SecA is conserved in bacteria, required for viability and 
virulence; moreover it has no counterpart in mammalian cells. Inhibition on the function of SecA 
homologues might reduce the virulence, inhibit bacteria growth, or/and kill bacteria, and with 
minimal human toxicity. Therefore these SecA homologues are potential good antibacterial drug 
targets, and identification SecA inhibitor might help to develop new anti-bacteria strategy. SecA 
proteins have ATPase activities, thus screening ATPase inhibitors might help to develop new 
antimicrobial agents. In this study, in collaboration with Dr. Binghe Wang‟s lab, three structural-
ly different classes of SecA inhibitors were developed and optimized. (1) RB is a membrane 
permeant ATPase inhibitor. RB could noncompetitively inhibit the ATPase activity of SecA1 
and SecA2, and SecA2 is more sensitive to RB than SecA1. RB show bactericidal and bacterios-
tatic effects against M. smegmatis without affecting H
+
-ATPase activity. The bactericidal effect 
of RB is independent of protein synthesis and growing phase. In M. smegmatis, SecA2 might be 
the first target. To develop more potent SecA inhibitors with less side effects and molecular 
weight, RB was systematically dissected to understand the importance of structural feature. The 
SAR studies lead to the development of two potent RB analogs, which molecular weight are less 
than one third of RB, and show better bacteriostatic effects and bactericidal effect than RB. (2) 
Pyrimidine analogs were derived from virtual screening based on the ATP binding pocket of Ec-
SecA and SAR study. In this study, new pyrimidine analogs were developed and optimized from 
SAR studies, which show better bacteriostatic effects and better bactericidal effects. (3) Bistria-
zole analog was derived from random screening, with good antimicrobial activities against 
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Gram-positive bacteria. New bistriazole analogs were developed and optimized from SAR stu-
dies, with better bacteriostatic effects. In our study, several potent SecA inhibitors show promis-
ing bacteriostatic effect and bactericidal effect against one E. coli leaky mutant strain and some 
Gram-positive bacteria, including MRSA and B. anthracis. These novel inhibitors with structural 
diversity will aid the understanding of the pharmacophore required for SecA inhibition. Our 
study will provide a starting point for developing more potent antimicrobials.   
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Introduction 
Due to the emergence and dissemination of multidrug resistance, bacterial pathogens 
have been causing a serious public health problem in recent years [6]. To address the existing 
drug resistant problem, there is an urgent need to find new antimicrobials, especially those 
against drug-resistant strains of bacteria. SecA is conserved in bacteria, required for viability and 
virulence [33-34]; moreover it has no counterpart in mammalian cells [40]. Thus, Inhibition on 
the function of SecA homologues might reduce the virulence, inhibit bacteria growth, or/and kill 
bacteria, and with minimal human toxicity. Therefore these SecA homologues are potential good 
antibacterial drug targets, and identification SecA inhibitor might help to develop new anti-
bacteria strategy. SecA proteins have ATPase activities and contain ATP binding domains, thus 
targeting ATP binding pocket of SecA might help to develop new antimicrobial agents. In this 
study, three different strategies were applied to develop SecA inhibitors: screening known AT-
Pase, virtual docking on ligand binding pocket, and random screening. This project is in collabo-
ration with Dr. Binghe Wang‟s lab. 
Rose Bengal (RB) is a polyhalogenated fluorescein derivative (Fig. 2.1). Previous studies 
demonstrated that RB can bind and inhibit the function of DNA polymerase and RNA polyme-
rase [108-110].  Rose Bengal is used as an ingredient in agar media to sep-
arate fungal from bacteria, and it could inhibit the growth of Staphylococ-
cus aureus [111-112]. Our lab‟s previous data showed that RB could inhi-
bit the ATPase activity of EcSecA and BsSecA (Fig. 2.4). To investigate 
whether RB could inhibit other SecA homologues, especially SecA homologues from pathogens 
causing drug resistant problems, SecA1 and SecA2 from M. smegmatis, S. aureus, B. anthracis 
MW: 973.67
Figure 2.1 RB structure 
94 
Figure 2.2 Structure of 
pyrimidine analogs 
 
were subjected to in vitro RB sensitivity assay; and M. smegmatis was used as surrogates of M. 
tuberculosis to do in vivo assay.  
RB is known to inhibit other ATPases [113] and to undergo photo-oxidation leading to 
DNA polymerase [108-110]. Moreover RB has been banned as a food dye because of its cytotox-
icity [114]. 10 mg/kg RB could cause DNA damage to the glandular stomach, colon, and urinary 
bladder in 3 hours [115]. Thus, in collaboration with Dr. Binghe Wang‟s lab, we want to modify 
the structure of RB, increasing inhibition effect, and decreasing side effects. RB is a large mole-
cule, molecular weight is 973.67, and it is consists of a polyiodinated xanthene moiety and a po-
lychlorinated benzoate moiety. We don‟t know whether chloro group, or carboxyl group, or the 
number and position of iodo group are essential for the inhibition effect of RB. In this study, new 
SecA inhibitors were developed from systematical dissection of RB and Structure-Activity Rela-
tionship study. This approach allowed us to determine the importance of iodo group, hydroxyl 
group, carboxyl group, and the necessity of ring A /B/D. Furthermore, the most effective RB 
analogues were used to study the inhibition mechanism of RB analogues.  
Pyrimidine analogues were developed from virtual screening 
based on the ATP binding pocket of E. coli SecA in our previous 
study [81]. SCA-8 showed strong inhibitory effect on the endogen-
ous ATPase activity of EcSecAN68, however it showed low bacte-
riostatic effects. SCA-8 is an aka dimer (Fig.2.2), and it might be too 
big to get through bacteria cell membrane. SCA-13 contains half 
structure of SCA-8; although inhibition effect on the ATPase activity of SecA was 10 times re-
duced, bacteriostatic effect was increased more than 5 to 50 times. In this study, new SecA inhi-
bitors were developed from further optimizing of structure SCA-13. Among tested compounds, 
 
SCA-13: R1=H 
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SCA-15 and SCA-93 showed promising bacteriostatic effects and bactericidal effects against B. 
anthracis Sterne and numerous drug resistant S. aureus strains.  
 Bistriazole analogs were derived from random screening. SCA-21 
showed good bacteriostatic effect and bactericidal effect on gram positive 
bacteria. Replacing half part of SCA-21 with chloro group, slightly increased 
in vitro inhibition effect, but significantly increased in vivo inhibition; further 
removing the floro group or methylthio group, decreased inhibition effect; 
the methyl group could be replaced with benzene ring. 
In our study, several potent SecA inhibitors had varying degrees of inhibitory effects 
against SecA homologues; and showed promising bacteriostatic effect and bactericidal effect 
against some gram positive bacteria and one E. coli leaky mutant strain. These new inhibitors 
with structural diversity will aid the understanding of the pharmacophore required for SecA inhi-
bition. Our study will provide a starting point for developing more potent antimicrobials.  
 
SCA-107: One of –S-R3 
was replaced with –Cl.
Figure 2.3 Structure 
of bistriazole analogs 
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Materials and Methods 
Medium for M. smegmatis: Middlebrook 7H9 broth with 0.2% glycerol, 1ADC (0.5% 
bovine serum albumin, fraction V, 0.2% dextrose, 0.85%NaCl), and 0.1% Tween 80 was used to 
grow M. smegmatis. Muller Hinton Agar was used to grow M. smegmatis on plate.  
Medium: LB medium was used to grow bacteria in this study.  
SecA inhibitors: were synthesized by Dr. Binghe Wang‟s lab.  
Strains: M. smegmatis mc
2
155 and M. smegmatis mc
2
2522 (SecA2 deletion mutant) 
were from Dr. Miriam Braunstein in Univ. of North Carolina. E. coli NR698, B. subtilis 168, S. 
aureus N315, S. aureus 6538, S. aureus Mu50, B. anthracis Sterne. 
In vitro inhibition assay: Because SecA homologues have ATPase activity, Malachite 
green colorimetric assay was used to investigate the inhibition of inhibitors on the ATPase activi-
ty of SecA homologues. In this assay, ATPase assay was carried in different concentration of 
inhibitors, and IC50 is the concentration of RB which could inhibit 50% ATPase activity of SecA 
homologeus. Because all compounds were not soluble except for RB, thus compounds were dis-
solved in 100% DMSO. In the final in vitro assay, there were 1-5% DMSO. 
Inhibition Assay on Plates: M. smegmatis wild type and M. smegmatis SecA2 deletion 
mutant were grown in 3 ml M7H9 broth (containing 0.5% Dextrose, 0.1% Tween 80, 0.2% gly-
cerol) in 12 ml culture tube; when OD600 ≈ 0.5, 500 μl culture was taken and mixed with 9.5 ml 
of 70% Muller Hinton Agar, then 5 ml mixture was spread on the top of 100% Muller Hinton 
Agar plates. 1 μl RB (different concentration) was dropped on those plates, then the plates were 
incubated at 37
o
C for one day.  
In vivo inhibition assay in medium: M. smegmatis wild type and M. smegmatis ΔSecA2 
were grown in 3 ml M7H9 broth (containing 0.5% Dextrose, 0.1% Tween 80, 0.2% glycerol) in 
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12 ml culture tube; when OD600 ≈ 1.0, they are diluted into 50 ml M7H9 medium; when 
OD600≈1.0, 100 μl culture were inoculated into 3 ml M7H9 medium which contains different 
concentration of RB; then incubate at 37
o
C, 240 rpm. OD600 was measured at different time 
point. For strains other than MS, Single colony of bacteria was inoculated in 3 ml LB medium in 
12 ml culture tube, then grow at 37
o
C; when OD600 ≈ 0.5, 300 μl culture were diluted into 3 ml 
LB medium, then 97.5 μl culture was aliquated into 1.5 ml eppendorf tube, then adding 2.5 μl of 
different concentration of RB analogues; incubated at 37
o
C, 200 rpm for 22 hours. OD600 was 
measured to determine inhibition effect.  
Killing assay: M. smegmatis wild type and M. smegmatis ΔSecA2 were grown in 3 ml 
M7H9 broth (containing 0.5% dextrose, 0.1% tween 80, 0.2% glycerol) in 12 ml culture tube; 
when OD600 ≈ 1.0, they are diluted into 50 ml M7H9 medium; when OD600 ≈ 0.5, 3 ml cell cul-
ture were aliquated into 12 ml culture tube, then add different concentration of RB into the cell 
culture; then incubate at 37
o
C, 240 rpm for 2 hours. The cell cultures were serially diluted with 
dd H2O and 100 μl or 200 μl was spread on plates or 1 μl was dropped onto plates. For strains 
other than M. smegmatis, single colony of bacteria was inoculated in 3 ml LB medium in 12 ml 
culture tube, then grow at 37
o
C; when OD600 ≈ 0.5, 97.5 μl cell culture was aliquated into 1.5 ml 
eppendorf tube, then 2.5 μl inhibitors was added into tube; incubated at 37oC, 1000 rpm for 1-2 
hours. The cell cultures were diluted with dd H2O and spread 150 μl on LB plates. 
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Results 
The Inhibition Effect of Rose Bengal  
SecA is conserved in bacteria, required for viability and virulence; moreover it has no 
counterpart in mammalian cells. Thus, inhibition on the function of SecA homologues might re-
duce the virulence, inhibit bacteria growth, or/and kill bacteria, and with minimal human toxici-
ty. Therefore these SecA homologues are potential good antibacterial drug targets, and identifi-
cation SecA inhibitor might help to develop new anti-bacteria strategy. Two NBDs are highly 
conserved in SecA proteins and enzymatic assay demonstrated that SecA proteins have ATPase 
activities, thus screening ATPase inhibitors might help to develop new antimicrobials. RB is a 
polyhalogenated fluorescein derivative. Previous studies demonstrated that RB is a membrane-
permeant ATPase inhibitor. Our lab‟s previous data showed that RB could inhibit the ATPase 
activity of EcSecA and BsSecA (Fig. 2.4). In this study, SecA1 and SecA2 from M. smegmatis, 
S. aureus, B. anthracis were subjected to in vitro RB sensitivity assay; and M. smegmatis was 
used as surrogates of M. tuberculosis to do in vivo assay. 
The Inhibition of RB on MtbSecA1 RB could inhibit intrinsic ATPase activity of 
MtbSecA1, and the IC50 is around 60 μM (Fig. 2.5a). Because the intrinsic ATPase activity of 
MsSecA1 is low, liposomes were used to stimulate the ATPase activity. The results show that 
RB also could inhibit the ATPase activity of MsSecA1 in the presence of liposomes, and IC50 is 
around 130 μM at 30oC (Fig. 2.5b), while at 20oC, IC50 is around 75 μM (Fig. 2.5c). These re-
sults indicated that lower temperature is good for RB binding with MtbSecA1.  
The Inhibition Effect of RB on MsSecA1 and MsSecA2 RB could inhibit the ATPase 
activity of MsSecA1 in presence of liposomes; IC50 is around 45 μM at 20
o
C and 125 μM at 
30
o
C (Fig. 2.6a). These results indicated that lower temperature is good for RB binding with 
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MsSecA1. In the presence of liposomes, 100 μM RB could noncompetitively inhibit ATPase ac-
tivity of MsSecA1 (Fig. 2.6b-c). MsSecA2 is more sensitive to RB than MsSeca1, and IC50 is 2 
μM (Fig. 2.7a). Kinetic results show that RB noncompetitively inhibited the endogenous ATPase 
activity of MsSecA2; Km is 3.88 mM, and Ki is 4.66 μM (Fig. 2.7b).  
The Inhibition of RB on SaSecA1 and SaSecA2 To do kinetic ATPase assay, the AT-
Pase activity of SaSecA1 was investigated at different time points. The result showed that its 
ATPase activity was linear within 60 min at 25
o
C (Fig. 2.8a).  Thus, we chose 40 min as reaction 
time. RB could inhibit the ATPase activity of SaSecA1 in the presence of liposomes, and IC50 is 
around 2.5 μM (Fig. 2.8b). Kinetic assay results show that RB noncompetitively inhibited the 
ATPase activity of SaSecA1 and it may have two noncompetitive ATP binding sites (Fig. 2.8c).  
The ATPase activity of SaSecA2 was investigated at different time points. The result 
showed that its ATPase activity was linear at first 25 min at 25
o
C (Fig. 2.9a). Thus, we chose 20 
min as reaction time. RB could inhibit the endogenous ATPase activity of SaSecA2, and IC50 is 
around 1 μM, which is lower than SaSecA1 (Fig. 2.9b). And this result was similar to RB sensi-
tivity of MsSecA2, suggesting that SecA2 might very sensitive to RB. Kinetic assays results 
show that RB has non competitive inhibition on the ATPase activity of SaSecA2 (Fig. 2.9c).   
The Inhibition Effect of RB on BaSecA1 and BaSecA2 The ATPase activity of BaSe-
cA1 was investigated at different time points. The result showed that its ATPase activity was li-
near within 60 min at 20
o
C (Fig. 2.10a).  Thus, we chose 40 min as reaction time. RB could inhi-
bit the ATPase activity of BaSecA1 in presence of liposomes, and IC50 is around 10 μM at 20
o
C 
(Fig. 2.10b). To determine the inhibition type of RB on BaSecA1, kinetic ATPase assays were 
carried out at different concentration of RB. The results show that RB noncompetitively inhibited 
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the ATPase activity of BaSecA1, and it might have two non-competitive binding sites (Fig. 
2.10c). 
The ATPase activity of BaSecA2 was investigated at different time points. The result 
showed that its ATPase activity was linear within 60 min at 30
o
C (Fig. 2.11a).  Thus, we chose 
40 min as reaction time. To determine whether RB could inhibit the ATPase activity of BaSe-
cA2, ATPase assay was carried in presence of different RB concentration. The result showed that 
RB could inhibit the endogenous ATPase activity of BaSecA2, and IC50 is around 3.5 μM at 
30
o
C (Fig. 2.11b). To determine the inhibition type of RB on BaSecA2, kinetic ATPase assays 
were carried out at different concentration of RB. The results show that RB noncompetitively 
inhibited the ATPase activity of BaSecA2 (Fig. 2.11c). 
Bacteriostatic Effect of RB against M. smegmatis MS wild type and MS ΔSecA2 were 
grown in M7H9 broth which contain different concentration of RB and OD600 was measured at 
different time point. Our results showed that RB could inhibit the growth of Ms wild type and 
MS ΔSecA2 (Fig. 2.12a-b). The bacteriostatic effect against of MS wild type was compared with 
the result of MS ΔSecA2. For wild type, MIC50 is 30 μM and MIC99 is 130 μM; but for MS 
ΔSecA2 MIC50 is 35 μM and MIC99 is 150 μM (Fig. 2.12c). MS ΔSecA2 was slightly more resis-
tant to RB than wild type. MS was grown in the M7H9 broth which contains 0.5% dextrose, the 
bactericidal effect of RB was not caused by inhibition the ATPase activity of H
+
-ATPases. Be-
cause MS is very easy to aggregate, OD reading might not be accurate. Therefore, we did plate 
inhibition assay. The result of plate inhibition assay confirmed that MS ΔSecA2 was more resis-
tant to RB than wild type. For wild type, MIC is 20 μM; while for MS ΔSecA2 MIC is 60 μM 
(Fig. 2.13).  
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Bactericidal Effect of RB against M. smegmatis After 2.5 hours incubation with differ-
ent concentration of RB, the cell culture was diluted and 1ul was put onto plates. The results 
showed that MS ΔSecA2 was more resistant to RB than wild type (Fig. 2.28). To kill two log 
number of cell die, for MS wild-type only need 3.9 μM RB, but for MS ΔSecA2 need 15.6 μM 
RB was needed (Fig. 2.14).  
The Bactericidal Effect of RB on Growing MS To investigate the effects of different 
dilution buffers on the cell number grown on the plates, 1X A buffer and dd H2O with or with 
Tween 80 were used to dilute the same cell culture (OD600 ≈ 0.5), then, 200ul was spread on the 
plates. The result showed that the 1X A buffer with Tween 80 had the best effect to inhibit the 
clump formation of MS (Fig. 2.15). Thus, this buffer was used to dilute the cell culture in the fol-
lowing experiment. MS was grown at 37
o
C to OD600 ≈ 0.5, then, different concentration of RB 
was added into the medium. After 1 hour incubation with RB, the MS cultures were diluted and 
spread onto plates, which were incubated at 37
o
C for three days then subjected to count the via-
ble cell colonies. The result showed that RB had bactericidal effect on growing MS (Fig. 2.16). 
Because MS was grown in the M7H9 broth which contains 0.5% dextrose, the bactericidal effect 
of RB was not caused by inhibition the ATPase activity of H
+
-ATPase. The result also showed 
that MS SecA2 mutant was more resistant to RB than MS wild type, suggesting SecA2 might be 
the first target of RB in MS.  
The Bactericidal Effect of RB on Non-growing MS To determine whether RB has bac-
tericidal effect on non-growing MS, different concentration of RB was added into the medium 
when MS grew into stationary phase. The results show that RB had bactericidal effect on non-
growing MS (Fig. 2.17). The result confirmed that MS SecA2 mutant was more resistant to RB 
than MS wild type. To compare the RB effect on growing and non-growing MS, the growth of 
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MS was monitored (2.18a), and culture was taken out at different growing phase to do the killing 
assay with or without dilution. The results showed that the bactericidal effect of RB was inde-
pendent of growing phase (Fig. 2.18b). 
The Bactericidal Effect of RB is Independent of Protein Synthesis Previous study 
demonstrated that RB could inhibit the function of RNA polymerase. To determine whether the 
bactericidal effect of RB related to protein synthesis, when MS was grown at 37
o
C to OD600≈1.0, 
20 μg/ml or 50 μg/ml Chromphenical (CM) was added into the medium; then after 1 hour incu-
bation, 320 μM RB was added into the medium; after additional 1 hour incubation, the MS cul-
ture were diluted and spread onto plates, which were incubated at 37
o
C for three days then sub-
jected to count the viable cell colonies. The result showed that 20 μg/ml CM was sufficient to 
inhibit MS growth (Fig. 2.25). And the bactericidal effect of RB on MS was in respect of the 
presence of CM in the medium. The result show that CM do not have negative effect on the re-
sult of killing assay, thus the bactericidal effect of RB is independence of protein synthesis (Fig. 
2.19). The result also showed that MS ∆SecA2 was slightly more resistant to RB than MS wild 
type. 
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Figure 2.4 Inhibition of RB on the intrinsic ATPase activity of BsSecA 
40 min reaction at 40
o
C; 2 mM Mg
2+
 and 2 mM ATP; without liposomes; IC50 ≈ 3 μM. 
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Figure 2.5a Inhibition of RB on the intrinsic ATPase activity of MtbSecA1 
 40 min reaction at 30
o
C; 2 mM Mg
2+
 and 2 mM ATP; IC50 ≈ 60 μM. 
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Figure 2.5b Inhibition of RB on the ATPase activity of MtbSecA1 in presence of liposomes  
2 mM Mg
2+
 and 2 mM ATP; protein : liposomes = 1:8; 40 min reaction at 30
o
C, IC50 ≈ 130 μM; 40 min reaction at 
20
o
C, IC50 ≈ 75 μM. 
IC50≈60 μM 
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Figure 2.6a Inhibition of RB on the ATPase activity of MsSecA1  
2 mM Mg
2+
 and 2 mM ATP; protein : liposomes = 1:8; 40 min reaction at 20
o
C, IC50 ≈ 45 μM; 40 min reaction at 
30
o
C; IC50 ≈ 125 μM. 
 
Figure 2.6b Non-competitive inhibition of RB on the ATPase activity of MsSecA1 
20 min reaction at 37
o
C; 2 mM Mg
2+
; ATP: 0.8-8 μM; protein: liposomes=1:8; Km ≈ 2.07 mM and Ki≈ 69.23 μM  
       
Figure 2.6c Non-competitive inhibition of RB on the ATPase activity of MsSecA1 
40 min reaction at 37
o
C; protein :  liposomes = 1 : 8; ATP: 0.8-8 μM; 2 mM Mg2+  
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Figure 2.7a Inhibition of RB on the intrinsic ATPase activity of MsSecA2 
40 min reaction at 30
o
C; 2 mM Mg
2+
 and 2 mM ATP; without liposomes; IC50 ≈ 2 μM.  
 
 
 
Figure 2.7b Non-competitive inhibition of RB on the intrinsic ATPase activity of MsSecA2  
40 min reaction at 30
o
C; without liposomes; 2 mM Mg
2+
; Km ≈ 3.88 mM; Ki ≈ 4.66 μM.  
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Figure 2.8a Time dependent ATPase activity of SaSecA1 
40 min reaction at 25
o
C; protein: liposomes = 1:8; 2 mM Mg
2+
; 2 mM ATP 
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Figure 2.8b Inhibit of RB on the ATPase activity of SaSecA1  
40 min reaction at 25
o
C; protein: liposomes = 1:8; 2 mM Mg
2+
; 2 mM ATP; IC50 ≈ 2.5 μM 
 
 
Figure2.8c Non-competitively inhibition of RB on the ATPase activity of SaSecA1 in presence of liposomes 
40 min reaction at 25
o
C; protein: liposomes = 1:8; 2 mM Mg
2+
; 2 mM ATP 
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Figure 2.9a Time dependent ATPase activity of SaSecA2 
25
o
C; without liposomes; 2 mM Mg
2+
, 2 mM ATP. 
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Figure 2.9b Inhibition of RB on the intrinsic ATPase activity of SaSecA2 
20 min reaction at 25
o
C; without liposomes; 2 mM Mg
2+
; 2 mM ATP; IC50 ≈ 1 μM. 
 
Figure 2.9c Non-competitive inhibition of RB on the intrinsic ATPase activity of SaSecA2 
20 min reaction at 25
o
C; without liposomes; 2 mM Mg
2+
; 2 mM ATP. 
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Figure 2.10a Time dependent ATPase activity of BaSecA1 in presence of liposomes 
20
o
C; BaSecA1: 5 μg; protein : liposomes=1 : 8; 2 mM Mg2+; 2 mM ATP. 
   
Figure 2.10b Inhibition of RB on the ATPase activity of BaSecA1 
40 min reaction at 20
o
C; BaSecA1: 5 μg; protein : liposomes=1:8; 2 mM Mg2+; 2 mM ATP; IC50 ≈ 10 μM.  
 
Figure 2.10c Non-competitive inhibition of RB inhibition on the ATPase activity of BaSecA1 
40 min reaction at 20
o
C; BaSecA1: 5 μg; protein : liposomes = 1 : 8; 2 mM Mg2+; 2 mM ATP. 
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Figure 2.11a Time dependent ATPase activity of BaSecA2  
30
o
C; without liposomes; 2 mM Mg
2+
; 2 mM ATP.  
 
 
Figure 2.11b Inhibition of RB on the intrinsic ATPase activity of BaSecA2 
 40 min reaction at 30
o
C; without liposomes; 2 mM Mg
2+
, 2 mM ATP. 
 
Figure 2.11c Non-competitive inhibition of RB on the ATPase activity of BaSecA2 
40 min reaction at 30
o
C; without liposomes; 2 mM Mg
2+
. 
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Figure 2.12a Bacteriostatic effect of RB against MS wild type 
 
Figure 2.12b Bacteriostatic effect of RB against MS ΔSecA2 mutant 
 
 
Figure 2.12c Bacteriostatic effect of RB against Ms wild type and Ms ΔSecA2 mutant 
MS wild type: MIC50 ≈ 30 μM, MIC99 ≈ 130 μM; MS ΔSecA2: MIC50 ≈ 35 μM, MIC99 ≈ 150 μM.  
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Figure 2.13 Result of RB plate inhibition assay against M. smegmatis 
Ms wild type: MIC ≈ 20 μM; MS ΔSecA2: MIC ≈ 60 μM. 
 
                      
                 
 
 
Figure 2.14 Result of RB spot-killing assay against M. smegmatis 
Culture was incubated with different conc. of RB at 37
o
C for 2.5 hours, then the cell culture was serially diluted, and 
1μl was dropped  onto plates, and incubated at 37oC for 3 days.*: 10-1; **:10-0.  
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Figure 2.15 Dilution buffer affect the result of killing assay against M. smegmatis 
RB was added in to culture when OD600 ≈ 0.5; 37
o
C; 1 hour killing. 
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Figure 2.16 Bactericidal effect of RB on growing M. smegmatis 
RB was added into culture when OD600 ≈ 0.5; 37
o
C; 1 hour killing. 
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Figure 2.17 Bactericidal effect of RB on non-growing M. smegmatis 
Stationary phase cell culture was incubated with RB to do killing assay at 37
o
C for 1 hour. 
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Figure 2.18a The growth curve of M. smegmatis 
Cell culture was taken out at different time point (labeled with red arrow), and subjected to killing assay. 
 
 
Figure 2.18b Bactericidal effect of RB on M. smegmatis is independent of growing phase 
Cell culture was taken out at different growing phase, and subjected to killing at 37
o
C for 1 hour. S phase: stationary 
phase. 
 
Figure 2.19 Bactericidal effect of RB is independent of protein synthesis  
When OD600 ≈ 1.0, Chromphenical was added into the medium; then after 1 hour incubation, RB was added into the 
medium to do killing assay at 37
o
C for 1 hour.  
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Table 2.1 In vitro inhibition effect of RB against on SecA1 and SecA2 
 
 
Iiposome IC50 (μM) 
Kinetic Assay 
Binding site Low ATP conc. (1-0.2 mM) High ATP conc.(2-8 mM) 
MsSecA1 + 45 1 Noncompetitive inhibition Noncompetitive inhibition 
MsSecA2 - 2 ND ND Noncompetitive inhibition 
SaSecA1 + 2.5 2 Noncompetitive inhibition Noncompetitive inhibition 
SaSecA2 - 1 ND ND Noncompetitive inhibition 
BaSecA1 + 10 2 Noncompetitive inhibition Noncompetitive inhibition 
BaSecA2 - 3.2 2 Noncompetitive inhibition Noncompetitive inhibition 
„+‟: with liposomes; „-‟: without liposomes; „ND‟: not determined;  
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Development of Novel SecA Inhibitors by Screening RB Analogs 
SecA, an essential component of Sec-dependent secretion pathway, is required for via-
bility and virulence of bacteria. Its high conservation among a wide range of bacteria, no human 
counterpart, and not fully developed properties make it an attractive target for exploring novel 
antimicrobial agents. Our results showed that RB could noncompetitively inhibit the ATPase ac-
tivity of SecA1 and SecA2 from different species, and RB showed bactericidal and bacteriostatic 
effects on the growth of M. smegmatis without affecting H
+
-ATPase activity. However RB is 
known to inhibit other ATPases and to undergo photo-oxidation leading to DNA alkylation [108-
110]. Moreover RB is known to be cytotoxic [114] [115], and has been banned as a food dye. 
Thus, we want to modify the structure of RB, increasing inhibition effect on SecA, and decreas-
ing side effects.  
RB is a large molecule with molecular weight of 973.67. RB con-
sists of a polyiodinated xanthen moiety and a polychlorinated benzoate 
moiety. There are some commercial fluorescein derivatives, which struc-
ture is similar to RB (Fig. 2.20). However, the in vitro inhibition effects of 
these fluorescein derivatives were much worse than RB (Fig. 2.21). We 
don‟t know whether chloro group, or carboxyl group, or the number and position of iodo group 
are essential for the inhibition effect of RB. To develop new SecA inhibitors, we began with 
SAR studies. In collaboration with Dr. Binghe Wang‟s group, RB was systematically dissected 
to understand the importance of structural feature by investigating the in vitro & in vivo inhibi-
tion effects of new analogues. In this study, we determined the importance of iodo group, hy-
droxyl group, carboxyl group, and the necessity of ring A/B/D.   
MW: 973.67
Figure 2.1 RB structure 
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4-Phenyl-chromene Might not Be the Basic Effective Structure of RB To determine 
the importance of D Ring and chloro groups, first batch RB analogues were synthesized with 4-
phenyl-chromene or 4-phenyl naphthalene as basic structure (Fig. 2.22). In these compounds, 
iodo groups were kept, or removed, or replaced with bromo groups. The in vitro inhibition assay 
result showed that 20 µM RB could inhibit nearly 60% ATPase activity of BaSecA2 and 75% 
ATPase activity of BsSecA and, but 100 μM or 200 μM of these RB analogues couldn‟t or only 
slight inhibit activity of BsSecA or BaSecA2 (Fig. 2.23a-b), suggesting that D ring or chloro 
group might be required for the inhibition on the ATPase activity of SecA proteins. SCA-23, 
SCA-24, and SCA-25 contain bromo or iodo group, and they didn‟t show in vitro inhibition ef-
fect at 200 μM (Fig. 2.23a-b),  however, they had some in vivo inhibition effect on the growth of 
B. subtilis 168 and E. coli NR698, suggesting that halo group was important for the in vivo inhi-
bition (Fig. 2.24a-b, Table 2.2). 
Xanthene with a Carbon Ring Might be the Basic Effective Structure of RB To de-
termine the importance of A ring, cholo group, and carboxyl group, second batch of RB analo-
gues were synthesized with xanthenes as basic structure (Fig. 2.25). In these compounds, A-ring 
was replaced by ketone group or 5-membered aliphatic ring; 4 iodo groups were partially or 
completely removed, or replaced by bromo group. 200 μM of these compounds were used to do 
the in vitro inhibition assay. The result showed that all five effective compounds are consisted of 
xanthene and a 5-membered ring (Fig. 2.26). Thus xanthene with a carbon ring might be the ba-
sic effective structure of RB. Among these compounds, SCA-41 had the best in vitro inhibition 
effects and it has simplest structure. Masking the hydroxyl group with methyl group dramatically 
decreased inhibition activities of SCA-41, suggesting hydroxyl group might be important for in 
vitro inhibition activity (Fig. 2.26). Adding four bromo groups to SCA-41 decrease inhibition 
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activities (Fig. 2.26), while adding two iodo groups decreased inhibition on BsSecA (Fig. 2.26), 
but didn‟t change inhibition activity on BaSecA2, suggesting the number of iodo group might 
affect in vitro inhibition activity (Fig. 2.26).  
A-ring and chloro group, carboxyl group, and iodo group were all removed in SCA-36. 
Our results showed that removing these groups dramatically decreased in vivo inhibition effects 
(Fig. 2.27a-b, Table 2.3).  Adding bromo group or iodo group regained some in vivo inhibition 
effect (Fig. 2.27a-b, Table 2.3). Replacing chlorinated benzoate group with a 5-membered ring 
remained good in vitro inhibition, and showed better in vivo inhibition effects than RB (Table 
2.3). SCA-41 has very simple structure it does not have chloro group, carboxyl group, and iodo 
group. This result suggests that carboxyl group and chloro group is not necessary for inhibition 
effect, and the aromatic A-ring could be replaced by an aliphatic 5-membered ring. Masking hy-
droxyl group with methyl group dramatically decreased inhibition effect, suggesting hydroxyl 
group is important for the in vivo inhibition effect (Fig. 2.27a-b, Table 2.3). These results indi-
cated that xanthene with a carbon ring and hydroxyl group might be essential for inhibitory ac-
tivity of RB. 
The Number of Iodine Groups Affected the Inhibition Effect RB has 4 iodine groups, 
while SCA-41 doesn‟t have any iodo group. To investigate whether iodo group could affect inhi-
bition effect, compounds with 2 iodo groups, 3 iodo groups, or 4 iodo groups were synthesized 
(Table 2.4). Our results showed that iodo group slightly increased in vivo inhibition effect, and in 
vitro inhibition against BaSecA2, but inhibition effect on BsSecA and EcSecA was dramatically 
reduced (Table 2.4). These results suggested that iodo group is not necessary for inhibition. And 
100 μM of these three compounds couldn‟t inhibit the growth of E. coli 4100 (Table 2.4), indi-
cating that the outer membrane of Gram-negative bacteria provide a permeability barrier that re-
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duces the absorption of the dye by the cells. Replacing 4-iodo groups with 4 bromo groups in-
creased IC50 (Table 2.4), suggesting bromo group reduces inhibition effect. 
The inhibition effects of these analogues were further investigated on the ATPase activity 
of E. coli F1F0 (EcF1F0). RB and some analogues could inhibition the ATPase activity of 
EcF1F0 (Table 2.4), suggesting they might be general ATPase inhibitor.  
To evaluate the importance of A-ring, it was replaced to cyclopentane, cyclohexane, i-
propane, and N-hexyl (Table 2.5). The assay result show that hexyl group have similar effect as 
cyclopentane; cyclohexane reduce some inhibition effect; i-propane group dramatically reduce 
inhibition effect, indicating that attaching 5 to 6 carbons to the top of xanthene moiety was ne-
cessary for inhibition effect (Table 2.5). To increase solubility, carboxyl group was adding to the 
5 carbon ring of SCA-41 (Fig. 2.28a), but our results showed that the carboxy group dramatically 
reduced inhibition effect both in vitro and in vivo (Fig. 2.28b-c). 
Bactericidal Effect of RB analogs In this study, B. subtilis 168 was used as a model to 
study the bactericidal effect of RB analogues, comparing the result of RB.  SCA-41 and SCA-50 
showed very good bactericidal effect on B. subtilis 168 (Fig. 2.29a). 20 μM of these two com-
pounds could kill 4 log numbers of B. subtilis 168, while 40 μM of RB only kill 1 log number. 
And increasing the killing assay time slightly increased killing effect (Fig. 2.29b). SCA-41was 
not soluble in water, and increasing temperature might be able to increase solubility. B. subtilis 
168 can grow at high temperature, thus, we further investigated the bactericidal effect of SCA-41 
at 42
o
C. However our results showed that, 10 μM SCA-41 kill two more log number of bacteria 
at 42
o
C than at 37
o
C, while 20 μM of SCA-41 showed similar result at both temperatures (Fig. 
2.29c). To investigate whether the inhibition effect of RB is growing phage dependent, the 
growth of B. subtilis168 was monitored (Fig. 2.30a), and cell culture was taken out at different 
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phase and subjected to killing assay. The result showed that RB has bactericidal effect on grow-
ing and no-growing B. subtilis 168 (Fig. 2.30b). For non growing cell, higher concentration of 
SCA-41 was needed because of the increasing of cell number.  
Bacteriostatic effect of RB analogs against MRSA Some RB analogs were subjected to 
in vivo inhibition assay on the growth of S. aureus Mu50, which is a Methicillin-resistant S. au-
reus strain. Our results showed that SCA-44, SCA-45, SCA-47 and SCA-48 had very good inhi-
bition effects with IC50<10 µM (Table 2.6a). But if comparing the inhibition effect of these com-
pounds with SCA-41, with or without iodo groups, their inhibition effects had no obvious differ-
ence, suggesting that iodo group might have inhibition effect, but iodo is not critical for inhibi-
tion effect of RB (Table 2.6a).  The inhibition effect of SCA-46 was around 75 µM, much worse 
than SCA-41, suggesting that replacing top five carbon ring with i-propane will reduce inhibition 
effect (Table 2.6a). We further investigated inhibition effect on two other MRSA strains, S. au-
reus Mu3 and S. aureus N315. Our results showed that bacteriostatic effects of SCA-41 on these 
MRSA strains were similar to their effects on S. aureus 6538, and much better than effects of RB 
(Table 2.6b). Both Mu50 and N315 are resistant to bleomycin, β-lactam, tetracyclines, several 
aminoglycosides, and MLS. Thus, RB analogs showed promising effect on control these MRSA.   
Bactericidal Effect of SCA-50 SCA-50 showed good bactericidal effect against S. au-
reus and B. anthracis Sterne. 40 μM of SCA-50 could kill a clinical strain, S. aureus 6538, as 
well as a MRSA strain-Mu50 (Fig. 2.31). 20 μM SCA-50 could kill 3 log numbers B. anthracis 
Sterne (Fig. 2.31).  
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Figure 2.20 Structure of some commercial RB analogs 
Inhibition on the ATPase activity of BaSecA2
0 10 20 30 40 50 60 70 80 90 100
0
25
50
75
100
125
150
Diiodofluoresceine
Eosin B
Eosin Y
EB
RB
Compound (M)
A
T
P
a
s
e
 a
c
ti
v
it
y
 (
%
)
 
Figure 2.21 In vitro inhibition effects of some commercial RB analogs against BaSecA2 
 
 
Figure 2.22 Structure of first batch RB analogs  
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Inhibition on the endogenous ATPase activity of BaSecA2
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Figure 2.23a In vitro inhibition effects of first batch RB analogs against BaSecA2  
30
o
C, 40 min; 5% DMSO. 
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Figure 2.23b In vitro inhibition effects of first batch RB analogs against BsSecA 
37
o
C, 40 min; 5% DMSO. 
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Figure 2.24a Bacteriostatic effects of first batch RB analogs against B. subtilis 168 
Incubation at 37
o
C, 1,000 rpm for 14 hrs; 2.5% DMSO. 
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Inhibition on th growth of E. coli NR698
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Figure 2.24b Bacteriostatic effects of first batch RB analogs against E. coli NR698 
Incubation at 37
o
C, 1,000 rpm for 14 hrs; 2.5% DMSO. 
 
Table 2.2 The importance of D-ring and chloro group for inhibition effects of RB analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1,000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, 40 min 
reaction with 5% DMSO; for EcSecAN68 and BsSecA, reaction at 37
o
C; for BaSecA2, reaction at 30
o
C. 
 
 
Figure 2.25 The structure of second batch of RB analogues 
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inhibition 
IC50 (μM) 
EcSecAN68 1 >100 100 (85%↓) TBD TBD 100 (75%↓) 100 (55%↓) 
BaSecA2 15 >200 >200 >200 >200 >200 >200 
BsSecA 20 >200 >200 >200 >200 >200 >200 
In vivo 
inhibition 
IC50 (μM) 
B. subtilis 168 34/78 >100 75 29 45 >100 >100 
E. coli NR698 10/18 >100 45 33 >100 >100 >100 
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Figure 2.26 In vitro inhibition effects of second batch RB analogs  
For BsSecA, reaction at 37
o
C 40 min with 5% DMSO; for BaSecA2, reaction at 30
o
C 40 min with 5% DMSO. 
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Figure 2.27a Bacteriostatic effects of second batch RB analogs against B. subtilis 168 
Incubation at 37
o
C, 1,000 rpm for 14 hrs; 2.5% DMSO. 
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Figure 2.27b Bacteriostatic effects of second batch RB analogs against E. coli NR698 
Incubation at 37
o
C, 1,000 rpm for 14 hrs; 2.5% DMSO. 
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Table 2.3 Importance of xanthene for inhibition effects of RB analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1,000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, 40 min 
reaction with 5% DMSO; for EcSecAN68 and BsSecA, reaction at 37
o
C; for BaSecA2, reaction at 30
o
C. 
 
 
Table 2.4 The importance of iodo group for inhibition effect of RB analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1,000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, 40 min 
reaction with 5% DMSO; for EcSecAN68, BsSecA, EcSecA, and EcF1F0, reaction at 37
o
C; for BaSecA2, reaction 
at 30
o
C. 
 
  
 
 
 
 
 
 
 
  
 
  RB 
(973.67) 
SCA-36 
(228.2) 
SCA-37 
(543.78) 
SCA-38 
(479.99) 
SCA-40 
(310.39) 
SCA-41 
(282.33) 
SCA-43 
(534.13) 
In vitro 
inhibition 
IC50 (μM) 
EcSecAN68 1 TBD 30 >100 TBD 8 3 
BaSecA2 15 >200 >200 >200 >200 30 13 
BsSecA 20 >200 >200 >200 >200 30 100 
In vivo 
inhibition 
IC50 (μM) 
B. subtilis 168 34/74 >100 75 79 >100 7 4 
E. coli NR698 10/18 >100 >100 75 TBD 9 9 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
RB 
973.67 
SCA-41 
282.33 
SCA-43 
534.13 
SCA-45 
660.02 
SCA-44 
785.92 
SCA-42 
597.92 
 EcSecAN68 1.3 8 3 1.3 1.7 4.5 
In vitro inhibition 
IC50 (μM) 
BaSecA2 15 30 13 17 18 45 
BsSecA 20 30 100 >100 >100 >100 
EcSecA 60 43 200 >100 >100 TBD 
 EcF1F0 14 60 17 <100 >100 100 (70%↓) 
In vivo inhibition 
IC50 (μM) 
B. subtilis 168 34/74 7 4 5 5 9 
E. coli NR698 10/18 9 9 18 3 19 
B. anthracis sterne 7 4 1 2 2 4 
S. aureus 6538 28 7 4 5 18 10 
E. coli MC4100 >100 >100 >100 TBD TBD TBD 
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Table 2.5 Replacing aromatic A-ring of RB with aliphatic ring or hexyl group  
 
For in vivo inhibition, incubation at 37
o
C, 1,000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, 40 min 
reaction with 5% DMSO; for EcSecAN68, BsSecA, EcSecA, and EcF1F0, reaction at 37
o
C; for BaSecA2, reaction 
at 30
o
C; TBD: not determined. 
 
 
Figure 2.28a Structure of RB analogs containing carboxyl group 
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Figure 2.28b Carboxyl group decrease in vitro inhibition effect of SCA-41 
For BsSecA, reaction at 37
o
C 40 min with 5% DMSO; for BaSecA2, reaction at 30
o
C 40 min with 5% DMSO. 
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In vivo inhibition 
IC50 (μM) 
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Inhibition on the growth of bacteria
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Figure 2.28c Carboxyl group decrease in vivo inhibition effect of SCA-41 
Incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO. 
 
 
Figure 2.29a Bactericidal effects of SCA-41 and SCA-50 against B. subtilis 168 
37
o
C, 1 hour killing with 2.5% DMSO. 
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Figure 2.29b Time effect on killing assay results of SCA-41 and SCA-50 
Killing at 37
o
C for 1 hour, or 1.5 hrs, or 2 hrs, with 2.5% DMSO. 
 
127 
Bacteriacidal effect on the growth of B. subtilis 168
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Figure 2.29c Temperature effect on killing assay result of SCA-41 
Killing at 37
o
C or 42
o
C for 1 hour with 2.5% DMSO. 
 
 
Figure 2.30a Bactericidal effect of SCA-41 is independent of growing phase 
Grow at 42
o
C; cell culture was taken out at labeled time point and subjected to killing assay. 
The bactericidal effect on growing and non-growing B. subtilis 168
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Figure 2.30b Bactericidal effect of SCA-41 is independent of growing phase 
Killing at 42
o
C for 1 hour with 2.5% DMSO. 
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Table 2.6a Bacteriostatic effects of RB analogs against MRSA 
 
Incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO. 
 
    Table 2.7b Bacteriostatic effects of RB analogs on MRSA  
 
Incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO. 
 
Bacteriostatic effect, IC50 (μM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
RB 
973.67 
MCII-89 
282.33 
MCII-93 
534.13 
MCII-99-2 
660.02 
MCII-99-1 
785.92 
MCII-92 
597.92 
S. aureus 6538 28 7 4 5 18 10 
S. aureus Mu50 26.5 5.5 2.7 4 7 10 
       
 
 
 
 
 
 
 
 
 
 
 
MCIII-110 
296.16 
MCIII-10 
298.16 
MCIII-6 
801.74 
MCII-122 
256.3 
MCII-135-2 
633.99 
MCII-135-1 
759.88 
S. aureus 6538 12 7 / / 7.4 6.9 
S. aureus Mu50 12 7 15 70 5.5 9 
 
  
 
 
 
 
 
  RB 
   973.67 
SCA-41 
282.33 
SCA-50 
298.16 
IC50 (μM) 
S. aureus 6538 28 7 7 
S. aureus Mu50 26.5 5.5 7 
S. aureus Mu3 >50 5 >10 
S. aureus N315 45 5 >10 
 
12.5
7.5 
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Figure 2.31 Bactericidal effects of SCA-50 against S. aureus and B. anthracis  
Killing at 37
o
C for 1 hour with 2.5% DMSO. 
                                     
130 
Development of Novel SecA Inhibitors by Optimizing Pyrimidine Analogs 
The emergence and dissemination of multidrug resistance has become a clinical issue, 
thus development of antibacterial agents with new mechanisms is an urgent need. SecA ATPase, 
an essential component of the Sec translocation system, is required for viability and virulence of 
bacteria, and is highly conserved among bacteria. Furthermore there is no human counterpart of 
this translocase. These properties make it an attractive target for ex-
ploring novel antimicrobial agents. Pyrimidine analogues were de-
rived from virtual screening based on the ATP binding pocket of E. 
coli SecA. SCA-8 showed strong inhibitory effect on the endogenous 
ATPase activity of EcSecAN68, however it showed low bacteriostat-
ic effects (Table 2.9). SCA-8 is an aka dimer (Fig. 2.2), and it might be too big to get through 
bacteria cell membrane. SCA-13 contains half structure of SCA-8; although inhibition effect on 
the ATPase activity of SecA was 10 times reduced, bacteriostatic effect was increased more than 
5 to 50 times (Table 2.7). In this study, many new pyrimidine analogues were synthesized with 
modification on R1 position and X-position, and the importance of A-ring and D-ring were de-
termined. 
The importance of D-ring To investigate the importance of D-ring, it was replaced to 
methyl group or carboxyl group. However, these modifications dramatically decreased both in 
vitro and in vivo inhibition effects, suggesting ring D was necessary for inhibition effect of pyri-
midine analogues (Table 2.7).  
The importance of A-ring To investigate the importance of A-ring, it was deleted, or re-
placed to –OCH3, CH3, or was attached with a benzene ring. All these modification dramatically 
reduced inhibition effect, suggesting that A-ring was required for inhibition effect (Table 2.8).  
 
 
Figure 2.2 Structure of pyri-
midine analogs  
 
SCA-13: R1=H 
D 
A 
B 
C 
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The effect of modifications on R1-position Modeling result suggested that the R1-
position can tolerate further modifications for optimization, improved physicochemical proper-
ties. Thus, R1-position was modified with azido group, -NH2, or triazole group. Majority of 
these modifications could improve inhibition effect on the ATPase activity of EcSecAN68, how-
ever only SCA-15 with azido group at R1 position showed good bacteriostatic effects (Table 
2.9a-b). Other modifications might be hard to get through cell membrane. Replacing azido group 
with methyl formate group and ethyl formate group increased inhibition effect on the ATPase 
activity of EcSecAN68, however these modifications decrease bacteriostatic effets (Table 2.9b).  
Replacing azido group with carboxylic acid group, boronic group, or pyridine group dramatically 
reduced both in vitro and in vivo inhibition effects (Table 2.9b).  
The importance of para-position of A-ring and azido group To investigate whether 
different position of A-ring and azido group could affect inhibition effect, SCA-65 and SCA-90 
were synthesized, which contain A-ring or azido group at meta-position. Our result showed that 
changing A-ring or azido group from para-position to meta-position could abolish inhibition ef-
fect (Table 2.10), suggesting that keeping A-ring or azido group at para-position were critical for 
inhibition effect.  
The effect of different modifications at X-position Modeling results suggested the X-
position can also be modified with the introduction of polar and ionizable function groups.  Thus, 
the =O group at X-position was replace to -NHOH, -Cl, -NHCH3, or -NH-C10O3-NH-Boc. Our 
results showed that NHOH slightly increased inhibition effect, and other modification reduced 
inhibition effect (Table 2.11a-b). 
The effect of modifications at A-ring To increase the solubility, two -OCH3 group and 
one COOCH3 group were add to ring A of SCA-15 and SCA-61. Our result showed that these 
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modifications could reduce in vivo inhibition effect (Table 2.12). But since SCA-82 retained rea-
sonable inhibition activities, it could be further modified for affinity labeling. 
Among tested pyrimidine analogs, SCA-15 and SCA-93 showed best bacteriostatic ef-
fects. In Table 2.13 & Table 2.14, we summarized of in vitro and in vivo inhibition of these two 
compounds comparing with results of SCA-8 and SCA-13. SCA-8 showed best in vitro inhibi-
tion effects, however SCA-15 and SCA-93 showed much better bacteriostatic effects. Thus, 
these two compounds were used to further investigate bactericidal effects.  
Bactericidal effect of SCA-15 SCA-15 showed good bactericidal effect on B. anthracis 
Sterne, S. aureus 6538, and S. aureus Mu50. 10 μM SCA-15 could kill two log numbers of B. 
anthracis Sterne (Fig. 2.32), while 25 μM could kill three log numbers of the other strains (Fig-
ure 2.32).  
 
  
133 
Table 2.7 Importance of D-ring for the inhibition effects of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
 
Table 2.8 Importance of A-ring for the inhibition effects of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
Table 2.9a Modification on R1-position of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
  
 
 
 
  
 
 
  SCA-8 
712.84 
SCA-13 
395.48 
SCA-89 
319.3 
SCA-66 
363.07 
SCA-77 
 
In vitro inhibition, 
IC50 (μM) 
EcSecA N68 2 20 >200 >100 30 
In vivo inhibition, 
IC50 (μM) 
B. anthracis 
sterne 
>250 5 >500 >250 75 
S. aureus 
6538 
>250 52 >500 >250 >100 
E. coli 
NR698 
>250 55/20 >500 >250 >100 
B. subtilis 
168 
>250 7 >500 >250 >100 
 
 
 
NHN
S
CN
O
OHO
MW-363.07
A
B
C
D
C
B
A
D
C
B
A
 
 
 
 
 
 
 
   
 
 SCA-13 SCA-78 SCA-84 SCA-87 SCA-88 SCA-85 SCA-86 
  DK-II-16 KW-I-15 DK-II-35 DK-II-36 KW-I-17 DK-II-30 
N68 19 TBD >100 >100 >100 >100 >100 
B. 
anthracis 
sterne 
5 >250 >250 >250 >250 >250 >250 
S. aureus 
6538 
52 >250 >250 >250 >250 >250 >250 
E. coli 
NR698 
55 >250 >250 >250 >250 >250 >250 
 
 
  SCA-13 
395.48 
SCA-15 
436.49 
SCA-17 
 
SCA-18 
 
SCA-19 
 
SCA-61 
534.59 
SCA-62 
534.59 
SCA-63 
520.5 
SCA64 
492.5 
Structure R1 position 
 
-H 
 
-N3 
 
-NH2 
 
  
 
 
 
 
 
 
 
 
In vitro inhibition, 
IC50 (μM) 
EcSecA N68 19 10 11 2.5 3 6 8 ND ND 
In vivo inhibition, 
IC50 (μM) 
B. anthracis 
sterne 
5 4 >100 19 >100 19 20μM<10%↓ >100 >100 
S. aureus 
6538 
52 15 >100 100 >100 >100 >100 >100 >100 
E. coli 
NR698 
55 35 >100 >100 >100 >100 >100 >100 >100 
B. subtilis 
168 
15 7 >100 >100 >100 >100 >100 >100 >100 
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Table 2.9b Modification on R1-position of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
Table 2.10 Importance of para-position of A Ring and N3 group for inhibition effects of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
Table 2.11a Modifications at X-position of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
  
SCA-13 
395.48 
SCA-15 
436.49 
SCA-71 
453.5 
SCA-72 
467.5 
SCA-75 
437.51 
SCA-76 
437.32 
Structure R1 position -H -N3 -COOCH3 -COOCH2CH3 -COOH B(OH2) 
In vitro inhibition, 
IC50 (μM) 
EcSecA N68 19 10 6 8.5 30 60 
In vivo inhibition, 
IC50 (μM) 
B. anthracis 
sterne 
5 4 8 15 >100 >100 
S. aureus 
6538 
52 15 15 90 >100 >100 
E. coli 
NR698 
55 35 200 >250 >100 >100 
B. subtilis 
168 
15 7 18 180 >100 >100 
 
      
  
 
  
 
  SCA-13 SCA-65 SCA-15 SCA-90 
In vitro inhibition, 
IC50 (μM) 
EcSecA N68 19 70 10 >200 
In vivo inhibition, 
IC50 (μM) 
B. anthracis 
sterne 
5 >100 4 >500 
S. aureus 6538 52 >100 15 >500 
E. coli NR698 55 >100 35 >500 
B. subtilis 168 15 >100 7 >500 
 
 
N
H
N
SC
N
O
M
W
-3
9
5
.1
1
 
N
H
N
S
O
C
N
N
3
D
C
B
A
D
C
B
A
D
C
B
A
D
C
B
A
Para
Para
Meta
Mera
 
Compound 
SCA-15 
436.49  
SCA-93  
451.1 
SCA-95  
454.9 
SCA-98  
449.1 
SCA-102 
 481.5 
SCA-103 
452.5  
SCA-109 
 450.5 
SCA-108  
450.5 
Structure 
R1 N3 N3 N3 N3 N3 N3 N3 N3 
X =O -NHOH -Cl -NHCH3 -NH(CH2)2OH -NHNH2 -OCH3 =O 
 Y H H H H H H H -CH3 
In vitro inhibition, 
IC50 (μM) 
EcSecA N68 10 6 8 3.5 >100 >100 ND ND 
In vivo inhibition, 
IC50 (μM) 
B. anthracis 
Sterne 
4 2.5 65 >200 >100 >100 >100 >100 
S. aureus 6538 15 9 >200 >200 >100 >100 >100 >100 
E. coli NR698 35 45 >200 >200 >100 >100 >100 >100 
B. subtilis 168 7 5 150 >200 >100 >100 >100 >100 
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 Table 2.11b Modification at X-position of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
 
Table 2.12 Modifications on A-ring of pyrimidine analogs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO. 
 
       Table 2.13 In vitro inhibition of pyrimidine analogs against SecA homologues  
         Proteins  
compound  
EcSecAN68 EcSecA EcSecA Tn BsSecA BaSecA2 SaSecA2 
Ec-F1F0-H
+-
ATPase 
SCA-8 2 ND 6 8 7 3 >200 
SCA-13 18 ND TBD 100 >200 TBD >200 
SCA-15 8 >100 30 >100 20 13 >100 
SCA-93 4.5 30 25 >100 TBD TBD TBD 
In vitro inhibition: IC50 (μM); 40 min reaction with 5% DMSO; for EcSecAN68, BsSecA, EcSecA, and EcF1F0, 
reaction at 37
o
C; for BaSecA2, reaction at 30
o
C; EcSecA Tn: translocation ATPase activity of EcSecA; TBD: not 
determined; IC50 of SCA-8: 50 μM, IC50 of SCA-13: 60 μM. 
 
 
 
  
 
Compound 
SCA-13 
395.48 
SCA-94 
438.5 
SCA-96 
409.5 
SCA-97 
413.0 
 R1 H H H H 
X =O -NH(CH2)2OH -OCH3 -Cl 
In vitro inhibition, 
IC50 (μM) 
EcSecA N68 19 55 ND ND 
In vivo inhibition, 
IC50 (μM) 
B. anthracis 
Sterne 
5 >200 >200 >200 
S. aureus 6538 52 >200 >200 >200 
E. coli NR698 55 >200 >200 >200 
B. subtilis 168 15 >200 >200 >200 
 
 
 
 
 
 
 
 
 SCA-15 
 
SCA-82 
 
SCA-71 
 
SCA-81 
 
EcSecA N68 10 20 6 / 
BaSecA2 20 14 / / 
B. anthracis sterne 4 5 8 20 
S. aureus 6538 15 55 15 >100 
E. coli NR698 35 >100 200 >100 
B, subtilis 168 7 50 18 >100 
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Table 2.14 Bacteriostatic effects of pyrimidine analogs 
            compounds 
Strains   
SCA-8 SCA-13 SCA-15 SCA-93 
MIC50 (μM) MIC50 (μM) MIC95 (μM) MIC50 (μM) MIC95 (μM) MIC50 (μM) MIC95 (μM) 
B. anthracis Sterne >250 5 6 4 5 3 4 
B. subtilis 168 >250 15/7 /10 7 10 4 6 
E. coli NR698 >250 55 >70 35 50* 70 200* 
S. aureus 6538 >250 52 >70 12 15 9 10 
S. aureus Mu50 >250 65 >100 22 38 9 10 
S. aureus N315 >250 60 >100 9 25 9 18 
S. aureus Mu3 230 >100 >100 35 100 50 >100 
MIC: 95% inhibition, *90% inhibition; incubation at 37
o
C, 1,000 rpm for 14 hrs with 2.5% DMSO. 
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Figure 2.32  Bactericidal effects of SCA-15 against S. aureus and B. anthracis  
37
o
C, 1 hour killing. 
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Development of Novel SecA Inhibitors by Optimizing Bistriazole Analogs 
In vitro Inhibition of SCA-21 SCA-21 (Fig. 2.33) is a bistriazole analog derived from 
random screening. It could inhibit the ATPase activity of SecA homologues (Table 2.15). The in 
vitro inhibition of SCA-21 was also affected by temperature. Increasing temperature from 40
o
C 
to 42
o
C, increased inhibition effect (Table 2.16); and liposomes could reduce inhibition effect at 
lower temperature (Table 2.16).  
In vivo Inhibition of SCA-21 SCA-21 showed good bacteriostatic effect on Gram-
positive bacteria (Table 2.17). Although SCA-21 could inhibit the growth of E. coli NR 698, and 
IC50 is around 10 μM, SCA-21 didn‟t inhibit the growth of E. coli RAM1398 at 100 μM (2.34), 
suggesting the compound had some permeability problem in Gram-negative bacteria.  
Optimization of SCA-21 SCA-21 is a dimer (Fig. 2.33). Replacing half part of SCA-
21with Chloro group slightly increased in vitro inhibition effect, and significantly increased in 
vivo inhibition (Table 2.17). Removing the floro group or methylthio group decreased inhibition 
effects (Table 2.17). The methyl group could be replaced with benzene ring (Table 2.17).  
Bactericidal effect of SCA-21 SCA-21 showed good bactericidal effect. 12.5 μM SCA-
21 could kill three log numbers of B. anthracis Sterne, and 50 μM could kill three log numbers 
of S. aureus 6538 and S. aureus Mu50 (Fig. 2.35).    
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 Table 2.15 In vitro inhibition of SCA-21 on the endogenous ATPase activity of SecA homologues 
 EcSecA N68 EcSecA EcSecA Tn BsSecA BaSecA2 SaSecA2 
SCA-21, IC50 (μM) 18 32 20 >100 45 43 
All reaction with 5% DMSO; for EcSecAN68, BsSecA, EcSecA, and EcF1F0, reaction at 37
o
C for 40 min; for Ba-
SecA2, reaction at 30
o
C for 40 min; for SaSecA2, reaction at 25
o
C for 20 min . 
 
 
 
Table 2.16 Temperature and liposomes affect on in vitro inhibition effects of SCA-21 
 Liposomes - Liposomes + 
 40
o
C 42
o
C 30
o
C 40
o
C 
EcSecA, IC50 (μM) 45 µM  20 µM  >100 µM  45 µM  
 
 
Table 2.17a In vitro and in vivo inhibition effects of bistriazole analgs 
 
 
 
Table 2.17b In vitro and in vivo inhibition effect of bistriazole analgs 
 
For in vivo inhibition, incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; for in vitro inhibition, reaction at 
37
o
C for 40 min with 5% DMSO; „ND‟: not determined. 
   
 
 
 
 
  
  SCA-21 
748.59 
SCA-107 
470.98 
SCA-110 
425.74 
SCA-111 
317.8 
SCA-112 
533.9 
In vitro inhibition 
IC50 (μM) 
EcSecAN68 18 30 150 >200 20 
In vivo inhibition 
IC50 (μM) 
B. anthracis 
Sterne 
3 0.73 2.5 80 0.7 
S. aureus 
6538 
1.5 0.55 2 >100 0.6 
S. aureus 
Mu50 
0.75 0.35 ND >100 0.5 
E. coli 
NR698 
60 6.3 18 >100 4 
B. subtilis 
168 
3 0.33 0.8 >100 0.5 
 
   
     
  SCA-21 
748.59 
SCA-106 
363.04 
SCA-107 
470.98 
SCA-117 
329.09 
SCA-123 
437.02 
SCA-116 
351.01 
In vitro inhibition 
IC50 (μM) 
EcSecAN68 18 30 30 ND ND ND 
In vivo inhibition 
IC50 (μM) 
B. anthracis 
Sterne 
3 17.5 0.73 >100 1.5 2 
S. aureus 
6538 
1.5 15 0.55 >100 7 20 
S. aureus 
Mu50 
0.75 ND 0.35 >100 7 15 
E. coli 
NR698 
60 32.5 6.3 >100 35 70 
B. subtilis 
168 
3 15 0.33 >100 7 30 
 
Figure 2.33 Structure of SCA-21 
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Figure 2.34 Bacteriostatic effect of SCA-21 on the growth of E. coli  
Incubation at 37
o
C, 1000 rpm for 14 hrs with 2.5% DMSO; C85: SCA-21. 
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Figure 2.35 Bactericidal effect of SCA-21 against S. aureus and B. anthracis 
37
o
C, 1 hour killing. 
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Competition assay 
In this study, three structurally different classes of SecA inhibitors were developed and 
optimized. Several SecA inhibitors show varied degree of in vitro inhibition effect on ATPase 
activities of SecA homologues. To determine whether these three classes of inhibitors bind to the 
same site or different site of SecA protein, RB, SCA-15, and SCA-21 were subjected to competi-
tion assay against the ATPase activity of BaSecA2.  
When RB and SCA-15 were added together, inhibition effect is greater than two com-
pounds individually. These two compounds have synergistic effect, suggesting that they might 
have different binding sites on BaSecA2. When SCA-15 and SCA-21 were added together or 
when RB and SCA-21 were added together, inhibition effect is the same as the sum of two com-
pounds individually. Thus SCA21 has additive effect with RB and SCA-15, suggesting that they 
might have different binding sites on BaSecA2.  
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Figure 2.36 Synergistic effect of RB and SCA-15 against the ATPase activity of BaSecA2 
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Figure 2.37 Additive effect of SCA-15 and SCA-21 against the ATPase activity of BaSecA2 
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Inhibition on the ATPase activity of BaSecA2
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Figure 2.38 The additive effect of RB and SCA-21 against the ATPase activity of BaSecA2 
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Conclusion and Discussion 
SecA is conserved in bacteria, required for viability and virulence; moreover it has no 
counterpart in mammalian cells. Thus, inhibition on the function of SecA homologues might re-
duce the virulence, inhibit bacteria growth, or/and kill bacteria, and with minimal human toxici-
ty. Therefore these SecA homologues are potential good antibacterial drug targets, and identifi-
cation SecA inhibitor might help to develop new anti-bacteria strategy. SecA proteins have AT-
Pase activities, thus screening ATPase inhibitors might help to develop new antimicrobial agents.  
Three different methods were used to develop SecA inhibitors: screening known ATPase, 
virtual docking, and random screening. In this study, three structurally different classes of SecA 
inhibitors were developed and optimized: (1) Rose Bengal (RB) and RB analogs derived from 
systematical dissection RB and Structure-Activity relationship (SAR) study; (2) pyrimidine ana-
logs derived from virtual screening based on the ATP binding pocket of EcSecA and SAR study; 
and (3) bistriazole analog derived from random screening and SAR study.  
RB could noncompetitively inhibit the ATPase activity of SecA1 and SecA2, and SecA2 
is more sensitive to RB than SecA1. RB showed bacteriostatic and bactericidal effect against 
MS. Because MS was grown in the M7H9 broth which contains 0.5% dextrose, the antimicrobial 
activeties of RB against MS were probably not caused by inhibition the ATPase activity of H
+
-
ATPases. MS ΔSecA2 was more resistant to RB than MS wild type, and MS SecA2 had higher 
affinity to RB than SecA1, suggesting RB might have dual targets in mycobacteria -SecA1 & 
SecA2, and SecA2 might be the first target. The bactericidal effect of RB was independent of 
protein synthesis and growing phase of MS.  
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To develop more potent SecA inhibitors with less side effects and molecular weight, RB 
was systematically dissected to understand the importance of structural feature. We found that 
xanthene with 5 to 6 carbon at C9 position and two hydroxyl group at C3 and C6 position was 
essential for inhibition effect; the aromatic A-ring could be replaced by an aliphatic 5 or 6 mem-
bered ring or hexyl goup; carboxyl group decrease inhibition effect; chloro groups are not neces-
sary; and iodo groups slightly increase inhibition effect, but not necessary for inhibition effect. 
The SAR studies lead to the development of two potent RB analogs, of which molecular weight 
are less than one third of RB, and show better bacteriostatic effects and bactericidal effect than 
RB.  
Pyrimidine analogues were derived from virtual screening based on the ATP binding 
pocket of E. coli SecA. SAR study results demonstrated that D-ring and A-ring are necessary for 
inhibition effect; keeping A-ring at para position are critical for inhibition effect; adding azido 
group to para position of D ring increase inhibition effect; replacing keto group 
to hydroxylamine at X-position slightly increase inhibition effect. SCA-15 and SCA-93 are the 
best pyrimidine analogs from our study.  
Bistriazole analog was derived from random screening. SCA-21 is a dimer. Replacing 
half part with chloro group slightly increase in vitro inhibition effect, and significantly increase 
bacteriostatic effects. SAR study results demonstrated that floro group, methylthio group, and 
sulfur are important for inhibition effect; the methyl group could be replaced with benzene ring. 
SCA-107 and SCA-112 are the best triazole analogs from our study. 
The in vitro inhibition effects of three classes SecA inhibitors were compared in Table 
2.18. SCA-8 has the best in vitro inhibition effect. The bacteriostatic effects of three classes of 
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SecA inhibitors were compared in Table 2.19. Bistriazole analogs have the best in vivo inhibition 
effect. Moreover, our SecA inhibitors show promising bacteriostatic effects (Table 2.19) and 
bactericidal effects (Table 2.20) again MRSA strain(s) and B. anthracis Sterne. At Table 2.21, 
the antimicrobial activities of our inhibitors with other antibiotics. Among the tested antibiotics, 
vancomycin has the best inhibition on S. aureus Mu50, MIC is around 5 μg/ml; five our SecA 
inhibitors have better bacteriostatic effect than vancomycin against S. aureus Mu50. Tetracycline 
and erythromycin have the best bacteriostatic effect against B. anthracis Sterne. Although inhibi-
tion effect of our inhibitors are not as good as tetracycline and erythromycin, but our inhibitors 
have bactericidal effect while these two antibiotics do not have. 
Several potent inhibitors developed from this study show different varying degrees of in-
hibitory effects against the intrinsic ATPase and translocation ATPase activity of SecA homolo-
gues; results of other lab members show that these inhibitors also could inhibit the in vitro pro-
tein translocation ATPase activity of EcSecA (IC50: 1-55 μM), and ion-channel activities of Sa-
SecA1, BaSecA1, and EcSecA in oocyte system (IC50: 0.4-5 μM). These SecA inhibitors show 
promising bacteriostatic effects against B. subtilis 168 and one E. coli leaky mutant strain 
NR698; moreover, they have very good bacteriostatic effects and bactericidal effect of B. anth-
racis Sterne, numerous clinical or drug-resistant S. aureus strains. However we need to further 
determine whether the antimicrobial activities of these inhibitors were due to inhibition on SecA.   
 
 
  
146 
Table 2.18 In vitro inhibition effects of three classes SecA inhibitors 
  RB RB analogs Pyrimidine analogs Triazole analogs 
  
RB 
MW: 974 
SCA-41 
MW: 282 
SCA-50 
MW: 298 
SCA-8 
MW: 713 
SCA-15 
MW: 436 
SCA-21 
MW: 749 
SCA-107 
MW: 471 
Intrinsic  
ATPase 
BsSecA 20 30 33 8 >100 >100 ND 
BaSecA2 15 30 20 7 20 45 65 
SaSecA2 1 6 ND 3 13 43 50 
EcSecA N68 1 8 4 2 8 18 30 
EcSecA 60 30 60 >100 30 32 ND 
Translocation 
ATPase 
EcSecA 1 15 60 6 30 20 28 
In vitro inhibition: IC50 (μM); 40 min reaction with 5% DMSO; for EcSecAN68, BsSecA, and EcSecA, reaction at 
37
o
C; for BaSecA2, reaction at 30
o
C; Translocation ATPase activity of EcSecA: 37
o
C 40 min reaction with E. coli 
BA13 membrane washed with 6 M Urea and E. coli preOmpA; “ND”: not determined;  
 
Table 2.19 Bacteriostatic effects of three classes SecA inhibitors 
Class RB RB analogs Primidine analogs Bistriazole analogs 
Compound 
RB 
MW: 974 
SCA-41 
MW: 282 
SCA-50 
MW: 298 
SCA-15 
MW: 436 
SCA-93 
MW: 451 
SCA-21 
MW: 749 
SCA-107 
MW: 471 
MIC (μM) 50% 95% 50% 95% 50% 95% 50% 95% 50% 95% 50% 95% 50% 95% 
B. subtilis 168 74 80 7 8 7 8 7 10 5 6 3 4 0.3 0.8 
E. coli NR698 18 25 9 25 14 22 35 50* 45 200* 40 75 6.3 9.5 
B. anthracis 
Sterne 
7 13 3 4 4 12.5 4 5 3 4 3 4 0.7 1.5 
S. aureus 6538 28 50 7 10 8 12.5 12 15 9 10 1.5 4 0.6 1.9 
S. aureus Mu50 27 40 6 7 11 19 23 25 9 10 0.8 2 0.4 2 
S. aureus Mu3 >50 >50 5 8 12.5 18.8 35 100 50 >100 1.5 4 0.6 2 
S. aureus N315 45 >50 5 6 7.5 9.4 9 25 9 18 0.8 2 0.4 2 
Incubation at 37
o
C, 1,000 rpm for 14 hrs with 2.5% DMSO; *:MIC90  
 
 
Table 2.20 Bactericidal effects of three classes SecA inhibitors 
 RB analogs Primidine analogs Bistriazole analogs 
 SCA-50 
MW: 436 
SCA-15 
MW: 436 
SCA-21 
MW: 749 
S. aureus 6538 3 (40 μM) 4 (50 μM) 3 (50 μM) 
S. aureus Mu50 3 (40 μM) 4 (50 μM) 3 (50 μM) 
B. anthracis Sterne 3 (20 μM) 2 (10 μM) 4 (12.5 μM) 
B. subtilis 168 4 (20 μM) ND ND 
Log # in cell killing/ml; 37
o
C 1 hour killing; „ND‟: not determined.  
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Table 2.21 Comparison of the antimicrobial activities of SecA inhibitors with other antibiotics 
Class  
Strains  
Antibiotics  
S. aureus Mu50 B. anthracis Sterne 
MIC95 (μg/ml)  Log #/ ml  MIC95 (μg/ml)  Log #/ ml  
RB & analogs  
RB  40.7  +  12.2  ND*  
SCA-41  1.7  ND*  1.1  ND*  
SCA-50  2.4  3.5 (8.9 μg/ml)  1.7  3 (6.0 μg/ml)  
Pyrimidine analogs  
SCA-15  10.9  3 (10.9 μg/ml) 2.2  2 (4.4 μg/ml)  
SCA-93  4.5  ND*  1.6  ND*  
Bistriazole analogs  
SCA-21  1.5  2 (19.0 μg/ml)  3.0 3.5 (19.0 μg/ml)  
SCA-107  0.5  ND*  0.7  ND*  
SCA-112  0.4  ND*  0.8  ND*  
Glycopeptides  Vancomycin  5 +  2.5 +  
Penicillins  Ampicillin  7.8 +  >20 +  
Aminoclycosides  
Kanamycin  >100 +  1 +  
Gentamycin  >500 +  5 +  
Polypeptides  Polymxin B  15 +  10 +  
Tetracyclines  Tetracycline  200 -  0.l -  
Macrolides  Erythromycin  >500 -  0.3 -  
others  Chloramphenicol  >40 -  10  -  
Incubation at 37
o
C, 1,000 rpm for 14 hrs; log #/ml: log number in cell killing/ml; “ND”: not determined; “+”: have 
bactericidal effect; “-”: do not have bactericidal effect.   
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Summary 
In this study, three structurally different classes of SecA inhibitors were developed and 
optimized. Several SecA inhibitors showed promising in vitro inhibition effect on ATPase activi-
ties of SecA homologues, as well as bacteriostatic effects and bactericidal effects against B. 
anthracis Sterne and numerous drug resistant S. aureus strains. However, to validate SecA as a 
real target of these inhibitors, we need to determine whether their antimicrobial activities are due 
to inhibition on SecA in vivo. SecA is involved in forming a protein conducting channel that 
spans the entire membrane. Thus, drugs targeting SecA might be directly accessible from the 
extracellular matrix and exert their effects without entering the cell, and bypassing the major 
negative effect of efflux transporters in bacteria, which is a major mechanism for the develop-
ment of current drug-resistance. Two major efflux pumps of S. aureus, NorA and MepA, had 
little negative effect on the antimicrobial activities of SecA inhibitors, suggesting that targeting 
SecA might be able to by-pass efflux pump. Sec system is responsible for the secretion of many 
toxins and virulence factors, which play important roles in the pathogenesis of bacterial infec-
tion. Our results showed SecA inhibitors could inhibit secretion of important virulence factors of 
S. aureus and B. anthracis Sterne, suggesting that these inhibitors could inhibit the function of 
SecA in vivo and reduce virulence of these important bacteria pathogens. Previous studies indi-
cated that photooxidation and halo group contribute to the antimicrobial activities of RB as well 
as inhibition on specific enzymes. However, our results showed that photooxidation might not 
contribute to the antimicrobial activities of RB analogs, which do not have halo group and have 
better antimicrobial activities than RB, suggesting that the ability of inhibition on specific en-
zyme is increased in RB analogs. The interaction between SecA homologues and inhibitors was 
confirmed by altered trypsin sensitivity assay. Target identification assays confirmed that SecA 
150 
inhibitor could identify SecA homologues from whole cell lysate of E. coli and S. aureus, sug-
gesting that these inhibitors were really targeting on SecA. These results validated that SecA is a 
good target for development antimicrobial agents. 
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Introduction 
In this study, three structurally different classes of SecA inhibitors were developed and 
optimized. (1) RB and RB analogs derived from systematical dissection RB and SAR study; (2) 
pyrimidine analogs derived from virtual screening based on the ATP binding pocket of EcSecA 
and SAR study; and (3) bistriazole analog derived from random screening and SAR study. Sev-
eral SecA inhibitors showed promising in vitro inhibition effect on ATPase activities of SecA 
homologues, as well as bacteriostatic effects and bactericidal effects against B. anthracis Sterne 
and numerous drug resistant S. aureus strains. However, to validate SecA as a real target of these 
inhibitors, we need to determine whether these antimicrobial activities of SecA inhibitors are due 
to in vivo inhibition on SecA. Thus, we further investigated their inhibition effects on secretion 
of toxins, the interaction between SecA homologues and inhibitors, and the ability of binding 
with SecA from whole cell lysate. 
Previous studies demonstrated that EcSecA exists as soluble form and membrane form 
[96-97]; SecA alone could form ring-like structures upon interaction with anionic phospholipids 
[38-39]; SecA alone could export preOmpA across liposomes (Hsieh, et al, 2012),  suggesting 
that SecA indeed is involved in forming a protein conducting channel that spans the entire mem-
brane. Thus, drugs targeting SecA might be directly accessible from the extracellular matrix and 
exert their effect without entering the cell, and bypassing the negative effect of efflux transpor-
ters in bacteria, which is a major mechanism for the development of current drug-resistance [72-
76]. Therefore, bacterial efflux pumps may have little negative effect on the ability for these in-
hibitors to inhibit bacterial growth. S. aureus Mu50 and S. aureus N315 are resistant to QacA 
efflux-mediated antibiotics [100]. SCA-41, SCA-50, SCA-15, SCA-93, and SCA-21 are best in-
hibitors developed from our study. They showed promising bacteriostatic effects or/and bacteri-
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cidal effect on S. aureus Mu50 or/and S. aureus N315, suggesting that these SecA inhibitors 
might be able to overcome QacA mediated efflux. NorA and MepA are two major efflux pumps 
of S. aureus. In this study, we further investigated whether NorA and MepA could affect bacte-
riostatic effect and bactericidal effect of our SecA inhibitors.  
Sec system is not only responsible for the secretion of many essential proteins, and it is 
also responsible for the secretion of many toxins and virulence factors [33-35]. In S. aureus, 
there are many secretory toxin precursors containing Sec-dependent signal peptide (Table 0.1) 
[34]. Table 0.1 showed these toxins play important roles in the pathogenesis of S. aureus infec-
tion, promoting adhesion, colonization, and spread in host tissue, protecting bacteria from envi-
ronmental toxic condition or from host immune defense system, causing serious host cell damage 
or toxic syndrome. Because both SecA1 and SecA2 were involved in secretion of virulence fac-
tors, dual targeting inhibition on these two SecA homologues would dramatically reduce viru-
lence. Virulence target-based therapies are not sufficient to combat infection, but targeting SecA 
homologues is not only reduce virulence but also decrease viability, dramatically increasing the 
chance of control bacterial infection and reduce the occurrence of drug resistance. Enterotoxin B, 
α-hemolysin, and toxic shock syndrome toxin 1 (TSST-1) are three toxins of S. aureus, which 
containing Sec-dependent signal peptide (Table 0.1) [34]. Lethal factor (LF), edema factor (EF), 
and protective antigen (PA), are three major component toxins of B. anthracis, and all of them 
have Sec-dependent signal peptide [35]. In this study, commercial antibodies for these toxins 
were used to assess the inhibition effect on toxin secretion.  
Previous studies indicated that there are three mechanism involved in the antimicrobial 
activity of RB. RB could specific binding to essential enzyme and inhibit its function, like DNA 
polymerase [108, 110], RNA polymerase [109]. RB might release chloro and iodo group at cer-
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tain condition, these halo groups have antimicrobial activity. RB is a photosensitizer [116], and it 
could generate singlet oxygen through photooxidation [117-118]. Singlet oxygen could cause 
cell damage and bacteria death. SCA-41 don‟t have halo group, but it showed better bacteriostat-
ic and bactericidal effect than RB. We don‟t know whether its antimicrobial activities are due to 
inhibition on SecA, other enzyme, or photooxidation. In this study, we investigate whether anti-
microbial activity of RB and RB analogs are due to inhibition on proton ATPase activity or due 
to photooxidation.  
To truly validate SecA as the target of those inhibitors developed in our study, we need to 
investigate interaction between SecA and inhibitors, identify how many proteins interact with 
inhibitors, and determine whether interactions with other proteins could contribute to observed 
antimicrobial effect. Affinity chromatography is the most widely used method to identify drug 
targets [119-120], however the application of affinity chromatography was limited, because of 
the need of vast structural diversity, the complexity of biologically active small molecules, and 
high level of nonspecific binding of non-target proteins [121-124]. Drug affinity responsive tar-
get stability (DARTS) is a new method to identify drug targets [121, 125]. The principle of this 
method is that binding with small ligand would stabilize the structure of its target protein and 
result in changing of protease resistance, which offered the chance of target identification [121, 
125]. Affinity chromatography is a positive target selection method by pulling out the target pro-
teins and leaving nontarget proteins behind [121], while DARTS is a negative drug target selec-
tion method by digesting away nontarget proteins while leaving behind the target proteins [121]. 
In this study, these two methods were used to validate that SecA is a real target. Azide is a SecA 
inhibitor, and previous study showed that azide enhances the formation of a trypsin-resistant 30 
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kDa fragment, which is related with SecA membrane insertion [37, 62, 88]. In this study, altered 
trypsin sensitivity assay was used to detect interaction between inhibitors and SecA homologues.  
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Material and Methods 
Medium: LB medium was used to grow bacteria in this study.  
SecA inhibitors: All inhibitors were synthesized by Dr. Binghe Wang‟s lab. 
Strains: E. coli NR698, B. subtilis 168, S. aureus N315, S. aureus 6538, S. aureus Mu50, 
B. anthracis Sterne. Five efflux pump related strains: S. aureus 8325, S. aureus K1758 (NorA
-
), 
S. aureus K2361 (NorA
+++
), S. aureus K2068 (MepA
+++
), and S. aureus K2908 (MepA
-
), were 
from Dr. GW Kaatz at Wayne State University School of medicine and Jon D. Dingell VA Med-
ical Center.  
Antibodies: Antibodies for S. aureus α-hemolysin, S. aureus Enterotoxin B, S. aureus 
TSST-1, B. anthracis lethal factor (LF), B. anthracis edema factor (EF), and B. anthracis protec-
tive antigen (PA), were purchased from abcam.com.  
In vitro inhibition assay: Because SecA homologues have ATPase activity, Malachite 
green colorimetric assay was used to investigate the inhibition of inhibitors on the ATPase activi-
ty of SecA homologues. In this assay, ATPase assay was carried in different concentration of 
inhibitors, and IC50 is the concentration of RB which could inhibit 50% ATPase activity of SecA 
homologeus. Because the compounds were not soluble, so the compounds were dissolved in 
100% DMSO. In the final in vitro assay there were 1-5% DMSO. 
In vivo inhibition assay in medium: Single colony of bacteria was inoculated in 3 ml 
LB medium in 12 ml culture tube, then grow at 37
o
C; when OD600 ≈ 0.5, 300 μl culture were di-
luted into 3 ml LB medium, then 97.5 μl culture was aliquated into 1.5 ml eppendorf tube, then 
adding 2.5 μl of different concentration of RB analogs; incubated at 37oC, 1,000 rpm, 14 hours in 
Thermo-mixer. OD600 was measured to determine inhibition effect.  
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Killing assay: Single colony of bacteria was inoculated in 3 ml LB medium in 12 ml cul-
ture tube, then grow at 37
o
C; when OD600 ≈ 0.5, 97.5 μl cell culture was aliquated into 1.5 ml 
eppendorf tube, then add 2.5 μl different concentration of RB analogs into tube; incubated at 
37
o
C, 1000 rpm for 1-2 hours. The cell culture was diluted with dd H2O and spread 150 μl on 
LB plates. 
Toxin secretion: Inhibitors were added to the mid-log phase of S. aureus Mu50 or B. 
anthracis Sterne. The growth of bacteria was monitored. Culture was collected after treating with 
inhibitor for 1 h, 3 hrs, and 5 hrs. For S. aureus cell culture, the supernatant and cell pellet were 
separated by centrifugation and 0.45 μM filter; while the supernatant of B. anthracis was sepa-
rated from cell by 0.45 μM filter only. The collected supernatant was subjected to TCA precipi-
tation, and the protein pellet was resuspended in Tris-buffer pH 7.5. Western blots with specific 
toxin antibodies were used to detect the amount of toxins. 
DARTS for purified protein binding: 10 μg protein was incubated at 37oC for 10 min 
with or without inhibitors, then exposed to UV for 0 sec or 90 sec, followed by digestion with 
1.2 μg trypsin on ice for 15 min to 25 min. The digestion was stopped by adding sample buffer 
and boiling for 20 min. 12% or 15% SDS-PAGE was used to investigate the trypsin digestion 
pattern. 
DARTS for whole cell lysate: E. coli MC4100, S. aureus Mu50, and B. anthracis Sterne 
were grown in LB medium overnight at 37
o
C. Bacteria cell were harvested by centrifugation and 
washed with Tris-buffer pH 7.5. Cell pellet was resuspended with Tris-buffer, which contain 
cocktail proteinase inhibitor, then French pressed at 10,000 psi. Unbroken cells were separated 
by 5,000 rpm centrifugation. 100 μg or 200 μg whole cell lysate was incubated on ice for 2 hrs 
with or without inhibitors, then exposed to UV for 0 sec or 90 sec, followed by digestion with 50 
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μg trypsin at 25oC for 10 min-20 min. The digestion was stopped by adding sample buffer and 
boiling for 20 min. 12%, 15%, or 10-20% SDS-PAGE was used to investigate the trypsin diges-
tion result. 
Pull down assay: E. coli MC4100 and S. aureus Mu50 were grown in LB medium over-
night at 37
o
C. Bacteria cell were harvested by centrifugation and washed with binding buffer (0.1 
M K3PO4 pH 7.2). Cell pellet was resuspended with binding buffer, which contain cocktail pro-
teinase inhibitors, then French pressed at 10,000 psi. Unbroken cells were separated by 5 k rpm 
centrifugation. Agarose beads and straptavidin beads were used in our study. For agarose beads, 
whole cell lysate was mixed with beads and rolling with or without inhibitors at 4
o
C for 1 hour, 
then rolling at room temperature for 10 min. For straptavidin beads, the whole cell lysate was 
pretreated with beads at 4
o
C for 1 hour, then centrifuged for 2 min at 0.5 k rpm; the supernatant 
was taken out and mixed with clean beads and rolling with or without inhibitors at 4
o
C for 1 
hour, then rolling at room temperature for 10 min. Both agarose beads and straptavidin bead 
were separated with cell lysate by centrifuged at 0.5 k rpm for 2 min, then beads were washed 
with binding buffer for 5 times. After washing, beads were mixed with binding buffer and sam-
ple buffer, then boiled for 30 min.  
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Results 
Effect of Efflux Pumps on the Antimicrobial Activities of SecA Inhibitors 
SecA might be involved in forming a protein-conducting channel that spans the entire 
membrane [38-39]. Thus, drugs targeting SecA might be directly accessible from the extracellu-
lar matrix and exert their effect without entering the cell, and bypassing the major negative effect 
of efflux transporters in bacteria, which is a major mechanism for the development of current 
drug-resistance [72-76]. S. aureus Mu50 and S. aureus N315 are resistant to beomycin, β-lactam, 
tetracyclines, several aminoglycosides and MLS [100]. And these two strains are resistant to Qa-
cA efflux-mediated antibiotics [100]. SCA-41, SCA-50, SCA-15, SCA-93, and SCA-21 are best 
inhibitors developed from our study. They showed promising bacteriostatic effects or/and bacte-
ricidal effect on S. aureus Mu50 or/and S. aureus N315, suggesting that the SecA inhibitors 
might be able to overcome QacA mediated efflux. NorA and MepA are two major efflux pumps 
of S. aureus. In this study, we further tested whether NorA and MepA could affect bacteriostatic 
effect and bactericidal effect of our SecA inhibitors.  
Effect of efflux pumps on bacteriostatic effect of RB and RB analogs Deletion NorA 
significantly increased sensitivity to RB, and over-expression NorA restore resistance to RB, 
suggesting that NorA was involved in RB resistance (Table 3.1). However, over-expression Me-
pA increased sensitivity to RB, and over-expression NorA or MepA slightly increased sensitivity 
to SCA-41 (Table 3.1a). For SCA-50, IC50 of NorA
-
 and NorA
+++
 were similar. Thus, NorA and 
MepA didn‟t show negative effect on bacteriostatic effect of SCA-41 and SCA-50.  All these re-
sults strongly suggest that RB analogs might be able to overcome the effect of efflux pumps in 
drug-resistance development.  
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Effect of efflux pumps on antimicrobial effect of pyrimidine analogs Deletion NorA 
or MepA slightly reduced bacteriostatic effect of SCA-15 and SCA-93, and over-expression No-
rA or MepA slightly increase bacteriostatic effect (Table 3.1b). Deletion NorA and MepA also 
slightly reduced bactericidal effects comparing to wild type, while over-expression MepA 
slightly increased killing effect comparing to MepA deletion mutant (Fig. 3.1). Thus, NorA and 
MepA didn‟t showed negative effect on the ability for these inhibitors to inhibit bacterial growth 
or kill bacteria.   
Effect of efflux pumps on antimicrobial effect of bistriazole analogs Deletion or over-
expression NorA or MepA didn‟t affect bacteriostatic effect of SCA-21 (Table 3.1b). Deletion or 
overexpression NorA didn‟t affect bactericidal effect of SCA-21, but deletion MepA reduced 
bactericidal effect and over-expression MepA increased bactericidal effect of SCA-21 (Fig. 3.2).   
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Table 3.1a Bacteriostatic effects of RB and RB analogs against S. aureus efflux strains 
                   Strains 
compounds 
WT 
8325-4 
NorA
-
 
K1758 
NorA
++
 
K2361 
MepA
-
 
K2908 
MepA
++
 
K2068 
RB 
MIC50 (μM) 15 5 18 19 7 
MIC95 (μM) 25 10 25 25 25 
SCA-41 
MIC50 (μM) 7 8 5 8 5 
MIC95 (μM) 8 10 8 10 8 
SCA-50 
MIC50 (μM) 9 7 8 13 9 
MIC95 (μM) 15 8 15 15 15 
 
Table 3.1b Bacteriostatic effects of pyrimidine analogs and bistriazole analogs against S. aureus efflux strains 
                   Strains 
compounds 
WT 
8325-4 
NorA
-
 
K1758 
NorA
++
 
K2361 
MepA
-
 
K2908 
MepA
++
 
K2068 
SCA-15 
MIC50 (μM) 22 25 23 30 19 
MIC95 (μM) 64 50 40 75 50 
SCA-93 
MIC50 (μM) 27 33 21 32 19 
MIC95 (μM) 50* >50 50* >50 50* 
SCA-21 
MIC50 (μM) 3.0 3.0 3.0 3.0 2.5 
MIC95 (μM) 4 4 4 4 4 
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Figure 3.1 Bactericidal effects of SCA-15 against S. aureus efflux strains  
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Figure 3.2 Bactericidal effects of SCA-21 against S. aureus efflux strains 
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Inhibition on the Secretion of Bacterial Toxins 
Being conserved throughout bacteria, the Sec-dependent protein export pathway is re-
sponsible for export precursor proteins, which contain classical amino-terminal signal sequences 
across the cytoplasmic membrane [31]. Sec system is not only responsible for the secretion of 
many essential proteins, but also responsible for the secretion of many toxins and virulence fac-
tors, promoting adhesion, colonization, and spread in host tissue, protecting bacteria from envi-
ronmental toxic condition or from host immune defense system, causing serious host cell damage 
or toxic syndrome. Because both SecA1 and SecA2 are involved in secretion of virulence fac-
tors, dual targeting inhibition on these two SecA homologues could dramatically reduce viru-
lence. Virulence target-based therapies are not sufficient to combat infection, but targeting SecA 
homologues is not only reduce virulence but also decrease viability, dramatically increasing the 
chance of control bacterial infection and reduce the occurrence of drug resistance.  Antibodies 
for several important extracellular toxins in both bacteria are commercially available, and were 
used for the assessment of the effects of the inhibitors on the SecA inhibition in this study.  
Inhibition of RB on the secretion of S. aureus Toxins RB was added to the mig-log 
phase of S.aureus Mu50 at OD600 ≈ 3. RB could inhibit the growth of S. aureus Mu50 at 15 μM-
60 μM (Fig. 3.3a).  SDS-PAGE gel results showed that the general secretion of S. aureus Mu50 
was inhibited by RB (Fig. 3.3b). Western Blot results showed that the amount of α-hemolysin, 
enterotoxin B, and TSST-1 were dramatically decreased by RB (Fig. 3.3c). To investigate 
whether these results were due to inhibition on secretion or due to inhibit on synthesis or stabili-
ty, this experiment was repeated and the toxins in medium and inside the bacteria were detected 
by antibody side by side. The results confirmed that 10 μM RB could inhibit the growth of S. au-
reus Mu50, while 4.5 mM sodium azide had more strong inhibition on the growth of S. aureus 
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Mu50 than 10 μM RB (Fig. 3.4a). Western blot results showed that 10 μM RB almost totally de-
creased the amount of α-hemolysin, enterotoxin B, and TSST-1 not only in medium but also in-
side of cell (Fig. 3.4b-c), suggesting that RB could affect the synthesis or stability of these tox-
ins; 4.5 mM sodium azide decreased the amount of these two toxins in medium, however the 
amount of these toxins were not obviously changed inside the cells (Fig. 3.4b-c). Because pre-
vious study showed that RB could bind to RNA polymerase, so it is possible the decreasing 
amount of toxins in the supernatant was due to inhibition on protein synthesis. But because our 
results showed that RB could inhibit the ATPase activity of SaSecA1 and SaSecA2, we couldn‟t 
exclude the possibility that the decreasing amount of toxins in the supernatant was due to inhibi-
tion on secretion and that there are might have some feed-back regulation system which control 
the amount of toxins inside bacteria.  
Inhibition of RB on the secretion of B. anthracis Toxins RB was added to the mig-log 
phase of B. anthracis Sterne at OD600 ≈ 3. RB could inhibit the growth of B. anthracis Sterne at 
10 μM-20 μM, while 5 μM RB didn‟t obviously change its growth (Fig. 3.5a).  SDS-PAGE gel 
results showed that the general secretion of S. aureus Mu50 was inhibited by RB (Fig. 3.5b). 
Western Blot results showed that the amount of lethal factor, edema factor, and protective anti-
gen were dramatically decreased by RB (Fig. 3.5c).  
Inhibition of RB analogs on the secretion of S. aureus Toxins When 10 μM SCA-41 
was added into the mid-log phase of S. aureus Mu50, the OD reading was slightly lower than 
control in 15 hours (Fig. 3.6a). Increasing concentration, OD became lower. 10 μM SCA-41 was 
enough to significantly reduce the total secretion profile (Fig. 3.6b). Western blot with specific 
toxin antibody showed that 10 μM SCA-41 was enough to significantly decrease the amount of 
α-hemolysin, enterotoxin B, and toxin shock syndrome toxin-1 (TSST-1) in the supernatant (Fig. 
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3.6c). To test whether this result was due to decreasing protein synthesis, the amount of three 
toxins inside and outside was compared side by side. 10 μM SCA-50 didn‟t obviously change 
OD reading (Fig. 3.7a), however it significantly decreased the amount of three toxins in the su-
pernatant and inside cell (Fig. 3.7b); and these toxins were not stable in the supernatant (Fig. 
3.7c).  Although adding RB analogues didn‟t increase the amount of toxins in cytosol, we 
couldn‟t exclude the possibility that there are might have some feed-back regulation system 
which control the amount of toxins inside bacteria. Because previous study showed that RB 
could bind to RNA polymerase, so it is possible the decreasing amount of toxins in the superna-
tant was due to inhibition on protein synthesis.  
Inhibition of RB analogs on the secretion of B. anthracis Toxins When 5 μM to 10 μM 
SCA-41 was added into the mid-log phase of B. anthracis Sterne., the OD reading was not ob-
viously changed comparing with control in 5 hours, while 20 μM SCA-41 slightly inhibited bac-
teria growth and drop OD reading (Fig. 3.8a). 5-10 μM SCA-41 slightly decreased the amount of 
secretory proteins in the supernatant in 1 hour sample (Fig. 3.8b). Western blot results showed 
that 5 μM SCA-41 was enough to significantly reduce the amount of lethal factor, edema factor, 
and protective antigen in the supernatant (Fig. 3.8c). 
Inhibition of pyrimidine analogs on secretion of S. aureus toxins When 10 μM to 30 
μM SCA-15 was added into the mid-log phase of S. aureus Mu50, the OD reading was not ob-
viously changed comparing without compound in 15 hours (Fig. 3.9a), however 10 μM SCA-15 
was enough to significantly reduce the total secretion profile, and increasing concentration of 
SCA-15 reduced more (Fig. 3.9b). Western blots with specific toxin antibodies showed that 10 
μM SCA-15 was enough to significantly decrease the amount of α-hemolysin, enterotoxin B, and 
TSST-1 in the supernatant, and increasing concentration of SCA-15 decreased more (Fig. 3.9c). 
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To test whether this result was due to decreasing protein synthesis, the amount of three toxins 
inside and outside was compared side by side. 10 μM SCA-15 and 10 μM SCA-93 didn‟t ob-
viously change OD reading (Fig. 3.10a), however these compounds significantly decreased the 
amount of three toxins in the supernatant, while the amount inside were not obviously changed 
(Fig. 3.10b); and these toxins were not stable in the supernatant (Fig. 3.10b).  Although adding 
SecA inhibitors didn‟t increase the amount of toxins in cytosol, we could not exclude the possi-
bility that there might have some feed-back regulation systems which control the amount of tox-
ins inside bacteria.  
Inhibition of pyrimidine analogs on secretion of B. anthracis toxins When 2.5 μM to 5 
μM SCA-15 was added into the mid-log phase of B. anthracis Sterne., the OD reading was not 
obviously changed comparing with control in 5 hours, while 10 μM SCA-15 slightly inhibited 
bacteria growth (Fig. 3.11a). 2.5 μM SCA-15 slightly decreased the amount of secretary proteins 
in the supernatant in 1 hour sample (Fig. 3.11b); 5 μM decreased a little more amount of protein 
in 5 hour samples (Fig. 3.11b); and 10 μM significantly decreased the amount of secretary pro-
tein in the supernatant (Fig. 3.11b). Western blot results showed that 2.5 μM SCA-15 was 
enough to significantly reduce the amount of lethal factor, edema factor, and protective antigen 
in the supernatant, and increasing concentration of SCA-15 reduced a little more (Fig. 3.11c). 
Inhibition of bistriazole analogs on secretion of S. aureus toxins When 2.5 μM SCA-
21 was added into the mid-log phase of S. aureus Mu50, the growth of bacteria was obviously 
inhibited (Fig. 3.12a), 10 μM SCA-21 totally stopped bacteria growth. 2.5 μM SCA-21 was 
enough to significantly reduce the total secretion profile (Fig. 3.12b). Western blot with specific 
toxin antibody showed that 2.5 μM SCA-21 was enough to significantly decrease the amount of 
α-hemolysin, enterotoxin B, and TSST-1 in the supernatant (Fig. 3.12c). To test whether this re-
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sult was due to decreasing protein synthesis, the amount of three toxins inside and outside was 
compared side by side. 2.5 μM SCA-21 inhibited the bacteria growth (Fig. 3.13a), decreased the 
amount of three toxins in the supernatant and inside cell (Fig. 3.13b); and these toxins were not 
stable in the supernatant (Fig. 3.13b).  Because bacteria growth was obvious inhibited by SCA-
21, it is hard to conclude that SCA-21 inhibit the secretion of S. aureus toxins. 
Inhibition of bistriazole analogs on secretion of B. anthracis toxins 1.25 μM SCA-21 
slightly inhibit the growth of B. anthracis Sterne. (Fig. 3.14a), while 2.5 μM SCA-21 totally 
stopped bacteria growth (Fig. 3.14a). 1.25 μM SCA-21 slightly decreased the amount of secre-
tary proteins in the supernatant (Fig. 3.14b); 2.5 μM SCA-21 blocked almost everything in the 
supernatant (Fig. 3.14b). Western blot results showed that 1.25 μM SCA-15 was enough to sig-
nificantly reduce the amount of lethal factor, edema factor, and protective antigen in the superna-
tant (Fig. 3.14c). 
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Figure 3.3a Inhibition of RB on the growth of S. aureus Mu50 
                
 
 
                 
Figure 3.3b Inhibition of RB on the secretion of S. aureus Mu50 
   
 
Figure 3.3c Inhibition of RB on secretion of specific toxins of S. aureus Mu50 
 
Figure 3.3 Inhibition of RB on the secretion of S. aureus toxins 
Different conc. of RB was added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 2.6; the growth of bacteria was 
monitored; 2 ml culture was collected after 1 h, 2.5 hrs, and 4 hrs, and the supernatant and cell pellet were separate; 
200 μl TCA was added into 1.8 ml supernatant to precipitate protein, and the protein pellet was suspended in 200 μl 
Tris-buffer; specific antibodies were used to detect α-hemolysin, enterotoxin B, and TSST-1. 
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Figure 3.4a Inhibition of RB and azide on the growth of S. aureus Mu50 
 
 
Figure 3.4b Inhibition of RB and azide on the secretion of α-hemolysin and enterotoxin B 
   
    
Figure 3.4c Inhibition of RB and azide on the secretion of TSST-1 
 
Figure 3.4 Inhibition of RB and azide on the secretion of S. aureus toxins 
10 μM RB and 4.5 mM Sodium Azide were added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 3; the growth 
of bacteria was monitored; then 2 ml culture was collected after 2 hrs and 4 hrs, and the supernatant and cell pellet 
were separated; 200 μl TCA was added into 1.8 ml supernatant to precipitate protein, and the protein pellet was sus-
pended in 200 μl Tris-buffer; specific antibodies were used to detect α-hemolysin, enterotoxin B, and TSST-1. 
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Figure 3.5a Inhibition of RB on the growth of B. anthracis Sterne 
 
 
Figure 3.5b Inhibition of RB on the general secretion of B. anthracis Sterne 
 
 
Figure 3.5c Inhibition of RB on the secretion of specific toxins of B. anthracis Sterne. 
 
Figure 3.5 Inhibition of RB on the secretion of B. anthracis toxins 
Different conc. of RB was added to the mid-log phase of B. anthracis Sterne at OD600 ≈ 3; the growth of bacteria 
were monitored; then 2 ml culture was collected after 1 h, 3 hrs, and 5 hrs, then the supernatant and cell pellet were 
separated. 110 μl TCA was added into 1 ml supernatant to precipitate proteins; the protein pellet was suspended in 
100 μl Tris-buffer. Specific antibodies were used to detect lethal factor (LF), edema factor (EF), and protective anti-
gen (PA).  
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Figure 3.6a Inhibition of SCA-41 on the growth of S. aureus Mu50 
 
 
         
Figure 3.6b Inhibition of SCA-41 on the secretion of S. aureus Mu50 
 
 
Figure 3.6c Inhibition of SCA-41 on the secretion of specific toxins of S. aureus Mu50 
 
 
Figure 3.6 Inhibition of SCA-41 on the secretion of S. aureus toxins 
Different conc. of SCA-41 were added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 3; the growth of bacteria 
was monitored; 200 μl TCA was added into 1.8 ml supernatant to precipitate protein; the protein pellet was resus-
pended  in 200 μl Tris-buffer; specific antibodies were used to detect α-hemolysin, enterotoxin B, and TSST-1. 
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Figure 3.7a Inhibition of SCA-41 and SCA-50 on the growth of S. aureus Mu50 
 
 
Figure 3.7b Inhibition of SCA-41 and SCA-50 on the secretion of α-hemolysin, Enterotoxin B, and TSST-1 
 
 
Figure 3.7 Inhibition of SCA-41 and SCA-50 on the secretion of S. aureus toxins 
30 μM SCA-41 or 10 μM SCA-50 was added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 2.6; the growth of 
bacteria was monitored; then 2 ml culture was collected after 2 hrs and 4 hrs, and the supernatant and cell pellet 
fraction were separated; specific antibodies were used to detect α-hemolysin, Enterotoxin B, and TSST-1.   
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Figure 3.8a Inhibition of SCA-41 on the growth of B. anthracis Sterne 
 
            
 
 
                  
Figure 3.8b Inhibition of SCA-41 on the general secretion of B. anthracis  
 
 
Figure 3.8c Inhibition of SCA-41 on the secretion of specific toxins of B. anthracis  
 
Figure 3.8 Inhibition of SCA-41 on the secretion of B. anthracis toxins 
Different conc. of RB was added to the mid-log phase of B. anthracis Sterne at OD600 ≈ 2.6; the growth of bacteria 
was monitored; then 2ml culture was collected after 1 hr, 3 hrs, and 5 hrs, and the supernatant and cell pellet were 
separated; 110 μl TCA was added into 1 ml supernatant to precipitate protein; the protein pellets were suspended in 
100 μl Tris-buffer; specific antibodies were used to detect lethal factor, edema factor, and protective antigen. 
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Figure 3.9a Inhibition of SCA-15 on the growth of S. aureus Mu50 
 
 
 
 
 
            
Figure 3.9b Inhibition of SCA-15 on the general secretion of S. aureus Mu50 
 
 
 
Figure 3.9c Inhibition of SCA-15 on secretion of specific toxins of S. aureus Mu50 
 
Figure 3.9 Inhibition of SCA-15 on the secretion of S. aureus toxins 
Different conc. of SCA-15 was added into the mid-log phase of S. aureus Mu50 at OD600 ≈ 3; the growth of bacteria 
was monitored; 2 ml cultures were collected after 1hr, 2.5 hrs, and 4 hrs, and the supernatant and cell pellet were 
separate; 200 μl TCA was added into 1.8ml supernatant to precipitate protein; the protein pellet was suspended  in 
200 μl Tris-buffer; specific antibodies were used to detect α-hemolysin, Enterotoxin B, and TSST-1. 
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Figure 3.10a Inhibition of SCA-15 and SCA-93 on the growth of S. aureus Mu50 
 
 
Figure 3.10b Inhibition of SCA-15 and SCA-93 on the secretion of α-Hemolysin, Enterotoxin B, and TSST-1 
 
 
Figure 3.10 Inhibition of SCA-15 and SCA-93 on the secretion of S. aureus toxins 
10 μM SCA-15 or 10 μM SCA-93 was added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 2.6; the growth of 
bacteria was monitored; 2 ml culture was collected after 2 hrs and 4 hrs, and the supernatant and cell pellet were 
separated; 200 μl TCA was added into 1.8 ml supernatant to precipitate protein; the protein pellet was suspended in 
200 μl Tris-buffer; specific antibodies were used to detect α-hemolysin, enterotoxin B, and TSST-1.   
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Figure 3.11a Inhibition of SCA-15 on the growth of B. anthracis Sterne 
 
 
Figure 3.11b Inhibition of SCA-15 on the general secretion of B. anthracis Sterne 
 
 
Figure 3.11c Inhibition of SCA-15 on the secretion of specific toxins of B. anthracis  
 
 
Figure 3.11 Inhibition of SCA-15 on the secretion of B. anthracis toxins 
Different conc. of SCA-15 was added to the mid-log phase of B. anthracis Sterne at OD600 ≈ 2.6; the growth of bac-
teria was monitored; 2 ml culture was collected after 1 h, 3 hrs, and 5 hrs, then the supernatant and cell pellet were 
separated; 110 μl TCA was added into 1 ml supernatant to precipitate protein; the protein pellet was resuspended in 
100 μl Tris-buffer; specific antibodies were used to detect lethal factor, edema factor, and protective antigen.  
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Figure 3.12a Inhibition of SCA-21 on the growth of S. aureus Mu50 
 
 
 
Figure 3.12b Inhibition of SCA-21 on general secretion of S. aureus Mu50 
 
 
Figure 3.12c Inhibition of SCA-21 on the secretion of α-hemolysin, enterotoxin B, and TSST-1  
 
Figure 3.12 Inhibition of SCA-21 on the secretion of S. aureus toxins 
Different conc. of SCA-21 was added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 3; the growth of bacteria 
was monitored; 2 ml culture was collected after 1 h, 2.5 hrs, and 4 hrs, then the supernatant and cell pellet were se-
parated; 200 μl TCA were added into 1.8 ml supernatant to precipitate protein; the protein pellet was resuspended in 
200 μl Tris-buffer; specific antibodies were used to detect α-hemolysin, enterotoxin B, and TSST-1.   
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Figure 3.13a Inhibition of SCA-21 on the growth of S. aureus Mu50 
 
 
Figure 3.13b Inhibition of SCA-21 on the secretion of α-Hemolysin and enterotoxin B 
 
 
 
 
Figure 3.13c Inhibition of SCA-21 on the secretion of TSST-1 
 
Figure 3.13 Inhibition of SCA-21 on the secretion of S. aureus toxins 
2.5 μM SCA-21 was added to the mid-log phase of S. aureus Mu50 at OD600 ≈ 2.6; the growth of bacteria was moni-
tored; 2 ml culture was collected after 2 hrs and 4 hrs, then the supernatant and cell pellet was separated; 200 μl 
TCA were added into 1.8 ml supernatant to precipitate protein; the protein pellet was resuspended in 200 μl Tris-
buffer; specific antibodies were used to detect α-hemolysin, enterotoxin B, and TSST-1.  
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Figure 3.14a Inhibition of SCA-21 on the growth of B. anthracis Sterne 
 
 
 
Figure 3.14b Inhibition of SCA-21 on the general secretion of B. anthracis  
 
 
 
Figure 3.14c Inhibition of SCA-21on the secretion of specific toxins of B. anthracis  
 
Figure 3.14 Inhibition of SCA-21 on the secretion of B. anthracis toxins 
Different conc. of SCA-21 was added to the mid-log phase of B. anthracis Sterne at OD600 ≈ 2.6; the growth of bac-
teria was monitored; 2 ml culture was collected after 1 hr, 3 hrs, and 5 hrs, then the supernatant and cell pellet were 
separated; 110 μl TCA was added into 1ml supernatant to precipitate protein; the protein pellet was suspended in 
100 μl Tris-buffer; specific antibodies were used to detect lethal factor, edema factor, and protective antigen.  
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The Antimicrobial Mechanism of RB analogs 
Previous studies indicated that there are three mechanism involved in the antimicrobial 
activity of RB. RB could specific binding to essential enzyme and inhibit its function, like DNA 
polymerase [108, 110], RNA polymerase [109]. RB might release chloro and iodo group at cer-
tain condition, these halo groups have antimicrobial activity. Moreover, iodine could enhance 
yield of singlet oxygen via photooxidation [126]. RB is a photosensitizer [116], and it could gen-
erate singlet oxygen through photooxidation [117, 126]. Singlet oxygen could cause cell damage 
and bacteria death. SCA-41 don‟t have halo group, but it showed better bacteriostatic and bacte-
ricidal effect than RB. We don‟t know whether its antimicrobial activities are due to inhibition 
on SecA, other enzyme, or photooxidation. In this study, different scavengers were used to inves-
tigate whether the antimicrobial activity of RB and RB analogs were due to photooxidation. 
Bacteriostatic Effect was not due to Inhibition on H
+
-ATPase Activity Because RB, 
SCA-41, and SCA-43 could inhibit the ATPase activity of EcF1F0 (Table 3.2), therefore 0.25% 
glucose was added into growth medium to bypass affecting the H
+
 ATPase activity. Our result 
showed that with or without glucose, the MIC50 of RB and RB analogs were the same (Table 
3.3), indicating the bacteriostatic effect of RB and RB analogs were independent of proton AT-
Pase activity.  
The Negative Effect of DMSO on the Enzymatic Effect of RB Because synthesized 
RB analogs were not soluble in water, they were dissolved in 100% DMSO. To investigate 
whether DMSO could affect the ATPase activity, BaSecA2 was incubate with 10% DMSO for 1 
hour, 30 min and 4 min, then subjected to ATPase assay. Although 30 min incubation result 
showed DMSO slightly increased ATPase activity (Fig. 3.15), 1 h and 4 min incubation result 
showed DMSO slightly decreased ATPase activity (Fig. 3.15), suggesting that 10 % DMSO do 
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not significantly affect the ATPase activity of BaSecA2. Interestingly, Fig. 3.15 showed that the 
ATPase activity of BaSecA2 was increased with pre-incubation time.  Previous study demon-
strated that RB could bind with DNA polymerase and inactivate its function via photooxidation 
[110]. DMSO could act as hydroxyl radical scavenger [118] and could protect cells from pho-
tooxidation damage. To test whether DMSO could affect inhibition effect of RB on the ATPase 
activity of BaSecA2, in vitro RB inhibition assay was carried with or without DMSO. Our results 
showed that DMSO could decrease the in vitro inhibition of RB (Fig. 3.16). Without DMSO, 
IC50 is around 3 μM, but in presence of 10 % DMSO, IC50 is around 25 μM (Fig. 3.16).  Al-
though our ATPase inhibition assay was carried at normal room light condition, this result sug-
gested that photooxidation might also contribute to inhibition on ATPase activity.  
The Negative Effect of DMSO on Bacteriostatic Effect of RB To determine whether 
DMSO affects the in vivo inhibition assay result, RB was subjected to do inhibition assay with 
2.5% DMSO or without DMSO. Our result showed that without DMSO, MIC50 of RB on the 
growth of E. coli NR698 and B. subtilis 168 were 9 μM and 42 μM (Fig. 3.17), but in presence 
of 2.5% DMSO, MIC50 were reduced to 18 μM and 72 μM (Fig. 3.17). DMSO could act as hy-
droxyl radical scavenger [118] and could protect cells from photooxidation damage. Although 
our inhibition assay was carried at normal room light condition, this result suggested that pho-
tooxidation might also contribute to the bacteriostatic effect of RB.  
The Negative Effect of DMSO on Bactericidal Effect of RB To determine whether 
DMSO affects the bactericidal effect, RB was subjected to killing assay with 2.5% DMSO or 
without DMSO. Our result showed that 40 μM RB could kill two log B. subtilis 168 without 
DMSO, however in presence of 2.5% DMSO could not kill even half log number of bacteria 
(Fig. 3.18). DMSO could act as hydroxyl radical scavenger [118] and could protect cells from 
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photooxidation damage. Although our inhibition assay was carried at normal room light condi-
tion, this result suggested that photooxidation might also contribute to the bactericidal effect of 
RB.  
The Effect of Light on Bactericidal Effect of RB and SCA-41 The growth of S. aureus 
6538 was monitored, SCA-41 or RB was added into cell culture when OD600 reach 1, or added 
into overnight culture, and the cell was growth with or without light. After adding RB or SCA-
41, cell culture was taken out at different time point and spread on LB plates with different dilu-
tion. Plate assay results showed that RB and SCA-41 had bactericidal effect on both log phase 
and stationary phase S. aureus 6538 (Fig. 3.19a-b). Light could dramatically increase bactericidal 
effect of 80 µM RB; while light slightly affect bactericidal result of 40 µM SCA-41 (Fig. 3.19a-
b). And in presence of 80 µM RB, bacteria can grow back after overnight incubation; however, 
in presence of 40 µM SCA-41, bacteria couldn‟t survive even after overnight incubation (Fig. 
3.19a). Thus, SCA-41 had much better bactericidal effect than RB, and photooxidation might 
contribute to the bactericidal effect of RB, not for SCA-41.  
Bactericidal effect of SCA-41 might be independent with Photooxidation Histidine is 
a scavenger of singlet oxygen [117-118], therefore it could protect bacteria against photo-
damage which is involved reaction with singlet oxygen [117]. Therefore, histidine was used to 
investigate whether singlet oxygen plays important role in antimicrobial activity of RB and SCA-
41. Killing assay results showed that histidine could dramatically reduce bactericidal effect of 
RB both in light (3 log numbers) and in dark (1 log number) (Fig. 3.20). Light slightly increased 
bactericidal effect of SCA-41, and histidine dramatically increased bactericidal effect of SCA-41 
(Fig. 3.20), suggesting that singlet oxygen might not contribute to the antimicrobial activity of 
SCA-41. Phloxine B is a RB analog, with four bromo groups instead of four iodo groups. And 
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previous study demonstrated that phloxine B had phototoxicity [117]. It could cause membrane 
and DNA damage through ROS pathway and free hydroxyl pathway [117]. The reaction of both 
pathway required Fe 2
+
. In this study, 100 μM phenanthroline was used to chelate Fe2+ and 
block these two pathways. Phenanthroline increased the bacteriostatic effect of SCA-41 (Fig. 
3.21), while it decreased the bacteriostatic effect of RB (Fig. 3.21), indicating that photooxida-
tion might not be the antimicrobial mechanism of SCA-41.   
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 Table 3.2 In vitro inhibition effect of RB analogs against EcF1F0 
 
 
Table 3.3 Bacteriostatic effects of RB and RB analogues were independent of inhibition on proton ATPase 
Inhibition on the growth of bacteria, MIC50 (μM) 
 S. aureus 6538 B. anthracis sterne E. coli NR698 
 0% Glu 0.25% Glu 0% Glu 0.25% Glu 0% Glu 0.25% Glu 
RB 26.5 25 6 5 13.5 13 
SCA-41  6 5.5 4 4 7.5 6 
SCA-43  3 3 1.5 1.5 9 5 
 
The endogenous ATPase activity of BaSecA2
1 hour 30 min 4 min
0
25
50
75
100 without DMSO
10% DMSO
A
T
P
as
e 
a
ct
iv
it
y 
(p
m
o
l/

g
/m
in
)
 
Figure 3.15 The effect of DMSO on the intrinsic ATPase activity of BaSecA2 
BaSecA2 was incubated with reaction buffer (Tris-HCl pH 7.5, 2 mM Mg
2+
), or/and 10% DMSO for 4 min, 30 min, 
or 1 hour, then add 2 mM ATP to do ATPase assay at 30
o
C for 40 min. 
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Figure 3.16 DMSO decrease the in vitro inhibition effect of RB against BaSecA2 
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Figure 3.17 DMSO decrease the bacteriostatic effect of RB  
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Figure 3.18 DMSO decrease bactericidal effect of RB against B. subtilis 168  
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Figure 3.19a The effect of light on the bactericidal effects of RB and SCA-41 against S. aureus  
Bactericidal effect on stationary phase of S. aureus 6538
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Figure3.19b The effect of light on bactericidal effects of RB and SCA-41 against S. aureus  
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Figure 3.20 The effect of singlet oxygen on the bactericidal effects of RB and SCA-41  
37
o
C, 2 hrs killing; histidine: 10 mM; light: 15 Watt fluorescent light.  
Light:            +              +             -              -                                  +              +             -               - 
Histidine:      -               -             +             +                                  -               -              +              +    
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Figure 3.21 The effect of photooxidation on bacteriostatic effects of RB and SCA-41 
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Interaction between Inhibitors and SecA Homologues 
To truly validate SecA as the target of our inhibitors, we need to investigate interaction 
between SecA and inhibitors, identify how many proteins interact with inhibitors, and determine 
whether interactions with other proteins could contribute to observed antimicrobial effect.  
Azide is a SecA inhibitor, and previous study showed that azide enhances the formation 
of a trypsin-resistant 30 kDa fragment, which is related with SecA membrane insertion [37, 62, 
88]. If compound could bind with target protein, it might induce conformational change and re-
sult in different trypsin digestion pattern. In this study, altered trypsin sensitivity assay was used 
to detect interaction between inhibitors and SecA homologues. First, we investigate whether inte-
raction between SCA-15 and EcSecAN68 could induce conformational change and result in dif-
ferent trypsin digestion pattern. Our result showed that adding 80 μM SCA-15 could dramatical-
ly change the trypsin digestion pattern of EcSecAN68 (Figure 3.22a), suggesting that the interac-
tion between the compound and protein induced conformational change of protein and changed 
protease sensitivity.  Adding ATP alone slightly changed trypsin digestion pattern, which is dif-
ferent with the pattern resulted by adding SCA-15 (Fig. 3.22a). And adding SCA-15 in addition 
to ATP resulted in similar trypsin digestion pattern as by adding SCA-15 alone (Fig. 3.22a). 
These results suggested that SCA-15 and ATP might bind to different sites of EcSecAN68. Fig. 
3.22b confirmed that SCA-15 could change trypsin resistance, and there were three distinct tryp-
sin resistant bands showed in the presence of 80 μM SCA-15. Increasing SCA-15 concentration 
to 160 μM caused similar results, and the trypsin resistant band around 15 kDa became more 
prominent (Fig. 3.22b). Since SCA-15 contains azido group, it might be able to photo-crosslink 
to protein by UV exposure, thus subsequent MS/MS results could identify binding domain of 
SCA-15. However, with or without UV showed similar MS/MS results, suggesting that photo 
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cross-linking rate might be too low (data not shown). Moreover, SCA-15 also could induce con-
formational change of SaSecA1 and SaSecA2 and change trypsin resistance (Fig. 3.23). High 
concentration of SCA-41 and RB could protect wild type EcSecA from trypsin digestion (Fig. 
3.24-3.25).  All these results supported that DARTS might be a good method to identify the drug 
targets of SCA-15. 
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Figure 3.22a SCA-15 change trypsin resistance of EcSecAN68 
10 μg EcSecA N68 was incubated at 37oC for 10 min with or without SCA-15, then added 1.2 μg trypsin and incu-
bate on ice for 25 min. 15% SDS-PAGE 
 
  
Figure 3.22b SCA-15 change trypsin resistance of EcSecAN68 
10 μg EcSecA N68 was incubated at 37oC for 10 min with or without SCA-15, then added 1.2 μg trypsin and incu-
bate on ice for 25 min. 15% SDS-PAGE 
 
Figure 3.23 SCA-15 change trypsin resistance of SaSecA1 and SaSecA2 
10 μg SaSecA1 and SaSecA2 was incubated at 25oC for 10 min with or without SCA-15, then added 1.2 μg trypsin 
and incubate on ice for 25 min. 15% SDS-PAGE 
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Figure 3.24 SCA-41 could protect EcSecA from trypsin digestion   
10 μg EcSecA was incubated at 30oC for 30 min with or without SCA-41, then added 1.2 μg trypsin and incubate on 
ice for 20 min.   
 
Figure 3.25 RB could protect EcSecA from trypsin digestion 
10 μg EcSecA was incubated at 30oC for 30 min with or without RB, then added 1.2 μg trypsin and incubate on ice 
for 20 min. 
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Target Identification at Whole Cell Extract Level 
To truly validate SecA as the target of those inhibitors developed in our study, we need to 
investigate interaction between SecA and inhibitors, identify how many proteins interact with 
inhibitors, and determine whether interactions with other proteins could contribute to observed 
antimicrobial effect. 
Affinity chromatography is the most widely used method to identify drug target, however 
the application of affinity chromatography was limited, because of the need of vast structural di-
versity, the complexity of biologically active small molecules, and high level of nonspecific 
binding of non-target proteins [121-124]. Drug affinity responsive target stability (DARTS) is a 
new method to identify drug targets [121, 125]. The principle of this method is that a small li-
gand would stabilize its target protein‟s structure and result in changing of protease resistance, 
which offer the chance of target identification [121, 125]. Affinity chromatography is a positive 
drug target selection method by pulling out the target proteins and leaving non-target proteins 
behind [121], while DARTS is a negative drug target selection method by digesting away non-
target proteins while leaving behind the target proteins [121]. In this study, these two methods 
were both used to validate that SecA is a real target of pyrimidine analogues.  
Targets of SCA-15 identified by using DARTS Next, DARTS was used to identify 
drug targets of SCA-15 from whole cell lysate of E. coli MC4100. Our results identified three 
trypsin resistant bands in 1-D Gel (Fig. 3.26a-b), and western blot result showed that one band 
was positive with EcSecA antibody (Fig. 3.26a). That band was cut and subjected to Moldi-
MS/MS, however MS/MS result didn‟t prove E. coli SecA was there. This result might because 
larger amount of protein might be required for MS/MS than Western blot.    
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Targets of SCA-21 identified by using DARTS DARTS was used to identify drug tar-
gets of SCA-21 from whole cell lysate of E. coli MC4100. Our results identified that three tryp-
sin resistant bands in 1-D Gel (Fig. 3.27a-b), and Western blot results showed that one band was 
positive with EcSecA antibody (Fig. 3.27a). That band was cut and subjected to Moldi-MS/MS, 
however MS/MS result didn‟t prove E. coli SecA was there. This result might because larger 
amount of protein required for MS/MS than western blot.   
Pull down assay To truly validate SecA as the target for the proposed inhibitiors, we 
need to do protein pull-down assay to identify potential target, and further determine whether 
interactions with proteins other than designed target could contribute to the observed antimi-
crobial effect. For this purpose, a long linker was attached to pyrimidine analogs. Our results 
showed that SCA-91 and SCA-101 retained reasonable inhibition effect on the ATPase activity 
of SecA homologues (Table 3.4). Thus, these compounds were further immobilized on beads or 
conjugated to biotin (Table 3.5). Conjugation with biotin slightly increased inhibition effect of 
SCA-91 (Table 3.4). Western blot results showed that these compounds could pull down EcSecA 
(Fig. 3.28) and SaSecA1 (Fig. 3.29) from whole cell lysate, supporting that SecA is a real target 
of SCA-15. 
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Figure 3.26a DARTS results confirm EcSecA as a target of SCA-15 
 
 
  
Figure3.26b DARTS results confirm EcSecA as a target of SCA-15 
200 μg whole cell lysate of E. coli MC4100 was incubated on ice for 2 hrs with or without SCA-15, then exposed to 
UV for 0 sec or 90 sec, followed by digesting with 50 μg trypsin at 25oC for 10-20 min. The digestion was stopped 
by adding sample buffer and boiling for 20 min. 10-20% SDS-PAGE.    
 
 
 
Figure 3.27a DARTS results confirmed EcSecA as a target of SCA-21 
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Figure 3.27b DARTS results confirmed EcSecA as a target of SCA-21 
Whole cell lysate of E. coli MC4100 was incubated on ice for 2 hrs with or without SCA-21, then exposed to UV for 
0 sec or 90 sec, followed by digesting with 50 μg trypsin at 25oC for 10-20 min. The digestion was stopped by add-
ing sample buffer and boiling for 20 min. 10-20% SDS-PAGE. 
 
 
 
Table 3.4 The effect of linker on in vitro inhibition effect of pyrimidine analogs 
 
 
      Table 3.5 Pyrimidine analogs were conjugated to biotin or immobilized on beads 
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Figure 3.28 EcSecA as a target of pyrimidine analogs 
 
 
Figure 3.29 SaSecA1 as a target of pyrimidine analogs            
  
  
EcSecA antibody
E. coli MC4100 whole cell lysate 0
Beads:          Streptavidin Aagrose beads Agarose beads
Compound:        - 104          - 105               - 113
EcSecA antibody
S. aureus whole cell lysate 0
cytosal Membrane
Compound:        - 105          - 105
195 
Conclusion and Discussion 
In this study, three structurally different classes of SecA inhibitors were developed and 
optimized. Several SecA inhibitors showed promising in vitro inhibition effect on ATPase activi-
ties of SecA homologues, as well as bacteriostatic effects and bactericidal effects against B. 
anthracis Sterne and numerous drug resistant S. aureus strains. However, to validate SecA as a 
real target of these inhibitors, we need to determine whether their antimicrobial activities are due 
to inhibition on SecA in vivo.  
SecA is involved in forming a protein-conducting channel that spans the entire membrane 
[38-39] [96-97]. Thus, drugs targeting SecA might be directly accessible from the extracellular 
matrix and exert their effects without entering the cell, and bypassing the major negative effect 
of efflux transporters in bacteria, which is a major mechanism for the development of current 
drug-resistance [72-76]. S. aureus Mu50 and S. aureus N315 are resistant to QacA efflux-
mediated antibiotics [100]. SCA-41, SCA-50, SCA-15, SCA-93, and SCA-21 are best inhibitors 
developed from our study. They showed promising bacteriostatic effects or/and bactericidal ef-
fect on S. aureus Mu50 or/and S. aureus N315, suggesting that these SecA inhibitors might be 
able to overcome QacA mediated efflux. NorA and MepA are two major efflux pumps of S. au-
reus, and they have little negative effect on the antimicrobial activities of SecA inhibitors, sug-
gesting that targeting SecA might be able to by-pass efflux pump.  
Sec system is responsible for the secretion of many toxins and virulence factors, which 
play important roles in the pathogenesis of bacterial infection [33-35]. Enterotoxin B, α-
hemolysin, and toxic shock syndrome toxin 1 (TSST-1) are three toxins of S. aureus, which con-
taining Sec-dependent signal peptide (Table 0.1) [34]. Lethal factor (LF), edema factor (EF), and 
protective antigen (PA), are three major component toxins of B. anthracis, and all of them have 
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Sec-dependent signal peptide [35]. Our results showed SecA inhibitors could inhibit secretion of 
these important toxins of S. aureus and B. anthracis Sterne, suggesting that these inhibitors could 
inhibit the function of SecA in vivo and reduce virulence of these important bacteria pathogens. 
Virulence target-based therapies are not sufficient to combat infection, but targeting SecA homo-
logues is not only reduce virulence but also decrease viability, dramatically increasing the chance 
of control bacterial infection and reduce the occurrence of drug resistance. 
Previous studies indicated that photooxidation and halo groups contribute to the antimi-
crobial activities of RB as well as inhibition on specific enzymes. However, our results showed 
that photooxidation might not contribute to the antimicrobial activities of RB analogs, which do 
not have halo group and have better antimicrobial activities than RB, suggesting that the ability 
of inhibition on specific enzyme is increased in RB analogs. And our results showed that the bac-
teriostatic effects of SCA-41 and SCA-43 were independent of inhibition on proton ATPase ac-
tivity. 
Binding with small ligand could stabilize the structure of its target protein and results in 
changing of protease resistance, which offered the chance of target identification. In this study, 
partial trypsin digestion was used to investigate whether inhibitors could bind with SecA homo-
logues. Our results showed that inhibitors could induce the change of trypsin resistance of SecA 
homologues, suggesting that inhibitors could bind with SecA homologues and change their con-
formation and stability. Affinity chromatography is a positive drug target selection method by 
pulling out the target proteins and leaving non-target proteins behind [121], while DARTS is a 
negative drug target selection method by digesting away non-target proteins while leaving be-
hind the target proteins [121]. Target identification assays confirmed that SecA inhibitor could 
identify SecA homologues from whole cell lysate of E. coli and S. aureus, supporting that SecA 
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homologues are the targets of these inhibitors. However, other proteins were also pulled down 
from affinity chromatography, including D-ribosomal binding protein, tryptophanase, Trp re-
pressor binding protein, Glutamate dehydrogenase, Acyl-CoA carboxylase, Acyl-CoA dehydro-
genase, and Enoyl-(acyl-carrier protein) reductase. It‟s possible that inhibitors have multiple tar-
gets inside bacteria. But when we analyze pull down assay data, we have to consider about the 
limitation of affinity chromatography, which is based on binding of the drug to its target pro-
teins. When we modify small molecules with long linker or conjugated with biotin, the binding 
ability and bioactivity of the small molecule might be changed, resulting in nonspecific binding 
with a lot of non-target proteins. Therefore, we need to evaluate whether inhibition on those pro-
teins could result in the antimicrobial phenotype of those inhibitors. The proteins identified from 
pull down assay might not be essential for bacteria, except for SecA and Enoyl-(acyl-carrier pro-
tein) reductase. Our inhibitors could inhibit the enzyme activity of SecA, have bacteriostatic ef-
fect and bactericidal effect against Gram-positive bacteria, inhibit the secretion of bacteria toxin, 
and they could bind with SecA homologues and pull down SecA homologues from whole cell 
lysate. All these results validate SecA homologues as drug targets of our inhibitors. Enoyl-(acyl-
carrier protein) reductase is an attractive target for developing antimicrobials, because it is a key 
enzyme of the type II fatty acid synthesis system, essential for bacteria, and the conservation 
across bacteria without human counterpart. We need further investigate whether our inhibitors 
could inhibit its enzyme activity. If a single small molecule could target two essential and specif-
ic bacteria proteins, that would be an exciting discovery.  
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GENERAL DISCUSSION 
The emergence and dissemination of multidrug resistance, bacterial pathogens have been 
causing a serious public health problem in recent years. To overcome the existing drug resistant 
problem, there is an urgent need to find new antimicrobials, especially those against drug-
resistant strains of bacteria. SecA is the central component of Sec-dependent secretion pathway, 
which is responsible for the secretion of many essential proteins as well as some toxins and viru-
lence factors. Two SecA homologues are indentified in some Gram-positive pathogenic bacteria. 
SecA1 is involved in general secretion pathway and essential for viability, whereas SecA2 con-
tribute to the virulence of some important Gram-positive pathogen by playing a role in a specia-
lized secretion pathway. SecA homologues are required for bacterial viability and virulence, 
moreover, highly conserved in bacteria with no human counterpart, therefore targeting these pro-
teins may represent a way to combat bacterial pathogens with minimal human toxicity. SecA 
contains small ligand binding domains, indicating that it is amenable for drug targeting. In vitro 
and in vivo assays have been developed to investigate the function of SecA, and those assays can 
be applied for high-throughput screening for SecA inhibitors. SecA homologues plays important 
role during all infection life stages. They have important functions not only in exponential phase 
but also in stationary phase; they are required for colonization and spread in human tissue; they 
can protect bacteria from host defensive attack; also play roles in eliciting immune responses 
[56-57].  Thus, SecA homologues are ideal targets for exploring novel antimicrobials. We hypo-
thesize that inhibition of SecA homologues could reduce virulence, inhibit bacteria growth, and 
kill bacteria. In those Gram-positive pathogens containing two SecA homologues, like MRSA, 
M. tuberculosis, B. anthracis, and C. diphtheria, dual targets inhibition could increase the 
chances of combat infection and reduce the occurrence of drug resistance. SecA is involved in 
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forming transmembrane channel. That means that it might be accessible directly from the extra-
cellular environment in Gram-positive bacteria. Thus, targeting SecA might be able to by-pass 
the effect of efflux, which is one of the major and common mechanisms for bacterial drug resis-
tance development. Antimicrobials which could by-pass the effect of efflux could have very sig-
nificant implications. Thus, SecA might be an excellent target for antimicrobial development.  
Alignment results showed that nine motifs of DEAD helicase were highly conserved in 
all SecA homologues. In E. coli SecA, these nine motifs form two nucleotide binding domains 
(NBD); NBD1 acts as the ATPase catalytic machinery; NBD2 is a regulator of ATP hydrolysis 
at NBD1. The conservation of these motifs suggested that SecA1 and SecA2 might be ATPase 
and have direct role on translocation, and targeting NBD of SecA homologues might result in 
dual target in those Gram-positive bacteria pathogens containing two SecA homologues. SecA1 
and SecA2 were cloned from M. tuberculosis H37Rv, M. smegmatis mc
2
155, S. aureus 35556, 
and B. anthracis Sterne, over-expressed in E. coli, and purified. All these SecA homologues 
showed ATPase activities, suggesting that they could be molecular motor. The ATPase activity 
of SecA1 can be stimulated by liposomes, while the ATPase activity of SecA2 cannot be stimu-
lated by liposomes. The ATPase activity of MsSecA1 could be obviously stimulated by BA13 
membrane and the preOmpA of E. coli. Majority of MsSecA1 are located on membrane, while 
majority of MsSecA2 are located in cytosol. Liposomes could induce conformational change of 
MtbSecA1 and form ring-like structures under TEM and AFM. All these results suggest that my-
cobacteria SecA1 might interact with membrane in the same way as EcSecA and might be in-
volved in forming transmembrane channel. Mycobacteria SecA1 and SecA2 failed to comple-
ment the temperature-sensitive defect EcSecA, suggesting that interaction between secretion fac-
tors of Sec system might be specific for different organisms. 
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All these SecA homologues showed ATPase activities, thus screening ATPase inhibitors 
might help to develop new antimicrobial agents. In collaboration with Dr. Beinghe Wang‟s lab, 
three structurally different classes of SecA inhibitors were developed and optimized in this 
study: (1) Rose Bengal (RB) and RB analogs derived from systematical dissection RB and Struc-
ture-Activity relationship (SAR) study; (2) pyrimidine analogs derived from virtual screening 
based on the ATP binding pocket of EcSecA and SAR study; and (3) bistriazole analog derived 
from random screening and SAR study. Several SecA inhibitors showed promising bacteriostatic 
effects and bactericidal effects against B. anthracis Sterne and numerous drug-resistant S. aureus 
strains. Our SecA inhibitors were compared with some other antibiotics for the antimicrobial ac-
tivities of against S. aureus Mu50 and B. anthracis Sterne. Among these antibiotics, vancomycin 
had the best inhibition on S. aureus Mu50, MIC95 ≈ 5 μg/ml. Five SecA inhibitors developed 
from this study have better bacteriostatic effect than vancomycin. Tetracycline and erythromycin 
showed the best inhibition on B. anthracis Sterne, MIC95 are around 0.1-0.3 μg/ml. Although 
inhibition effect of our inhibitors (The best with MIC95 ≈ 0.7 μg/ml) are not as good as tetracyc-
line and erythromycin, but our inhibitors had bactericidal effect while these two antibiotics do 
not. 
SecA is involved in forming a protein conducting-channel that spans the entire membrane 
[38-39, 96-97]. Thus, drugs targeting SecA might be directly accessible from the extracellular 
matrix and exert their effects without entering the cell, and bypassing the major negative effect 
of efflux transporters in bacteria, which is a major mechanism for the development of current 
drug-resistance [72-76]. S. aureus Mu50 and S. aureus N315 are resistant to QacA efflux-
mediated antibiotics [100]. SCA-41, SCA-50, SCA-15, SCA-93, and SCA-21 are best inhibitors 
developed from our study. They show promising bacteriostatic effects or/and bactericidal effect 
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on S. aureus Mu50 or/and S. aureus N315, suggesting that these SecA inhibitors might be able to 
overcome QacA mediated efflux. Two major efflux pumps of S. aureus, NorA and MepA, have 
little negative effect on the antimicrobial activities of SecA inhibitors, suggesting that targeting 
SecA might be able to by-pass efflux pump. Antimicrobials, which could by-pass the effect of 
efflux, could have very significant implications. 
Sec system is not only responsible for the secretion of many essential proteins, and it is 
also responsible for the secretion of many toxins and virulence factors [33-35]. Because both Se-
cA1 and SecA2 are involved in secretion of virulence factors, dual targeting inhibition on these 
two SecA homologues would dramatically reduce virulence. Moreover SecA inhibitors could 
inhibit secretion of important toxins of S. aureus and B. anthracis Sterne, which precursor con-
tain N-terminal signal peptide required for secretion through Sec-pathway, suggesting that these 
inhibitors could inhibit the function of SecA in vivo and reduce virulence of these important bac-
teria pathogens. Virulence target-based therapies are not sufficient to combat infection, but tar-
geting SecA homologues is not only reduce virulence but also decrease viability, dramatically 
increasing the chance of control bacterial infection and reduce the occurrence of drug resistance. 
Partial trypsin digestion results showed that inhibitors could induce the change of trypsin 
resistance of SecA homologues, suggesting that inhibitors could bind with SecA homologues and 
change their conformation and stability. Target identification assays confirmed that SecA inhibi-
tor could identify SecA homologues from whole cell lysate of E. coli and S. aureus, supporting 
that SecA homologues are drug targets of these inhibitors. Those inhibitors developed in our 
study could inhibit the enzyme activity of SecA, have bacteriostatic effect and bactericidal effect 
against Gram positive bacteria, inhibit the secretion of bacteria toxins, and they could bind with 
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SecA homologues and pull down SecA homologues from whole cell lysate. All these results va-
lidate SecA homologues as drug targets of our inhibitors. 
These novel inhibitors with structural diversity will aid the understanding of the pharma-
cophore required for SecA inhibition. This study will provide a starting point for developing 
more potent antimicrobials. To develop more potent SecA inhibitors with improved water solu-
bility, affinity-labeling and crystallographic analysis will be used to identify and characterize the 
SecA1 and SecA2 binding sites for selected inhibitors developed from this study.  Since SecA is 
essential for the secretion of many proteins including virulent factors/toxins, SecA inhibitors are 
expected to inhibit protein secretion with no effect on protein synthesis in general. However, 
blockage of SecA-dependent protein secretion may trigger other physiological responses. Thus, 
exploration of these cellular responses with secretome and transcriptome analysis is important 
for the clear understanding on how these inhibitors work other than the proposed mechanism, 
and may lead to the identification of potential targets of these inhibitors other than SecA. Data 
collected from this study will beneficial in understanding the molecular mechanism through 
which SecA inhibition achieves antimicrobial effect and for the future refinement of these com-
pounds. 
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